<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64960</article-id><article-id pub-id-type="doi">10.7554/eLife.64960</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-217186"><name><surname>Richter</surname><given-names>William F</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4469-6428</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-217187"><name><surname>Shah</surname><given-names>Rohan N</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-28518"><name><surname>Ruthenburg</surname><given-names>Alexander J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2709-4564</contrib-id><email>aruthenburg@uchicago.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Molecular Genetics and Cell Biology, The University of Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Pritzker School of Medicine, The University of Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Biochemistry and Molecular Biology, The University of Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shi</surname><given-names>Xiaobing</given-names></name><role>Reviewing Editor</role><aff><institution>Van Andel Institute</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Murphy</surname><given-names>Maureen E</given-names></name><role>Senior Editor</role><aff><institution>The Wistar Institute</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>15</day><month>07</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e64960</elocation-id><history><date date-type="received" iso-8601-date="2020-11-17"><day>17</day><month>11</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-07-05"><day>05</day><month>07</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2020-12-04"><day>04</day><month>12</month><year>2020</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2020.12.04.411215"/></event></pub-history><permissions><copyright-statement>© 2021, Richter et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Richter et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-64960-v2.pdf"/><abstract><p>MLL-rearranged leukemia depends on H3K79 methylation. Depletion of this transcriptionally activating mark by DOT1L deletion or high concentrations of the inhibitor pinometostat downregulates <italic>HOXA9</italic> and <italic>MEIS1</italic>, and consequently reduces leukemia survival. Yet, some MLL-rearranged leukemias are inexplicably susceptible to low-dose pinometostat, far below concentrations that downregulate this canonical proliferation pathway. In this context, we define alternative proliferation pathways that more directly derive from H3K79me2 loss. By ICeChIP-seq, H3K79me2 is markedly depleted at pinometostat-downregulated and MLL-fusion targets, with paradoxical increases of H3K4me3 and loss of H3K27me3. Although downregulation of polycomb components accounts for some of the proliferation defect, transcriptional downregulation of FLT3 is the major pathway. Loss-of-FLT3-function recapitulates the cytotoxicity and gene expression consequences of low-dose pinometostat, whereas overexpression of constitutively active <italic>STAT5A</italic>, a target of FLT3-ITD-signaling, largely rescues these defects. This pathway also depends on MLL1, indicating combinations of DOT1L, MLL1 and FLT3 inhibitors should be explored for treating <italic>FLT3-</italic>mutant leukemia.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>chromatin</kwd><kwd>leukemia</kwd><kwd>MLL-rearranged</kwd><kwd>H3K79me2</kwd><kwd>MV4;11</kwd><kwd>FLT3</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>130230-RSG-16-248-01-DMC</award-id><principal-award-recipient><name><surname>Ruthenburg</surname><given-names>Alexander J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01-GM115945</award-id><principal-award-recipient><name><surname>Ruthenburg</surname><given-names>Alexander J</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>NIH</institution></institution-wrap></funding-source><award-id>T32-GM007183</award-id><principal-award-recipient><name><surname>Richter</surname><given-names>William F</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>FLT3-ITD/STAT5A signaling is more sensitive to Dot1L inhibition than the canonical MLL-fusion activated drivers of leukemogenesis, providing a potential therapeutic avenue for one of the most frequent lesions in leukemia.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>MLL1-rearrangements (MLL-r) account for ~10% of all leukemia cases and are especially prominent in infants (70–80%) and, lacking an effective standard of care, bear a very poor prognosis (<xref ref-type="bibr" rid="bib64">Marks et al., 2013</xref>; <xref ref-type="bibr" rid="bib46">Jabbour et al., 2015</xref>; <xref ref-type="bibr" rid="bib63">Mann et al., 2010</xref>; <xref ref-type="bibr" rid="bib85">Pieters et al., 2007</xref>; <xref ref-type="bibr" rid="bib110">Winters and Bernt, 2017</xref>). A growing body of evidence suggests that MLL-rearrangements rely on additional mutations to cause leukemia. Leukemia patients with MLL-fusions often have additional mutations that affect growth signaling pathways (<xref ref-type="bibr" rid="bib35">Grossmann et al., 2013</xref>; <xref ref-type="bibr" rid="bib62">Liang et al., 2006</xref>; <xref ref-type="bibr" rid="bib5">Armstrong et al., 2003</xref>) and MLL-fusions in mouse models cause leukemias with longer-than-expected latencies, suggesting that additional mutations are required for full progression (<xref ref-type="bibr" rid="bib81">Ono et al., 2005</xref>; <xref ref-type="bibr" rid="bib21">Corral et al., 1996</xref>; <xref ref-type="bibr" rid="bib32">Forster et al., 2003</xref>). Yet, few studies have examined the genetic context of MLL-fusion proteins and how additional lesions may cooperate to promote disease at the molecular level.</p><p><italic>MLL1</italic> (Mixed Lineage Leukemia protein, also known as <italic>KMT2A</italic>) is a histone H3 lysine methyltransferase involved in regulating <italic>HOX</italic> gene expression during development and normal hematopoiesis (<xref ref-type="bibr" rid="bib42">Hess, 2004</xref>). Translocations of MLL1 fuse its amino terminus to the carboxy-terminus of a growing list of over 130 different fusion partners (<xref ref-type="bibr" rid="bib67">Meyer et al., 2018</xref>). Although these MLL-fusions lack methyltransferase activity, a functional copy of the MLL1 gene is necessary to target and hypermethylate H3K4 at MLL-fusion target genes to induce leukemogenesis (<xref ref-type="bibr" rid="bib68">Milne et al., 2005</xref>; <xref ref-type="bibr" rid="bib10">Cao et al., 2014</xref>; <xref ref-type="bibr" rid="bib69">Milne et al., 2010</xref>). In more than 75% of acute myeloid leukemia (AML) cases and &gt;90% of acute lymphoblastic leukemia (ALL) cases involving MLL translocations, the MLL-fusion partner is one of seven members of the transcriptional elongation complex, most commonly, AF9 and AF4, respectively (<xref ref-type="bibr" rid="bib65">Marschalek, 2011</xref>). These fusion partners aberrantly recruit DOT1L, the sole histone H3 lysine 79 methyltransferase to MLL1 target genes including the HOXA gene cluster (<xref ref-type="bibr" rid="bib71">Mohan et al., 2010</xref>; <xref ref-type="bibr" rid="bib78">Okada et al., 2005</xref>; <xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>). By mechanisms that remain unclear, DOT1L-mediated hypermethylation of H3K79 promotes expression of MLL-fusion targets (<xref ref-type="bibr" rid="bib68">Milne et al., 2005</xref>; <xref ref-type="bibr" rid="bib6">Bernt et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Guenther et al., 2008</xref>; <xref ref-type="bibr" rid="bib99">Stubbs et al., 2008</xref>; <xref ref-type="bibr" rid="bib14">Chen et al., 2015a</xref>), establishing an expression profile with a surprising degree of target gene overlap across different MLL-fusions (<xref ref-type="bibr" rid="bib4">Armstrong et al., 2002</xref>). Ablation of H3K79 methylation through knockout or pharmacological targeting of <italic>DOT1L</italic> abrogates the MLL-fusion target gene expression profile, selectively induces apoptosis and differentiation of leukemia cells in culture and dramatically extends the survival of mice in xenograft experiments (<xref ref-type="bibr" rid="bib6">Bernt et al., 2011</xref>; <xref ref-type="bibr" rid="bib23">Daigle et al., 2013</xref>).</p><p>Viral co-transduction of the MLL-AF4 targets (<xref ref-type="bibr" rid="bib116">Zeisig et al., 2004</xref>) H<italic>OXA9</italic> and <italic>MEIS1</italic> is sufficient to cause acute leukemia in mouse bone marrow progenitors, arguing that these transcription factors represent a major etiologic pathway in MLL-r leukemia (<xref ref-type="bibr" rid="bib21">Corral et al., 1996</xref>; <xref ref-type="bibr" rid="bib12">Chang et al., 2010a</xref>; <xref ref-type="bibr" rid="bib47">Jo et al., 2011</xref>; <xref ref-type="bibr" rid="bib55">Kroon et al., 1998</xref>; <xref ref-type="bibr" rid="bib9">Calvo et al., 2002</xref>). However, exogenous expression of <italic>MLL-AF9</italic> in mice requires a long latency period (4–9 months) and chemotherapy induced MLL-translocations cause disease 3–5 years after treatment, suggesting that additional mutations are required for leukemagenesis (<xref ref-type="bibr" rid="bib21">Corral et al., 1996</xref>; <xref ref-type="bibr" rid="bib27">Dobson et al., 1999</xref>). In the prevailing model, MLL-fusions recruit DOT1L to hypermethylate and activate expression of <italic>MEIS1</italic> and <italic>HOXA9</italic> (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib78">Okada et al., 2005</xref>; <xref ref-type="bibr" rid="bib6">Bernt et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Guenther et al., 2008</xref>; <xref ref-type="bibr" rid="bib22">Daigle et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Deshpande et al., 2013</xref>). However, the genetic manipulations used to define this paradigm may have missed more subtle and graded effects afforded by kinetically-staged antagonism with highly specific small-molecule inhibitors. Therefore, to better understand the direct effects of H3K79me2 in several MLL-r cell lines we employed pharmacologic inhibition of DOT1L methyltransferase activity.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Low doses of DOT1L inhibitor ablate bulk H3K79me2 and curtail MV4;11 proliferation without impacting expression of canonical target genes.</title><p>(<bold>A</bold>) Conventional model depicting how DOT1L methyltransferase activity activates transcription of key proliferative oncogenic transcription factors (<xref ref-type="bibr" rid="bib78">Okada et al., 2005</xref>; <xref ref-type="bibr" rid="bib6">Bernt et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Guenther et al., 2008</xref>; <xref ref-type="bibr" rid="bib4">Armstrong et al., 2002</xref>; <xref ref-type="bibr" rid="bib116">Zeisig et al., 2004</xref>; <xref ref-type="bibr" rid="bib55">Kroon et al., 1998</xref>). (<bold>B</bold>) Proliferation assay of MV4;11 cells treated with the indicated concentrations of the DOT1L inhibitor pinometostat (EPZ5676). Cell viability was assayed every 2 days, starting 1 day after treatment commenced using the CellTiter Glo 2.0 reagent. Relative cell viability is presented as the mean fraction of pinometostat versus cells treated with the equivalent volume of DMSO from three independent experiments ± S.E.M. (<bold>C</bold>) Western blots for H3K79me2 with H4 or MBD3 loading controls in MV4;11 cells treated with 10–200 nM pinometostat for 5 or 7 days. (<bold>D</bold>) RT-qPCR analysis of <italic>HOXA9</italic> and <italic>MEIS1</italic> expression fold-change in MV4;11 cells treated with 100 nM or 1 µM pinometostat for 7 days. Results are shown as mean ± S.E.M. of three independent experiments. Student’s t-test (ns p &gt; 0.05, ** p ≤ 0.01, *** p ≤ 0.001). (<bold>E</bold>) Western blot of HOXA9 and MEIS1 with H4 as a loading control from MV4;11 cells treated with 100 nM pinometostat for 7 days.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Low-dose DOT1L inhibition has little effect on Hox gene expression.</title><p>(<bold>A</bold>) Proliferation assay of MV4;11 cells treated with the DOT1L inhibitor SGC0946 using CellTiter-Glo 2.0 to measure viability represented as the luminescence fraction of treated over mock-treated cells. Data are represented as mean ± SE of three independent experiments. (<bold>B</bold>) RT-qPCR analysis of <italic>HOXA9</italic> and <italic>MEIS1</italic> expression in MV4;11 cells ± 50 nM SGC0946 DOT1L inhibitor for 7 days. Results are displayed as mean fold-change vs. DMSO-treated cells ± S.E.M. of three independent experiments. Student’s t-test (ns p &gt; 0.05). (<bold>C</bold>) Bar graph of Cuffdiff (<xref ref-type="bibr" rid="bib101">Trapnell et al., 2012</xref>) output for non-native RNA ‘spike-ins’ for ± 100 nM pinometostat cDNA libraries used for RNA-seq from MV4;11 cells. Bar graphs represent the average of three independent experiments ± S.E.M. Student’s t-test (ns p &gt; 0.05). (<bold>D</bold>) Venn diagram displaying the overlap between genes upregulated in MV4;11 cells by 100 nM pinometostat treatment (7 days) and treatment with 3 µM of the pinometostat-related compound EPZ004777 for 6 days (<xref ref-type="bibr" rid="bib22">Daigle et al., 2011</xref>). (<bold>E</bold>) Bar graph of Cuffdiff (<xref ref-type="bibr" rid="bib101">Trapnell et al., 2012</xref>) output for the expression of HOXA cluster genes and HOX domain-containing oncogenes <italic>MEIS1</italic>, <italic>RUNX1</italic>, and <italic>PBX3</italic> from RNA-seq in MV4;11 cells ± 100 nM pinometostat. Values are represented as log<sub>10</sub> (FPKM + 1) for three independent experiments with standard deviation. Student’s t-test (ns p &gt; 0.05, * p &lt; 0.05, ** p &lt; 0.01). (<bold>F</bold>) RT-qPCR analysis of <italic>SPI1</italic> and <italic>CEBPA</italic> expression from three independent experiments of MV4;11 cells treated with 100 nM pinometostat for 7 days. Fold change over DMSO-treated cells is depicted ± S.E.M. Student’s t-test (ns p &gt; 0.05, ** p &lt; 0.01).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-fig1-figsupp1-v2.tif"/></fig></fig-group><p>Pinometostat (EPZ5676), a highly specific DOT1L inhibitor (<xref ref-type="bibr" rid="bib23">Daigle et al., 2013</xref>; <xref ref-type="bibr" rid="bib22">Daigle et al., 2011</xref>; <xref ref-type="bibr" rid="bib3">Anglin and Song, 2013</xref>; <xref ref-type="bibr" rid="bib114">Yu et al., 2012</xref>) displays 37,000-fold selectivity over its closest related paralogs and a host of other lysine and arginine methyltransferases. Interestingly, several cell lines that all have the <italic>MLL-AF4</italic> translocation display pinometostat sensitivities that differ by nearly three orders of magnitude (<xref ref-type="bibr" rid="bib23">Daigle et al., 2013</xref>). One of these lines (MV4;11) displays a pinometostat IC50 for proliferation that is 20 times lower than the IC50 for <italic>HOXA9</italic> and <italic>MEIS1</italic> expression (<xref ref-type="bibr" rid="bib23">Daigle et al., 2013</xref>), suggesting that these drivers of leukemogenesis, though downregulated at higher concentrations (1 µM) (<xref ref-type="bibr" rid="bib23">Daigle et al., 2013</xref>), may not contribute to cell-type-specific effects at lower concentrations.</p><p>We sought to understand low-dose pinometostat effects by treating a variety of MLL-r cell lines with a concentration that reduces proliferation in only a subset, with MLL-r cell lines harboring <italic>FLT3-ITD</italic> mutations being the most susceptible. Under these conditions, <italic>HOXA9</italic> and <italic>MEIS1</italic> expression remain unaffected, presenting a clear exception to the existing paradigm, but we found thousands of other differentially expressed genes, including the <italic>PBX3</italic> and <italic>FLT3</italic> oncogenes. Capitalizing on the sensitivity of internally calibrated ChIP-seq (ICeChIP-seq) (<xref ref-type="bibr" rid="bib36">Grzybowski et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Grzybowski et al., 2019</xref>), we observed larger reductions in H3K79me2 density at a subset of MLL-AF4 targets, a genome-wide reduction in H3K27me3 and stark H3K4me3 increases at transcription start sites. Remarkably, we could nearly completely rescue not only pinometostat- but also MLL1 inhibitor-induced effects on proliferation and apoptosis through expression of a constitutively active form of the downstream FLT3-ITD target <italic>STAT5A</italic> (<italic>STAT5A-CA</italic>), arguing that disruptions to this pathway represent the main source of toxicity from low-dose DOT1L inhibition. In addition, DOT1L inhibition also downregulated the <italic>EZH2</italic> and <italic>EED</italic> components of the PRC2 complex, likely accounting for global reductions in H3K27me3 and imparting modest, but distinct effects on proliferation and a correspondingly moderate proliferation rescue from EZH2 overexpression. Collectively, our data argue that the FLT3-ITD signaling and PRC2 pathways, are more sensitive to disruptions of MLL-fusion-mediated gene activation than the canonical oncogenic drivers in MLL-r, <italic>FLT3<sup>ITD</sup></italic> leukemias, defining a new molecular understanding of how MLL-fusions cooperate with other oncogenic factors to induce leukemia.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>MLL-r leukemia is sensitive to DOT1L inhibitor via a non-canonical pathway</title><p>Leukemias harboring MLL-rearrangements are uniquely susceptible to DOT1L inhibition and MV4;11, a biphenotypic leukemia cell line harboring an <italic>MLL-AF4</italic> translocation, is one of the most sensitive (<xref ref-type="bibr" rid="bib23">Daigle et al., 2013</xref>). To determine the basis of this susceptibility, we systematically examined how low-dose regimes of pinometostat affect proliferation and global H3K79me2 levels in cells treated for 7 days with 10–500 nM pinometostat. This range of concentrations is slightly above the previously determined MV4;11 proliferation IC50 (3.5 nM) but is below the 1 µM or higher typically used in published investigations of the effects of H3K79me ablation (<xref ref-type="bibr" rid="bib23">Daigle et al., 2013</xref>; <xref ref-type="bibr" rid="bib33">Godfrey et al., 2019</xref>; <xref ref-type="bibr" rid="bib79">Okuda et al., 2017</xref>). Consonant with previous findings (<xref ref-type="bibr" rid="bib23">Daigle et al., 2013</xref>), pinometostat concentrations as low as 10 nM significantly reduce global levels of H3K79me2 and cause a 30 ± 10% reduction in MV4;11 proliferation, while 100 nM inhibitor reduced cell proliferation by 80 ± 10% (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). Notably, after treating MV4;11 cells with 100 nM inhibitor for 7 days we observed no discernable effect on the expression of <italic>HOXA9</italic> and <italic>MEIS1</italic> (<xref ref-type="fig" rid="fig1">Figure 1D and E</xref>), despite the emphasis on these genes as the critical mediators of DOT1L’s effects in MLL-r leukemia (<xref ref-type="bibr" rid="bib78">Okada et al., 2005</xref>; <xref ref-type="bibr" rid="bib6">Bernt et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Guenther et al., 2008</xref>; <xref ref-type="bibr" rid="bib22">Daigle et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Deshpande et al., 2013</xref>). Treatment with a low-dose regime of SGC0946, a distinct, yet highly selective DOT1L inhibitor (<xref ref-type="bibr" rid="bib114">Yu et al., 2012</xref>) also reduced MV4;11 proliferation without affecting HOXA9 and MEIS1 expression (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>). Consistent with prior observations (<xref ref-type="bibr" rid="bib23">Daigle et al., 2013</xref>), a much higher dose of 1 µM pinometostat significantly downregulates both <italic>HOXA9</italic> and <italic>MEIS1</italic> expression (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p></sec><sec id="s2-2"><title>DOT1L inhibition at low concentrations downregulates leukemic oncogenes</title><p>With the extant model (<xref ref-type="bibr" rid="bib78">Okada et al., 2005</xref>; <xref ref-type="bibr" rid="bib6">Bernt et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Guenther et al., 2008</xref>; <xref ref-type="bibr" rid="bib22">Daigle et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Deshpande et al., 2013</xref>) unable to explain reductions in proliferation caused by the DOT1L inhibitor in this concentration regime, we reasoned that the expression of other genes crucial to the survival of these cells are likely affected. To define these genes, we performed RNA-seq in MV4;11 cells that had been treated with 100 nM pinometostat for 7 days and observed that 1916 genes were downregulated and 2007 genes were upregulated (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) relative to a DMSO treated control. To account for any handling biases, we included four RNA ‘spike-in’ controls and found no significant differences in read counts between treatment groups (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). The downregulated genes significantly overlap with MLL-AF4 targets identified by Kerry et al. by ChIP-seq in MV4;11 cells (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>; <xref ref-type="fig" rid="fig2">Figure 2B</xref>). Relative to prior high-dose (3 µM) treatment with a compound structurally related to pinometostat in MV4;11 cells, the numbers of differentially expressed genes are similar, and there is marked overlap between the sets, particularly the downregulated cohort (<xref ref-type="bibr" rid="bib22">Daigle et al., 2011</xref>; <xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Consistent with our RT-qPCR measurements, <italic>HOXA9</italic> was unaltered in its expression (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>) and <italic>MEIS1</italic> displayed extremely modest mRNA reduction (20%) not observed by RT-qPCR and not reflected in apparent protein levels (<xref ref-type="fig" rid="fig1">Figure 1D–E</xref>). Of the other <italic>HOXA</italic> cluster genes only <italic>HOXA11</italic> and <italic>HOXA13</italic> exhibited expression changes with a 1.7-fold decrease and 2.5-fold increase, respectively (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>DOT1L inhibition downregulates a subset of MLL-AF4 targets including the leukemic oncogene FLT3.</title><p>(<bold>A</bold>) MA plot showing genes differentially expressed in MV4;11 cells treated with 100 nM pinometostat or DMSO 7 days as log<sub>2</sub>-mean of expression (FPKM) of the DMSO and pinometostat-treated samples versus the log<sub>2</sub>-fold change of the mean normalized pinometostat versus DMSO-treated FPKM for three independent replicates. Red represents genes that meet the significance threshold, with an FDR-adjusted <italic>p</italic> ≤ 0.5. (<bold>B</bold>) Venn diagram depicting overlapping genes between those downregulated by 100 nM pinometostat and MV4;11 MLL-AF4 targets identified by <xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>, p-value computed by two-tailed Fisher Exact test. (<bold>C</bold>) Venn diagram displaying the overlap between genes downregulated in MV4;11 cells by 100 nM pinometostat treatment (7 days) and treatment with 3 µM of the pinometostat-related compound EPZ004777 for 6 days (<xref ref-type="bibr" rid="bib22">Daigle et al., 2011</xref>). p-Value computed by two-tailed Fisher Exact test. (<bold>D</bold>) Bar plot depicting upregulated genes with the highest fold changes from RNA-seq analysis of three independent experiments of DMSO- (blue) or pinometostat-treated (red) MV4;11 cells with uncertainty presented as the standard deviation computed by CuffDiff (<xref ref-type="bibr" rid="bib101">Trapnell et al., 2012</xref>) with immune response genes outlined in gray. (<bold>E</bold>) RT-qPCR analysis showing the fold-change for <italic>HLA-DRA, HLA-DRB1</italic>, and <italic>CIITA</italic> gene expression in MV4;11 cells ± 100 nM pinometostat treatment for 7 days. Results are shown as mean ± S.E.M. of three independent experiments. Student’s t-test (*****p ≤ 0.00001). (<bold>F</bold>) Bar plot depicting the top pinometostat-downregulated genes from the RNA-seq analysis that are previously described MLL-AF4 targets (<xref ref-type="bibr" rid="bib39">Guenther et al., 2008</xref>) including the oncogenes <italic>MEF2C, FLT3</italic>, and <italic>PBX3</italic>. (<bold>G</bold>) RT-qPCR analysis of <italic>MEF2C, FLT3</italic>, and <italic>PBX3</italic> expression in MV4;11 cells ± with 100 nM pinometostat for 7 days. Results are displayed as mean fold-change ± S.E.M. of three independent experiments; Student’s t-test (**** p ≤ 0.0001). (<bold>H</bold>) Western blot for FLT3 with RBBP5 as loading control in MV4;11 cells treated with 100 nM pinometostat for 5 or 7 days. (<bold>I</bold>) Venn diagram displaying the overlap between genes upregulated in MV4;11 cells by 100 nM pinometostat treatment (7 days) and genes downregulated in leukemic cells from patients with <italic>FLT3-ITD</italic> vs normal <italic>FLT3</italic> karyotypically normal AML (<xref ref-type="bibr" rid="bib11">Cauchy et al., 2015</xref>). p-Value computed by two-tailed Fisher Exact test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>DOT1L inhibition upregulates components of the interferon gamma pathway and markers of differentiation.</title><p>(<bold>A</bold>) Gene Ontology analysis (DAVID) (<xref ref-type="bibr" rid="bib43">Huang et al., 2009a</xref>; <xref ref-type="bibr" rid="bib44">Huang et al., 2009b</xref>) of pinometostat-upregulated genes showing top functional classification categories and the number of genes in each category that are significantly upregulated. (<bold>B</bold>) Bar graph of Cuffdiff (<xref ref-type="bibr" rid="bib101">Trapnell et al., 2012</xref>) output for the expression of <italic>INFG</italic> (IFN-γ) from RNA-seq in MV4;11 cells ± 100 nM pinometostat. Values are represented as FPKM + 1 for three independent experiments with standard deviation. Student’s t-test (ns p &gt; 0.05). (<bold>C</bold>) Bar graph of Cuffdiff (<xref ref-type="bibr" rid="bib101">Trapnell et al., 2012</xref>) output for the expression of <italic>ITGAM (CD11b), ITGAX (CD11c)</italic>, and <italic>CD86</italic> macrophage cell surface marker expression in MV4;11 cells ± 100 nM pinometostat for 7 days. Values are represented as FPKM + 1 for three independent experiments with standard deviation. Student’s t-test (** p &lt; 0.01, *** p ≤ 0.001). (<bold>D</bold>) GSEA (<xref ref-type="bibr" rid="bib100">Subramanian et al., 2005</xref>; <xref ref-type="bibr" rid="bib73">Mootha et al., 2003</xref>) of the set of differentially expressed genes in MV4;11 cells ± 100 nM pinometostat compared to KEGG_HEMATOPOIETIC_CELL_LINEAGE and IVANOVA_HEMATOPOIESIS_CELL_LINEAGE gene sets from the MSigDB data base. NES - normalized enrichment score. (<bold>E</bold>) RT-qPCR analysis of <italic>CSF3R</italic> and <italic>CSF1R</italic> expression in MV4;11 cells ± 100 nM pinometostat for 7 days. Results are displayed as mean fold-change vs. DMSO-treated cells ± S.E.M. of three independent experiments. Student’s t-test (** p &lt; 0.01, *** p ≤ 0.001). (<bold>F</bold>) Venn diagram displaying the overlap between genes downregulated in MV4;11 cells by 100 nM pinometostat treatment (7 days) and genes upregulated in leukemic cells from patients with <italic>FLT3-ITD</italic> vs normal <italic>FLT3</italic> karyotypically normal AML (<xref ref-type="bibr" rid="bib11">Cauchy et al., 2015</xref>). p-Value computed by two-tailed Fisher Exact test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-fig2-figsupp1-v2.tif"/></fig></fig-group><p>Although H3K79me2 is considered transcriptionally activating, the upregulated genes had much larger expression fold-changes. 906 genes were upregulated at least twofold (and some &gt; 80-fold), while only 86 genes were downregulated ≥ 2-fold (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The list of upregulated transcripts includes MHC class II and innate immune response genes (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). We confirmed the expression increases of <italic>CIITA</italic> (the master regulator of interferon-inducible MHC class II genes), and the MHC class II genes <italic>HLA-DRA</italic> and <italic>HLA-DRB1</italic> by RT-qPCR (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Gene ontology analysis of the upregulated genes indicated enrichment for ‘immune response’ and ‘interferon-gamma signaling pathway’ (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>; <xref ref-type="bibr" rid="bib43">Huang et al., 2009a</xref>; <xref ref-type="bibr" rid="bib44">Huang et al., 2009b</xref>). Despite there being no discernable effect on interferon-gamma (<italic>IFNG</italic>) expression in the RNA-seq analysis (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>), marked activation of IFN-γ-inducible genes is apparent. We hypothesize that this may be due to perturbations to signaling effectors of the IFN-γ pathway which includes the STAT family of transcription factors that are often aberrantly expressed in leukemia and other cancers (<xref ref-type="bibr" rid="bib8">Caldarelli et al., 2013</xref>; <xref ref-type="bibr" rid="bib96">Spiekermann et al., 2002</xref>; <xref ref-type="bibr" rid="bib75">Muhlethaler-Mottet et al., 1998</xref>). The activation of so many genes involved in antigen processing and presentation as well as macrophage cell surface markers (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>) may indicate that these cells are undergoing differentiation toward a more macrophage-like state, consistent with apparent differentiation observed in other DOT1L loss-of-function paradigms (<xref ref-type="bibr" rid="bib6">Bernt et al., 2011</xref>; <xref ref-type="bibr" rid="bib22">Daigle et al., 2011</xref>). By Gene Set Enrichment Analysis (GSEA) (<xref ref-type="bibr" rid="bib100">Subramanian et al., 2005</xref>; <xref ref-type="bibr" rid="bib73">Mootha et al., 2003</xref>), the set of differentially expressed genes were enriched for hematopoietic differentiation factors and anticorrelated with hematopoietic progenitor expression signatures (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). Notably, the cytokine receptors CSF1R and CSF3R, critical signaling inducers of hematopoietic differentiation, were upregulated (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>; <xref ref-type="bibr" rid="bib74">Mossadegh-Keller et al., 2013</xref>; <xref ref-type="bibr" rid="bib52">Klimiankou et al., 2017</xref>).</p><p>Among the most downregulated genes were many MLL-AF4 target genes (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Guenther et al., 2008</xref>; <xref ref-type="bibr" rid="bib109">Wilkinson et al., 2013</xref>) including the oncogene FMS-Like Tyrosine Kinase 3 (<italic>FLT3</italic>), the protooncogene Myocyte Enhancer Factor 2C (<italic>MEF2C</italic>), and Pre-B-cell leukemia homeobox 3 (<italic>PBX3)</italic> (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). These genes all have previously described roles in the development of MLL-rearranged leukemias (<xref ref-type="bibr" rid="bib99">Stubbs et al., 2008</xref>; <xref ref-type="bibr" rid="bib76">Nagel et al., 2017</xref>; <xref ref-type="bibr" rid="bib53">Krivtsov et al., 2006</xref>; <xref ref-type="bibr" rid="bib61">Li et al., 2016</xref>). FLT3 is a receptor tyrosine kinase that regulates proliferation and cell survival via STAT and other signaling pathways. Mutations that constitutively activate FLT3 by internal tandem duplication of its juxtamembrane domain (FLT3-ITD) or point mutations within its kinase domain collectively represent the most frequently occuring genetic lesions in acute myeloid leukemia (<xref ref-type="bibr" rid="bib76">Nagel et al., 2017</xref>; <xref ref-type="bibr" rid="bib58">Levis and Small, 2003</xref>; <xref ref-type="bibr" rid="bib70">Mizuki et al., 2003</xref>). MV4;11 cells are homozygous for the <italic>FLT3-ITD</italic> mutation and highly sensitive to FLT3 inhibition (<xref ref-type="bibr" rid="bib5">Armstrong et al., 2003</xref>; <xref ref-type="bibr" rid="bib57">Levis et al., 2002</xref>). The transcription factor <italic>MEF2C</italic> cooperates with <italic>SOX4</italic> to induce leukemogenesis in mouse models and <italic>MLL-AF9</italic>-expressing hematopoietic progenitors to promote colony formation (<xref ref-type="bibr" rid="bib53">Krivtsov et al., 2006</xref>; <xref ref-type="bibr" rid="bib28">Du et al., 2005</xref>). PBX3 is a transcription factor that acts to stabilize both HOXA9 and MEIS1 localization at a subset of target genes and coexpression of either oncogene with <italic>PBX3</italic> can cause leukemogenesis (<xref ref-type="bibr" rid="bib61">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib60">Li et al., 2013b</xref>; <xref ref-type="bibr" rid="bib106">Wang et al., 2006</xref>). We verified the reductions in <italic>FLT3, MEF2C</italic> and <italic>PBX3</italic> expression with pinometostat by RT-qPCR and examined FLT3 protein levels by Western blot (<xref ref-type="fig" rid="fig2">Figure 2G–H</xref>).</p><p>We wondered if downregulation of one or more of these genes could be responsible for the reductions in cell proliferation from low-dose pinometostat treatment. Using previously published datasets of MEF2C and FLT3-regulated genes, we first looked at the expression of 15 genes that were downregulated by MEF2C knockout in mouse hematopoietic progenitors (<xref ref-type="bibr" rid="bib98">Stehling-Sun et al., 2009</xref>). Of these genes, only FLT3 was downregulated in our pinometostat-treated cells. Because the expression of nearly all the set of MEF2C-regulated genes was unaffected in our analysis, we moved our focus to FLT3. Previous work by Cauchy et al. identified 138 genes significantly upregulated in karyotypically normal <italic>FLT3-ITD+</italic> AML compared to WT <italic>FLT3</italic> AML patient samples (<xref ref-type="bibr" rid="bib11">Cauchy et al., 2015</xref>). A comparison of those FLT3-ITD-upregulated genes to our pinomeostat downregulated genes yielded a small but significant overlap (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>). We saw a more pronounced overlap between genes downregulated in FLT3-ITD+ patient samples and those upregulated by pinometostat, including 10 MHC class II receptors (<xref ref-type="fig" rid="fig2">Figure 2I</xref>). <italic>PBX3</italic> is the only MLL-AF4 target upregulated in the <italic>FLT3-ITD</italic> samples, suggesting it could be a crucial convergence point of the MLL-AF4 and FLT3-ITD pathways. Collectively, these data suggest that FLT3-ITD may represent an important pathway through which DOT1L inhibition reduces leukemia cell survival. Before delving further into the delineation of the responsible molecular pathways, we first sought to quantitatively define the consequences of low dose DOT1L inhibition on the distribution of the H3K79me2 mark and its causal connection to these gene expression-level changes.</p></sec><sec id="s2-3"><title>MLL-AF4 targets downregulated by low dose DOT1L inhibition are highly enriched for H3K79me2</title><p>Despite extensive global reductions in H3K79me2 levels, only a subset of MLL-AF4 targets were downregulated by 100 nM pinometostat, necessitating more nuanced measurement of the mark, particularly at MLL-AF4 target genes. The current model, that MLL-AF4 recruits DOT1L to target genes resulting in aberrantly high levels of H3K79me2 and transcriptional activation (<xref ref-type="bibr" rid="bib6">Bernt et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Guenther et al., 2008</xref>; <xref ref-type="bibr" rid="bib23">Daigle et al., 2013</xref>), has not been rigorously examined by quantitative methods that would be sensitive to small changes. Indeed, the limitations of conventional ChIP-seq preclude unambiguous quantitative analyses for direct comparisons of histone modifications upon global depletion (<xref ref-type="bibr" rid="bib36">Grzybowski et al., 2015</xref>; <xref ref-type="bibr" rid="bib82">Orlando et al., 2014</xref>). To circumvent these problems, we used ICeChIP-seq, a form of native ChIP that uses barcoded internal-standard modified nucleosomes to permit direct quantitative comparison of histone modification density (HMD) at high-resolution across samples (<xref ref-type="bibr" rid="bib36">Grzybowski et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Grzybowski et al., 2019</xref>; <xref ref-type="bibr" rid="bib94">Shah et al., 2018</xref>).</p><p>With ICeChIP we were able to measure a positive correlation (R<sup>2</sup> = 0.53) between transcript abundance and H3K79me2 levels in MV4;11 cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), consistent with the speculated role for H3K79me2 in transcriptional activation (<xref ref-type="bibr" rid="bib78">Okada et al., 2005</xref>; <xref ref-type="bibr" rid="bib6">Bernt et al., 2011</xref>; <xref ref-type="bibr" rid="bib14">Chen et al., 2015a</xref>; <xref ref-type="bibr" rid="bib22">Daigle et al., 2011</xref>). However, only 30 of the 250 most highly expressed genes, were downregulated by 100 nM pinometostat treatment, suggesting that H3K79me2 is not necessary to maintain high levels of gene expression at all sites where it is enriched. The genes that were downregulated by 100 nM pinomeostat had higher H3K79me2 levels compared to upregulated genes or all expressed genes, rivalling the most highly expressed genes (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Although previous conventional ChIP-seq measurements observed enrichment of H3K79me2 at MLL-fusion target genes (<xref ref-type="bibr" rid="bib6">Bernt et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Guenther et al., 2008</xref>), our ICe-ChIP-seq analysis revealed equivalent average density at MLL-AF4 targets and the 250 most highly expressed genes (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Given that only 12 MLL-AF4 targets are included in that highly expressed gene list, this higher H3K79me2 density is likely due to very efficient recruitment of DOT1L by MLL-AF4 rather than deposition via the transcriptional apparatus (<xref ref-type="bibr" rid="bib93">Schübeler et al., 2004</xref>; <xref ref-type="bibr" rid="bib38">Guenther et al., 2007</xref>). Interestingly, the subset of MLL-AF4 targets that are downregulated by 100 nM pinometostat exhibit still higher levels of H3K79me2 than even MLL-AF4 targets as a whole and appear to be more dependent on H3K79me2 for their expression (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). The only other group of genes analyzed with comparable peak H3K79me2 levels were ‘MLL-spreading’ genes which display a binding profile that stretches further downstream into the gene body (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>). The exceptional precision and accuracy of ICeChIP is due to the use of internal calibration standards and is clear from the correlation of HMD measurements of different immunoprecipitation replicates (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). Indeed, H3K79me2 enrichment at these gene groups was remarkably similar in two additional ICeChIP-seq replicates (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Low-dose DOT1L inhibition disrupts H3K79me2 with more pronounced effects on downregulated MLL-AF4 targets.</title><p>(<bold>A</bold>) Scatterplot of the mean normalized log<sub>2-</sub>FPKM (three independent replicates) of genes expressed in DMSO-treated MV4;11 cells plotted versus the log<sub>2-</sub>HMD (H3K79me2) for +1000 bp from the TSS. Colors signify: red, MLL-AF4 targets (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>); purple, MLL-AF4 targets downregulated by 100 nM pinometostat. (<bold>B</bold>) (top) Quantitative measurement of H3K79me2 modification density from ICeChIP-seq of MV4;11 cells treated with 100 nM pinometostat for 7 days contoured over the promoters (−2 to +two kp from the TSS) of indicated gene sets, including genes up- or down-regulated by 100 nM pinometostat, the most highly-expressed genes, MLL-AF4 target genes (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>) as well as those MLL-AF4 targets downregulated by 100 nM pinometostat. (bottom) Heatmaps depicting H3K79me2 density (HMD) for the gene promoter regions shown above ranked by HMD. (<bold>C</bold>) Scatterplot of genes in MV4;11 cells downregulated by 100 nM pinometostat depicting log<sub>2</sub>-fold change H3K79me2 HMD (+1000 bp from TSS) versus the log<sub>2</sub>-fold change of the mean normalized FPKM (three independent replicates) for 100 nM pinometostat or DMSO treated cells. Colors signify: red, MLL-AF4 targets (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>); orange, FLT3-ITD upregulated genes (<xref ref-type="bibr" rid="bib11">Cauchy et al., 2015</xref>); blue, FLT3-ITD downregulated genes (<xref ref-type="bibr" rid="bib11">Cauchy et al., 2015</xref>); yellow, labeled genes in gray font. (<bold>D</bold>) H3K79me2 meta promoter profiles as in <bold>B</bold>, but including curves for 100 nM pinometostat treatment at 4 days, and the promoter set where this complex spreads (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>). (<bold>E</bold>) The FLT3 locus as representative of an MLL-AF4 target (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Guenther et al., 2008</xref>) downregulated by 100 nM pinometostat, displaying MV4;11 ICeChIP-seq tracks for H3K79me2 100 nM pinometostat 4- and 7-day treatment and H3K27me3 and H3K4me3 tracks from 100 nM pinometostat 7-day treatment as well as DMSO control-treated cells and an RNA-seq track (FPKM) from a single replicate of 100 nM pinometostat 7-day treatment and DMSO-treated cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>H3K79me2 loss is poorly correlated with reductions in gene expression.</title><p>(<bold>A</bold>) Plots of H3K79me2 density from ICeChIP-seq in MV4;11 cells treated with 100 nM pinometostat for 4 or 7 days. H3K79me2 modification density (HMD) is displayed from ± 2000 bp of the TSS of all genes expressed, non-MLL-AF4 targets (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>) downregulated by 100 nM pinometostat and MLL-AF4 targets not downregulated by 100 nM pinometostat. (<bold>B</bold>) Scatterplot of genes downregulated by 100 nM pinometostat plotted as the log<sub>2</sub> fold-change in gene expression vs the log<sub>2</sub> fold-change in HMD with MLL-AF4 targets in red, FLT3-ITD upregulated genes (<xref ref-type="bibr" rid="bib11">Cauchy et al., 2015</xref>) in orange, FLT3-ITD downregulated genes (<xref ref-type="bibr" rid="bib11">Cauchy et al., 2015</xref>) in cyan and labeled genes highlighted in yellow. Regression analysis of all genes (R<sup>2</sup> = 0.13) or the MLL-AF4 target subset (R<sup>2</sup> = 0.20) reveals poor correlation between the fold changes of H3K79me2 and RNA expression. (<bold>C</bold>) Scatterplot showing the reproducibility of H3K79me2 HMD from 0 to +2000 bp from the TSS from ICeChIP of (left) immunoprecipitation replicates performed simultaneously in MV4;11 cells treated with DMSO for 4 days; (Right) immunoprecipitation performed by different individuals on separate occasions from MV4;11 cells treated with DMSO for 4 or 7 days. (<bold>D</bold>) H3K79me2 HMD of ICeChIP replicates from MV4;11 cells ± 100 nM pinometostat from ± 2000 bp of the TSS of the gene groups identified, for comparison to replicate one presented in <xref ref-type="fig" rid="fig3">Figure 3D</xref>. (<bold>E</bold>) Scatterplots demonstrating the linearity of H3K79me2 calibrant immunoprecipitation from denaturative ICeChIP-seq from MV4;11 cells treated with 0 or 100 nM pinometostat for 7 days for replicate 1. Similar scatter plots for treated and untreated 7 day points for native ICeChIP of H3K4me3 and H3K27me3 ICeChIP are displayed.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-fig3-figsupp1-v2.tif"/></fig></fig-group><p>In all gene categories we examined, 100 nM pinometostat dramatically reduced apparent H3K79me2 density in gene bodies, eliminating the sharp peaks near the TSS and proportionally reducing methylation as it tapers toward the 3’ end of the gene body (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The upregulated gene set displayed lower-than-average density both before and after treatment, consistent with the transcriptional upregulation occurring as an indirect effect of the dosing. The 100 nM pinometostat downregulated genes, 250 highest expressed genes and MLL-AF4 targets all experienced much higher yet similar reductions in H3K79me2 HMD. The similar reductions in methylation at gene groups that had such different overall responses to gene expression from pinometostat treatment suggests that the expression of some genes is more dependent on H3K79me2-mediated transcriptional activation. Given the modest correlation between H3K79me2 early in the gene body and transcriptional output, we observed an unexpectedly poor linear correlation between fold-change in H3K79me2 HMD versus fold-change in gene expression of differentially expressed genes (R<sup>2</sup> = 0.13) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). However, comparing the absolute differences in HMD to fold-change of gene expression more clearly reveals some interesting trends (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Those genes with the largest reductions in HMD (including MLL-AF4 targets) are nearly uniformly downregulated though not in proportion to HMD loss. Conversely, MLL-AF4 targets with smaller HMD reductions are more evenly distributed between both up- and downregulated genes. FLT3-ITD-upregulated genes identified in patient samples (<xref ref-type="bibr" rid="bib11">Cauchy et al., 2015</xref>) have only small reductions in HMD, suggesting their downregulation is not a direct result of HMD loss but, instead, a secondary effect of FLT3 downregulation.</p><p>Interestingly, the MLL-AF4 targets downregulated by low-dose pinometostat (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) had the largest reductions in H3K79me2 of any gene category examined (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). These data show that a subset of MLL-AF4 targets have higher levels of H3K79me2 and greater reductions from DOT1L inhibition and are more dependent on this methylation for even moderate levels of expression. Gene expression sensitivity to low-dose DOT1L inhibition may more accurately define ‘true’ MLL-AF4 target genes whose expression is upregulated by the fusion protein and H3K79me2 hypermethylation than those genes that merely align with MLL1 and AF4 ChIP-seq peaks.</p><p>To further define the H3K79me2 depletion trajectory, we also examined the distribution of this modification within gene bodies at an earlier timepoint of pinometostat treatment. Treating MV4;11 cells with 100 nM pinometostat for 4 days had little effect on H3K79me2 HMD at the most highly expressed genes, which likely depend more on DOT1L recruitment by the transcriptional apparatus than by the MLL-fusion protein (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Pinometostat treatment for 4 days diminished the 5’ H3K79me2 peak at genes downregulated by 7-day pinometostat treatment and at MLL-AF4 targets while only slightly reducing H3K79me2 levels within gene bodies of MLL-AF4 targets. Within the gene bodies of 100 nM (7 day) pinometostat-downregulated genes there was actually an increase in H3K79me2 HMD at the 4-day timepoint. This 3’ shift in methylation density away from the transcription start site was even more evident in ‘MLL-spreading’ genes, which showed little reduction in peak methylation levels seen in other groups. The shifting and near total depletion of H3K79me2 density from 4-day and 7-day 100 nM pinometostat treatment, respectively, is exemplified by several MLL-AF4 target loci (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1.F</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1.G</xref>).</p><p>The absence of correlation between H3K79me2 loss and reductions in gene expression suggests that this modification does not have a universal and proportionate effect on gene activation. Rather, it appears some MLL-AF4 targets have higher levels of H3K79me2 and are more sensitive to its depletion. It is possible that the higher methylation levels result in greater dependence on this modification for gene expression at a subset of MLL-AF4 targets. Given the correlation of H3K79me2 depletion with <italic>FLT3-ITD</italic> expression decrements (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), we next sought to determine if these consequences, were direct, and whether the functional consequences of DOT1L inhibition can be explained by this pathway.</p></sec><sec id="s2-4"><title>MLL-r cells with <italic>FLT3-ITD</italic> mutations are hypersensitive to both DOT1L and FLT3 inhibition</title><p>As our mechanistic analyses relied on MV4;11 cells (<italic>MLL-AF4</italic>, <italic>FLT3<sup>ITD/ITD</sup>)</italic>, we investigated the effects of low dose DOT1L inhibition on three other cell lines to determine whether <italic>FLT3-ITD</italic> could account for increased sensitivity to H3K79me2 ablation. Unlike MV4;11, the MOLM13 cell line harbors an <italic>MLL-AF9</italic> translocation and is heterozygous for the <italic>FLT3-ITD</italic> mutation (<xref ref-type="bibr" rid="bib86">Quentmeier et al., 2003</xref>), lesions that have been shown to cooperate to reduce the latency of leukemia onset in mice (<xref ref-type="bibr" rid="bib99">Stubbs et al., 2008</xref>). We also examined two MLL-translocation cell lines without <italic>FLT3</italic> mutations: THP-1 (<italic>MLL-AF9</italic>); and SEM (<italic>MLL-AF4</italic>). We note that previous studies of DOT1L inhibitor dosing sensitivity of some MLL-r cell lines (<xref ref-type="bibr" rid="bib23">Daigle et al., 2013</xref>) could be explained by the <italic>FLT3</italic> mutational status, although given the many other genetic background differences in outgrown cell lines it is reasonable that this correlation was not noted.</p><p>We treated all four cell lines with 100 nM pinometostat for 7 days. When comparing each cell line to its counterpart with the same MLL-translocation, those with the <italic>FLT3-ITD</italic> mutation were significantly more sensitive to DOT1L inhibition than those with normal <italic>FLT3</italic> alleles (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, left). After 7 days of 100 nM pinometostat treatment MV4;11 viability was drastically reduced by 74 ± 3% while the viability of SEM, its <italic>MLL-AF4</italic> counterpart with intact <italic>FLT3</italic>, was unaltered within experimental error. MOLM13 viability was somewhat reduced (21 ± 3%) while there was no significant difference in the viability of THP-1 cells. As in MV4;11 cells, MOLM13 cells displayed no change in <italic>HOXA9</italic> or <italic>MEIS1</italic> expression under these conditions (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>DOT1L inhibition reduces STAT5A activation and downregulates STAT5A targets in <italic>FLT3-ITD</italic> leukemia lines.</title><p>(<bold>A</bold>) MLL-rearranged leukemia lines with genotypes indicated were treated with 100 nM pinometostat (left panel, DOT1L inhibitor) or 30 nM tandutinib (right panel, FLT3 inhibitor MLN518), and relative growth monitored by CellTiter Glo 2.0 assay on the indicated days. Relative viability presented is the mean fraction of luminescence of treated versus side-by-side mock treated cultures (same volume of DMSO) for three independent replicates ± S.E.M. Student’s t-test (** p ≤ 0.01, *** p ≤ 0.001). (<bold>B</bold>) Western blots of phosphorylated STAT5 (active) or total STAT5A with H3 or HNRNPK as loading controls across the cell lines from panel A treated as indicated; H3K79me2 is monitored in pinometostat-treated lines to confirm inhibition. (<bold>C</bold>) Time course of gene expression by RT-qPCR, presented as mean fold-change of <italic>FLT3, PBX3, PIM1</italic>, and <italic>MEF2C</italic> in MV4;11 cells ± 100 nM pinometostat at each time point indicated ± S.E.M.; n = 3; Student’s t-test (ns p &gt; 0.05, * p ≤ 0.05, **** p ≤ 0.0001, ***** p &lt; 0.00001). (<bold>D-E</bold>) DOT1L and FLT3 inhibition downregulate STAT5A targets in <italic>FLT3-ITD</italic>. RT-qPCR expression analysis presented as mean fold-change ± S.E.M. for the indicated transcript in MV4;11 cells treated with indicated inhibitor versus mock-treatment for 7 days. Student’s t-test (** p &lt; 0.01, **** p &lt; 0.0001, ***** p &lt; 0.00001). (<bold>F</bold>) Proliferation assay as in panel A, with three clonal populations of MV4;11 cells virally transduced, selected, then induced to express shRNA to FLT3 (<xref ref-type="bibr" rid="bib34">Green et al., 2015</xref>) or a scrambled shRNA (<xref ref-type="bibr" rid="bib115">Yuan et al., 2009</xref>) control by 1 µg/mL doxycycline. Means of fractional viability relative to uninduced cells ± S.E.M. are shown for three independent experiments; Student’s t-test (** p &lt; 0.01). (<bold>G</bold>) RT-qPCR analysis of <italic>PIM1, PIM2</italic>, and <italic>ARID3B</italic> expression in MV4;11 cells expressing an inducible shRNA targeting FLT3 (<xref ref-type="bibr" rid="bib34">Green et al., 2015</xref>) for 7 days. Results are depicted as fold-change expression of control cells expressing shRNA to GFP (<xref ref-type="bibr" rid="bib91">Scheeren et al., 2005</xref>). (<bold>H</bold>) Proliferation assay of K562, PL-21, and EOL-1 cells treated with 10 µM or 100 nM pinometostat using CellTiter Glo 2.0 to measure viability, showing the luminescence fraction of inhibited over DMSO-treated cells. Means ± SE are shown for three independent experiments. Student’s t-test of day 7 (EOL-1 cells), day 9 (PL-21), or days 9 and 11 (K562 and PL-21) values: ns p &gt; 0.05, * p &lt; 0.05, **** p &lt; 0.0001. (<bold>I</bold>) Gene expression analysis by RT-qPCR in PL-21 cells treated for 9 days with 10 µM pinometostat. Results are displayed as fold-change over DMSO-treated cells with means ± SE for three independent experiments (ND = not detected). Student’s t-test (**** p &lt; 0.0001). (<bold>J</bold>) Western blots of (left) cell extract from PL-21 cells treated with 10 µM pinometostat for 9 days and (right) EOL-1 cells treated with 100 nM pinometostat for 7 days and then blotted for H3K79me2 and p-STAT5 with H2B or HNRNPK as a loading controls. (<bold>K</bold>) Gene expression analysis by RT-qPCR in EOL-1 cells treated for 7 days with 100 nM or 10 µM pinometostat. Results are displayed as fold-change over DMSO-treated cells with means ± SE for three independent experiments. Student’s t-test (ns p &gt; 0.05, **** p &lt; 0.0001).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>FLT3 knockdown reduces STA5A activation.</title><p>(<bold>A</bold>) RT-qPCR analysis of <italic>HOXA9</italic> and <italic>MEIS1</italic> expression from three independent experiments of MOLM13 cells treated with 100 nM pinometostat for 7 days. Fold change over DMSO-treated cells is depicted ± S.E.M. Student’s t-test (ns p &gt; 0.05). (<bold>B</bold>) (left) RT-qPCR analysis of <italic>FLT3</italic> and <italic>PIM1</italic> expression in MV4;11 cells ± 50 nM SGC0946 for 7 days. Results are displayed as mean fold-change vs. DMSO-treated cells ± S.E.M. of three independent experiments. Student’s t-test (* p &lt; 0.05, *** p ≤ 0.001). (right) Western blots from MV4;11 cells (left) treated with 50 nM SGC0946 for 7 days blotted for phosphorylated STAT5, H3K79me2, or histone H2B as a loading control. (right) MV4;11 cells treated with increasing concentrations of SGC0946 for 7 days blotted for H3K79me2 or H2B as a loading control. (<bold>C</bold>) Quantitative western blot of whole cell extracts from 3 experiments of MV4;11 cells ± 100 nM pinometostat for 7 days, stained with antibodies for phosphorylated STAT5 or histone H3 as a loading control. The blot includes a dilution series of the extract from the DMSO-treated sample one that encompasses the range of signal observed in each of the replicates and is used to calibrate a relative quantification of phosphorylated STAT5A signal integrated in ImageJ and shown in the bar graph at right as a 65 ± 8% reduction of the DMSO treated samples ± SD. Student’s t-test (** p &lt; 0.01). (<bold>D</bold>) Gene Set Enrichment Analysis (GSEA) (<xref ref-type="bibr" rid="bib100">Subramanian et al., 2005</xref>; <xref ref-type="bibr" rid="bib73">Mootha et al., 2003</xref>) of the set of downregulated genes in MV4;11 cells ± 100 nM pinometostat compared to genes upregulated by exogenous expression of constitutively active STAT5A in the WIERENGA_STAT5A_TARGETS GROUP1 gene set (<xref ref-type="bibr" rid="bib108">Wierenga et al., 2008</xref>) from the MSigDB database. (<bold>E</bold>) Bar graph of Cuffdiff (<xref ref-type="bibr" rid="bib101">Trapnell et al., 2012</xref>) output for the expression of STAT5A targets <italic>ARID3B</italic>, <italic>PIM1</italic>, and <italic>PIM2</italic> from RNA-seq in MV4;11 cells ± 100 nM pinometostat. Values are represented as log(10) FPKM + 1 for three independent experiments with standard deviation. Student’s t-test (** p &lt; 0.01, *** p &lt; 0.001). (<bold>F</bold>) RT-qPCR analysis of <italic>PBX3</italic>, <italic>PIM1, FLT3</italic>, and <italic>MEF2C</italic> expression from three independent experiments of MOLM13 cells treated with 100 nM pinometostat for 7 days. Fold change over DMSO-treated cells is depicted ± S.E.M. Student’s t-test (ns p &gt; 0.05, *** p &lt; 0.001, **** p &lt; 0.0001). (<bold>G</bold>) Proliferation assay of MV4;11 cells treated with DOT1L or FLT3 inhibitors alone or in combination using CellTiter Glo 2.0 to measure viability, showing the luminescence fraction of inhibited over uninhibited cells. Data are represented as mean ± SE of three independent experiments. Student’s t-test for significance of day 7 values: 100 nM pinometostat vs. combined ** p &lt; 0.01, 30 nM tandutinib vs combined *** p &lt; 0.001. (<bold>H</bold>) Same as G but cells were treated with DOT1L and PIM1 inhibitors alone or in combination. Student’s t-test of day 7 values: 100 nM pinometostat vs. combined * p &lt; 0.05, 10 µM quercetagenin vs combined ** p &lt; 0.01. Purple asterisks indicate Student’s t-test for significance of day 5 for 100 nM pinometostat vs. combination treatment ** p &lt; 0.01. (<bold>I</bold>) Western blots of MV4;11 cell extract from clonal cell lines expressing shRNA to FLT3 (clone 3) or GFP blotted for phosphorylated STAT5 or histone H3 as a loading control. (<bold>J</bold>) Western blots of cell extract from MV4;11 cells treated with 100 nM pinometostat for the indicated number of days and then blotted for H3K79me2 and HNRNPK as a loading control.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-fig4-figsupp1-v2.tif"/></fig></fig-group><p>If the heightened sensitivity of MLL-r cell lines to DOT1L inhibition is indeed mediated by reduced <italic>FLT3-ITD</italic> expression then we would expect to see a similar heightened sensitivity to disruption of FLT3 signaling. The small molecule tandutinib (MLN518) inhibits FLT3 kinase activity, severely reducing phosphorylation-mediated activation of downstream targets such as STAT5A (<xref ref-type="bibr" rid="bib19">Clark et al., 2004</xref>). We treated our MLL-r cell lines with 30 nM tandutinib for 7 days. As with the DOT1L inhibition experiments, cell lines with <italic>FLT3-ITD</italic> mutations were significantly more susceptible to the inhibitor’s effects (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, right). Given the variety of other genetic differences amongst these cell lines, these observations can at best be taken as consistent with the hypothesis that the co-occurring <italic>FLT3-ITD</italic> mutations may sensitize MLL-r leukemias to DOT1L inhibition, motivating us to seek more direct examination of FLT3 signaling.</p></sec><sec id="s2-5"><title>Impaired FLT3 signaling by DOT1L inhibition culminates in reduced transcription of STAT5A target genes</title><p>The <italic>FLT3-ITD</italic> mutation allows FLT3 to phosphorylate STAT5A, a transcription factor that is not activated by wild type FLT3 (<xref ref-type="bibr" rid="bib16">Choudhary et al., 2005</xref>). This aberrant STAT5A phosphorylation licenses translocation to the nucleus to drive target gene transcription, resulting in a hyperproliferative state necessary for leukemia cell survival (<xref ref-type="bibr" rid="bib80">Onishi et al., 1998</xref>; <xref ref-type="bibr" rid="bib17">Choudhary et al., 2007</xref>). We hypothesized that <italic>FLT3-ITD</italic> downregulation by DOT1L inhibition would thereby reduce STAT5A phosphorylation. Indeed, 100 nM pinometostat as well as SGC0946 treatment for 7 days reduced STAT5A phosphorylation in MV4;11 cells without affecting STAT5A protein levels (<xref ref-type="fig" rid="fig4">Figure 4B</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), where pinometostat reduced STAT5A phosphorylation by 65 ± 8% (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). We observed that pinometostat treatment slightly reduced STAT5 phosphorylation in MOLM13 cells, consistent with the lower <italic>FLT3-ITD</italic> allele dose, whereas lines with wild type <italic>FLT3</italic> (THP-1, SEM) did not display these effects. As a point of direct comparison, small molecule inhibition of FLT3 signaling yielded markedly reduced STAT5 phosphorylation in lines bearing the <italic>FLT3-ITD</italic> (MV4;11 and MOLM13), with a more modest reduction in SEM cells while phospho-STAT5 was barely detectable in THP-1 cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>).</p><p>To examine whether FLT3 effects precede other pro-proliferation pathways, we obtained more granular expression kinetics of several downregulated MLL-AF4 targets that have been implicated in leukemogenesis. Expression of <italic>FLT3, PBX3, PIM1</italic> and <italic>MEF2C</italic> was significantly reduced after 72 hr treatment with pinometostat (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), however, <italic>FLT3</italic> was the only gene whose expression was reduced 48 hr after treatment, suggesting it is more sensitive to H3K79me2 reductions than the others examined. Though <italic>FLT3</italic> and <italic>MEF2C</italic> are targets of the HOXA9-MEIS1-PBX3 complex, these genes are all targets of the MLL-fusion protein (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>). The reduction in <italic>FLT3</italic> expression in advance of decreased <italic>PBX3</italic> or <italic>MEF2C</italic> expression lends tentative support to the possibility that DOT1L inhibition directly affects <italic>FLT3</italic> gene expression independently of <italic>PBX3</italic> or <italic>MEF2C</italic>.</p><p>Given the early reductions in FLT3-ITD expression and reduced phosphorylation of its target STAT5A, we hypothesized that the pinometostat-induced reductions in proliferation were due to a loss of STAT5A signaling. We performed GSEA (<xref ref-type="bibr" rid="bib100">Subramanian et al., 2005</xref>; <xref ref-type="bibr" rid="bib73">Mootha et al., 2003</xref>) with the pinometostat-downregulated genes and genes upregulated by STAT5A overexpression in human CD34+ hematopoietic progenitors (<xref ref-type="bibr" rid="bib108">Wierenga et al., 2008</xref>) and observed a negative correlation indicative of significant pathway overlap (NES = −1.87, FDR = 0.003, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). We then reexamined our RNA-seq data for previously described STAT5A target genes downregulated by pinometostat and found several, including <italic>PIM1</italic> and <italic>ARID3B</italic> (<xref ref-type="bibr" rid="bib49">Kim et al., 2005</xref>; <xref ref-type="bibr" rid="bib88">Ribeiro et al., 2018</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>). The PIM proteins are a family of 3 protooncogene serine/tyrosine kinases (PIM1-3) that are upregulated in, and indicative of poor prognosis in leukemia, prostate, mesothelioma and other cancers (<xref ref-type="bibr" rid="bib70">Mizuki et al., 2003</xref>; <xref ref-type="bibr" rid="bib49">Kim et al., 2005</xref>; <xref ref-type="bibr" rid="bib2">Amson et al., 1989</xref>; <xref ref-type="bibr" rid="bib18">Cibull et al., 2006</xref>; <xref ref-type="bibr" rid="bib84">Peltola et al., 2009</xref>; <xref ref-type="bibr" rid="bib25">Deneen et al., 2003</xref>). However, only <italic>PIM1</italic> and <italic>PIM2</italic> expression is increased in FLT3 inhibitor-resistant <italic>FLT3-ITD</italic> patient samples and exogenous expression of either <italic>PIM1</italic> or <italic>PIM2</italic> can rescue proliferation defects caused by loss of FLT3 activity in MOLM14 cells (<italic>MLL-AF9</italic>, <italic>FLT3-ITD</italic> heterozygous) (<xref ref-type="bibr" rid="bib1">Adam et al., 2006</xref>; <xref ref-type="bibr" rid="bib34">Green et al., 2015</xref>; <xref ref-type="bibr" rid="bib30">Fathi et al., 2012</xref>). Although <italic>PIM1</italic> and <italic>PIM2</italic> are both downregulated in our RNA-seq analysis (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>), we observed a much greater reduction in <italic>PIM1</italic> expression by RT-qPCR (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Similar gene expression changes were also observed with a different DOT1L inhibitor (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). Treating MV4;11 cells with tandutinib (FLT3 inhibitor) resulted in downregulation of <italic>PIM1</italic>, <italic>ARID3B</italic>, and <italic>PBX3</italic> but not <italic>PIM2</italic> (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Treating MOLM13 cells with pinometostat also reduced expression of <italic>MEF2C, FLT3</italic> and <italic>PIM1,</italic> but caused no change in <italic>PBX3</italic> expression (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F</xref>).</p><p>If the FLT3 and DOT1L inhibitors have overlapping functions through inhibition or downregulation of <italic>FLT3,</italic> respectively, then we could potentially observe synergy in the effects on MV4;11 proliferation if we treated with both inhibitors simultaneously. We performed a coarse analysis using a combination of inhibitors at concentrations that individually have modest effects on proliferation to examine if they might produce a greater effect on viability when combined (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G</xref>). We also treated MV4;11 cells with the PIM1 inhibitor quercetegenin and observed increased toxicity when combining the inhibitors on day 5 that was overtaken by pinometostat only at day 7 when cell viability is very low for both treatments (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G</xref>). The DOT1L inhibitor has a delayed effect compared to the PIM1 and FLT3 inhibitors, which complicates comparisons, but nonetheless, through our coarse analysis of one set of concentrations for both inhibitors we observed small but significant differences in proliferation when using inhibitors singly or in combination.</p><p>To directly interrogate the effects of <italic>FLT3</italic> on MLL-r leukemia proliferation without complications from different genetic backgrounds, we used viral transduction to insert a tet-inducible shRNA targeting <italic>FLT3</italic> into MV4;11 cells. With modest knockdown of <italic>FLT3</italic> (<xref ref-type="fig" rid="fig4">Figure 4G</xref>), we observed significant reductions in the proliferation of three different clonal lines as compared to a scrambled shRNA (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). <italic>FLT3</italic> knockdown reduces MV4;11 proliferation and STAT5A phosphorylation (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1I</xref>), analogous to the effects of pinometostat treatment. Akin to the DOT1L and FLT3 inhibitors (<xref ref-type="fig" rid="fig4">Figure 4D–E</xref>), <italic>FLT3</italic> knockdown also significantly reduced the expression of the STAT5A target genes <italic>PIM1</italic> and <italic>ARID3B</italic>, with <italic>PIM2</italic> expression reduced in only 1 of 3 clones (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). We observe more modest reduction in STAT5A signaling upon FLT3-ITD knockdown compared to pinometostat treatment, perhaps indicating that other kinases such as JAK1-3 or TYK2, with previously observed roles in STAT5A activation, may also activate STAT5A in this context and further, that the function of one or more of these other kinases may also be reduced by pinometostat treatment (<xref ref-type="bibr" rid="bib83">Paukku and Silvennoinen, 2004</xref>). Interestingly, <italic>FLT3</italic> knockdown also resulted in <italic>PBX3</italic> downregulation, suggesting that FLT3 can regulate the expression of this oncogenic transcription factor, in line with previous observations (<xref ref-type="bibr" rid="bib11">Cauchy et al., 2015</xref>). Collectively, these data suggest that the DOT1L inhibitors may act, in part, by disrupting FLT3 signaling culminating in a reduction in STAT5A target expression and function.</p></sec><sec id="s2-6"><title>DOT1L inhibition reduces proliferation in MLL-PTD and non-MLL-rearranged FLT3 mutant leukemia</title><p>The pronounced sensitivity of the FLT3-ITD/STAT5A signaling axis to DOT1L inhibition raises the possibility that non-MLL-rearranged leukemias with FLT3-ITD mutations, representing 30–40% of acute myeloid leukemias, may also be susceptible to DOT1L inhibition. We observed a reduction in the viability of the <italic>FLT3-ITD</italic> heterozygous, non-MLL-rearranged leukemia cell line PL-21 after treatment with 10 µM pinometostat for 9 days (<xref ref-type="fig" rid="fig4">Figure 4H</xref>), accompanied by a reduction in both <italic>FLT3</italic> and <italic>PIM1</italic> expression (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). Whereas the viability of K562 cells, an erythroleukemic cell line with a BCR-ABL translocation was not affected after treatment with 10 µM pinometostat for 11 days. We observed reductions in H3K79me2 and STAT5A phosphorylation after 9 days pinometostat treatment, suggesting that DOT1L inhibition may also reduce the viability of non-MLL-rearranged FLT-ITD leukemias through disruption of FLT3-ITD/STAT5A signaling (<xref ref-type="fig" rid="fig4">Figure 4J</xref>). Furthermore, expression of the MLL-r leukemic drivers <italic>HOXA9</italic> and <italic>MEIS1</italic> were not detectable by RT-qPCR in PL-21 cells (<xref ref-type="fig" rid="fig4">Figure 4I</xref>), arguing that FLT3-ITD targeting by pinometostat is completely distinct.</p><p>In a previous study, DOT1L inhibition in leukemia cell lines with MLL1 partial tandem duplications (MLL-PTD) reduced cell viability, downregulated MLL1 target genes including <italic>HOXA9</italic> and induced apoptosis and differentiation (<xref ref-type="bibr" rid="bib56">Kühn et al., 2015</xref>). We recapitulate these findings with 10 µM pinometostat reduced EOL-1 (MLL-PTD, intact <italic>FLT3</italic>) proliferation and <italic>HOXA9</italic> expression, noting also reductions in <italic>FLT3</italic> and <italic>PIM1</italic> expression but no change in <italic>MEIS1</italic> expression (<xref ref-type="fig" rid="fig4">Figure 4H,K</xref>). Surprisingly, a 10-fold lower dose of pinometostat also reduced EOL-1 viability (<xref ref-type="fig" rid="fig4">Figure 4H</xref>) and <italic>FLT3</italic> expression with no discernable changes in <italic>HOXA9, MEIS1</italic> or <italic>PIM1</italic> expression (<xref ref-type="fig" rid="fig4">Figure 4K</xref>). This finding is congruent with and potentially explains how low-dose pinometostat treatment was able to reduce the viability of EOL-1 xenografts in rats without affecting <italic>HOXA9</italic> expression (<xref ref-type="bibr" rid="bib56">Kühn et al., 2015</xref>). There was no observable reduction in STAT5A phosphorylation after 7 days 100 nM pinometostat (<xref ref-type="fig" rid="fig4">Figure 4J</xref>), consistent with previous studies showing that WT <italic>FLT3</italic> has little effect on STAT5A activation (<xref ref-type="bibr" rid="bib16">Choudhary et al., 2005</xref>). WT <italic>FLT3</italic> is typically upregulated by MLL-fusions and is able to activate other pathways involved in cell growth and proliferation such as PI3K/AKT (<xref ref-type="bibr" rid="bib4">Armstrong et al., 2002</xref>; <xref ref-type="bibr" rid="bib11">Cauchy et al., 2015</xref>; <xref ref-type="bibr" rid="bib16">Choudhary et al., 2005</xref>) One or more of these FLT3-activated growth signaling pathways may be essential for EOL-1 and MLL-PTD leukemia cell survival just as the STAT5A signaling pathway appears to be for FLT3-ITD leukemia. To further interrogate the H3K79me2-dependence of leukemia survival on FLT3-ITD/STAT5A signaling, we sought to ectopically restore this signaling pathway upon DOT1L inhibition to potentially rescue viability.</p></sec><sec id="s2-7"><title>Overexpression of constitutively active STAT5A rescues proliferation and reductions in gene expression caused by DOT1L inhibition</title><p>Unfortunately, overexpression of <italic>FLT3-ITD</italic> for an attempted rescue of DOT1L inhibition proved technically challenging, as retrovirally introduced ectopic expression was rapidly silenced or dropped out during selection as has been observed in other contexts (<xref ref-type="bibr" rid="bib96">Spiekermann et al., 2002</xref>). To further interrogate this pathway’s functional significance, we sought to perturb signaling downstream of FLT3-ITD via STAT5A alterations.</p><p>To potentiate STAT5A activity, we overexpressed a constitutively active STAT5A mutant to examine whether this could counteract the reduction of upstream FLT3-ITD levels by DOT1L inhibition. STAT5A is ‘activated’ through phosphorylation at multiple sites, facilitating translocation into the nucleus and activation of gene targets. Previous work showed that H299R and S711F mutations create a constitutively active murine <italic>Stat5a</italic> able to activate target genes independently of upstream signaling (<xref ref-type="bibr" rid="bib80">Onishi et al., 1998</xref>), which phenocopies the effects of exogenous <italic>FLT3-ITD</italic> expression including hyperproliferation and inhibition of myeloid maturation (<xref ref-type="bibr" rid="bib72">Moore et al., 2007</xref>). We used a lentiviral system to generate individual MV4;11 clonal cell lines with stably incorporated, inducible human <italic>STAT5A</italic> mutated at the corresponding residues H298R and S710F (<italic>STAT5A-CA</italic>), all of which exhibit several-fold induction with doxycycline (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Ectopic expression of <italic>STAT5A-CA</italic> was able to partially rescue proliferation when challenged with 30 nM FLT3 inhibitor tandutinib, confirming the capacity of this mutant to complement impaired FLT3-ITD signaling (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Exogenous expression of constitutively active <italic>STAT5A</italic> partially rescues proliferation and gene expression effects of DOT1L inhibition.</title><p>(<bold>A</bold>) RT-qPCR analysis of <italic>STAT5A</italic> expression from three monoclonal isolates of MV4;11 cells virally transduced with a tet-inducible constitutively active <italic>STAT5A</italic> (<italic>STAT5A-CA</italic>) depicted as fold-change over untransduced cells with standard error of the mean. Student’s t-test (* p &lt; 0.05, *** p &lt; 0.001). (<bold>B</bold>) Proliferation assay of MV4;11 clonal isolates from panel <bold>A</bold>. induced to express <italic>STAT5A-CA</italic> or eGFP with 1 µg/mL doxycycline and treated concomitantly with 100 nM pinometostat. We determined the fractional viability of each clone as the luminescence from a CellTiter Glo 2.0 assay with pinometostat-treatment normalized to DMSO-treated cells, both induced to express <italic>STAT5A-CA or eGFP</italic>, to accommodate for any potential increases in viability. Means ± SE are shown for three independent experiments with Student’s t-test for day 7 values (**** p ≤ 0.0001). (<bold>C</bold>) Gene expression analysis by RT-qPCR of STAT5A target genes in WT MV4;11 cells or MV4;11 <italic>STAT5A-CA</italic> clones from <bold>A</bold>. induced with 1 µg/mL doxycycline and treated with 100 nM pinometostat for 7 days. Results are displayed as fold-change over DMSO-treated WT cells. (<bold>D</bold>) Quantitative measurement by flow cytometry of live, apoptotic (Annexin V-FITC) and necrotic cells (propidium iodide) of WT MV4;11 cells or cells exogenously expressing <italic>STAT5A-CA</italic> (clone 1) and treated with increasing concentrations of pinometostat. Images of gated FITC vs. PI signal are shown for one of three independent experiments, with all replicates quantified in the bar plot in <bold>E</bold>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title><italic>STAT5A-CA</italic> overexpression partially rescues proliferation and gene expression effects caused by FLT3 inhibition.</title><p>(<bold>A</bold>) Western blots of whole cell extracts from WT MV4;11 cells or three clonal lines isolated from MV4;11 cells virally transduced with constitutively active <italic>STAT5A</italic> (<italic>STAT5A-CA</italic>). Membranes were blotted for STAT5 or GAPDH as a loading control.(<bold>B</bold>) Proliferation assay of MV4;11 clonal isolates overexpressing <italic>STAT5A-CA</italic> or GFP through induction with 1 µg/mL doxycycline and treated with 30 nM tandutinib using CellTiter Glo 2.0 to measure viability, showing the luminescence fraction of inhibited over uninhibited cells, both with induced transgene (either STAT5A-CA or eGFP). Means ± SE are shown for three independent experiments. Student’s t-test of day 7 values: ** p &lt; 0.01. (<bold>C</bold>) Proliferation assay done as in <bold>B</bold>. with MV4;11 WT or virally transduced with <italic>GFP</italic> or <italic>MEF2C-GFP</italic> and induced to express either construct with 1 µg/mL doxycycline and treated with 100 nM pinometostat. Means ± SE are shown for three independent experiments. Student’s t-test of day 7 values: ns p &gt; 0.05. (<bold>D</bold>) Gene expression analysis by RT-qPCR of STAT5A target genes in WT MV4;11 cells or MV4;11 <italic>STAT5A-CA</italic> clones from <bold>A</bold> induced with 1 µg/mL doxycycline to express STAT5A-CA and treated with 30 nM tandutinib for 7 days. Results are displayed as fold-change over DMSO-treated WT cells. (<bold>E</bold>) Proliferation assay of MV4;11 <italic>STAT5A-CA</italic> clones or GFP as in <bold>B</bold>, treated with 50 nM SGC0946. Means ± SE are shown for three independent experiments. Student’s t-test of day 7 values: ** p &lt; 0.01, * p &lt; 0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Remarkably, <italic>STAT5A-CA</italic> overexpression also rescued pinometostat-induced proliferation reductions (<xref ref-type="fig" rid="fig5">Figure 5B</xref>) in proportion to each clone’s <italic>STAT5A-CA</italic> expression level (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Similar results were also observed with a different DOT1L inhibitor (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>). Clone three was unable to rescue proliferation substantially, perhaps because it had the lowest expression of <italic>STAT5A/STAT5A-CA</italic> (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and S5E). As another control, we similarly overexpressed MEF2C, yet it displayed no effect on the viability of MV4;11 cells treated with 100 nM pinometostat (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>).</p><p>To gain a molecular understanding of how ectopic <italic>STAT5A-CA</italic> expression could rescue proliferation of inhibitor-treated cells, we measured expression of the STAT5A targets <italic>PIM1</italic>, <italic>PIM2</italic>, and <italic>ARID3B</italic> by RT-qPCR. Expression of <italic>STAT5A-CA</italic> restored expression of <italic>PIM1</italic>, <italic>PIM2</italic>, and <italic>ARID3B</italic> in both DOT1L inhibitor- and FLT3 inhibitor-treated MV4;11 cells (<xref ref-type="fig" rid="fig5">Figure 5C</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>).</p><p>Because ectopic expression of <italic>STAT5A-CA</italic> is able to rescue proliferation of MV4;11 cells and the expression of STAT5A targets including the anti-apoptotic <italic>PIM1</italic> oncogene, we examined whether <italic>STAT5A-CA</italic> overexpression could rescue MV4;11 cells from apoptosis. A previous study observed that ~30% of MV4;11 cells treated with 1 µM pinometostat for 6 days were undergoing apoptosis (<xref ref-type="bibr" rid="bib23">Daigle et al., 2013</xref>). We analyzed apoptosis in MV4;11 cells treated with increasing concentrations of pinometostat for 7 days (<xref ref-type="fig" rid="fig5">Figure 5D and E</xref>). We observed 25.5 ± 0.3% apoptotic cells when treating with 1 µM pinometostat and a still sizeable proportion (15 ± 1%) of apoptotic cells when treating with just 100 nM pinometostat. Yet upon treatment of STAT5A-CA clone 1 with 100 nM pinometostat for 7 days, we observed no significant induction of apoptosis as compared to the DMSO control (<xref ref-type="fig" rid="fig5">Figure 5D and E</xref>). Thus, we concluded that recovering STAT5A function can rescue MV4;11 cells from apoptosis induced by 100 nM pinometostat. It is striking that despite marked gene expression changes caused by low-dose DOT1L inhibition, one signaling pathway, FLT3-ITD to STAT5A, is able to account for the bulk of the phenotypic and molecular changes we measured. Given that the rescue was nevertheless incomplete, we investigated other potential secondary contributors to the proliferation and gene expression consequences of low-dose DOT1L inhibition.</p></sec><sec id="s2-8"><title>An ancillary DOT1L-dependent pathway limits proliferation through PRC2 signaling</title><p>Although H3K79me2 potentiates transcription, our RNA-seq analysis revealed the upregulation of thousands of genes when treating with pinometostat. One potential explanation for this effect is the downregulation of the repressive PRC2 complex members <italic>EZH2</italic> and <italic>EED</italic> and consequent reductions in global levels of the transcriptionally repressive H3K27me3 mark (<xref ref-type="fig" rid="fig6">Figure 6A–B</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). PRC2 deposits the facultative heterochromatin H3K27me3 modification and, although antagonistic to MLL1 and H3K4me3 deposition (<xref ref-type="bibr" rid="bib50">Kim et al., 2013</xref>), is necessary for MLL-r leukemogenesis (<xref ref-type="bibr" rid="bib95">Shi et al., 2013</xref>; <xref ref-type="bibr" rid="bib118">Zhou et al., 2011</xref>; <xref ref-type="bibr" rid="bib77">Neff et al., 2012</xref>). Analysis by quantitative ICeChIP revealed that 100 nM pinometostat decreased H3K27me3 genome-wide (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Promoter H3K27me3 levels are reduced by 2–5% on average with more pronounced decreases observed among downregulated genes and MLL-AF4 targets than upregulated or all genes (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). However, H3K27me3 levels in untreated cells were much higher in pinometostat-upregulated genes, perhaps indicating that these genes are more reliant on PRC2 to buffer their expression. H3K27me3 levels are lower throughout gene bodies in DOT1L inhibited cells, as apparent at individual loci (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D-G</xref>). Analysis by ICeChIP-qPCR of H3K27me3 through two additional independent experiments focusing on representative promoters of genes both up- and downregulated by 100 nM pinometostat revealed methylation reductions consistent with the sequencing data (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1H</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>PRC2 function is an ancillary pathway dependent on DOT1L and necessary for leukemia proliferation.</title><p>(<bold>A</bold>) RT-qPCR analysis of the components of the polycomb complex <italic>EZH2</italic> and <italic>EED</italic> expression in MV4;11 cells ± 100 nM pinometostat for 7 days. Results are displayed as mean fold-change vs. DMSO-treated cells ± S.E.M. of three independent experiments. Student’s t-test (*** p &lt; 0.001, **** p &lt; 0.0001). (<bold>B</bold>) Western blot of EZH2, H3K27me3 and LEDGF as loading control in MV4;11 cells treated ± 100 nM pinometostat for 7 days. (<bold>C</bold>) Quantitative ICe-ChIP-seq from MV4;11 cells treated with 100 nM pinometostat for 7 days displaying H3K27me3 histone methylation density contoured over promoters from −2000 to +4000 of the TSS of either all expressed genes, genes up- or downregulated by 100 nM pinometostat or MLL-AF4 target genes (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>). (<bold>D</bold>) Western blot for H3K27me3 with GAPDH as a loading control in MV4;11 cells treated with EI1 for 7 days. (<bold>E</bold>) RT-qPCR analysis of MHC class II genes and master regulator <italic>CIITA</italic> expression from MV4;11 cells ± 10 µM EZH2 inhibitor EI1. Results are displayed as mean fold-change vs. DMSO-treated cells ± S.E.M. of three independent experiments. Student’s t-test (** p = 0.01, *** p = 0.001). (<bold>F</bold>) Fold change of RT-qPCR analysis of gene expression MV4;11 cells ± 10 µM EZH2 inhibitor EI1. Results are the average three independent experiments ± S.E.M. Student’s t-test (* p &lt; 0.05, ** p &lt; 0.01, *** p = 0.001). (<bold>G</bold>) Proliferation assay of MV4;11 cells virally transduced with tet-inducible EZH2 or eGFP treated with 100 nM pinometostat and induced with 1 µg/mL doxycycline to express EZH2 or eGFP for 7 days showing the luminescence fraction of inhibited over uninhibited from a CellTiter Glo 2.0 assay. Means ± SE are shown for three independent experiments. Student’s t-test of day 7 values (** p = 0.01).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>PRC2 inhibition reduces leukemia survival without affecting STAT5A actiation.</title><p>(<bold>A</bold>) Bar graph of Cuffdiff (<xref ref-type="bibr" rid="bib101">Trapnell et al., 2012</xref>) output for the expression of polycomb complex members.<italic> EED</italic> and <italic>EZH2</italic> from RNA-seq in MV4;11 cells ± 100 nM pinometostat for 7 days. Values are represented as log(10) FPKM + 1 for three independent experiments with standard deviation. Student’s t-test (** p &lt; 0.01). (<bold>B</bold>) Proliferation assay of MV4;11 cells treated with 10 µM EI1 EZH2 inhibitor using CellTiter Glo 2.0 to measure viability, showing the luminescence fraction of inhibited over DMSO-treated cells. Means ± SE are shown for three independent experiments. Student’s t-test of day 7 values: * p &lt; 0.05, ** p &lt; 0.01. (<bold>C</bold>) Western blot of extract from MV4;11 cells ± 10 µM EI1 for 7 days and blotted for phosphorylated STAT5 or GAPDH as a loading control. (<bold>D-G</bold>) ICeChIP-seq tracks of H3K79me2, H3K27me3, and H3K4me3 HMD and an RNA-seq track (FPKM) from a single replicate for MV4;11 cells treated with 100 nM pinometostat or DMSO for 7 days for MLL-AF4 (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>) and STAT5A (<xref ref-type="bibr" rid="bib72">Moore et al., 2007</xref>) target genes: (<bold>D</bold>) <italic>MEF2C</italic>; (<bold>E</bold>) <italic>PIM1;</italic> (<bold>F</bold>) the HOXA gene cluster and G. <italic>PBX3</italic>. H. Validation by two additional independent H3K27me3 ICeChIP experiments, quantified by qPCR at the TSS compared to average HMD of a 500 bp region at the TSS from the ICe-ChIP-seq experiment (hash marked) at a number of loci where there was a detectable loss of H3K27me3 upon pinometostat treatment observed in the ICeChIP-seq experiment (the intergenic region displayed little change in the seq experiment).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-fig6-figsupp1-v2.tif"/></fig></fig-group><p>We next sought to interrogate the functional impact of the PRC2 signaling axis by experimental perturbation. As PRC2 is necessary for repression of <italic>IFNG</italic> (IFN-γ) and proper differentiation in T-cells (<xref ref-type="bibr" rid="bib7">Borkin et al., 2015</xref>), we wondered if the upregulated genes found in our RNA-seq analysis, many of which are components of the IFN-γ-response, were upregulated as a result of a loss of H3K27me3-mediated repression. To investigate this possibility, we treated MV4;11 cells with 10 µM EI1 EZH2 inhibitor (<xref ref-type="bibr" rid="bib102">Ueda et al., 2014</xref>) and observed dramatically reduced global H3K27me3 (<xref ref-type="fig" rid="fig6">Figure 6D</xref>) and proliferation (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>), consistent with previously observed sensitivities of MOLM13 and MV4;11 (<xref ref-type="bibr" rid="bib102">Ueda et al., 2014</xref>). EI1 treatment had comparatively little effect on the class of genes massively overexpressed during DOT1L inhibition (<xref ref-type="fig" rid="fig6">Figure 6E</xref>, compare to <xref ref-type="fig" rid="fig2">Figure 2D and E</xref>). Surprisingly, EZH2 inhibition downregulated <italic>HOXA9</italic> and <italic>MEIS1</italic> expression (which only occurs with higher doses of pinometostat <xref ref-type="bibr" rid="bib23">Daigle et al., 2013</xref>), with no changes in <italic>FLT3</italic> expression (<xref ref-type="fig" rid="fig6">Figure 6F</xref>) or STAT5 phosphorylation (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>). The greater reduction in global H3K27me3 from 10 µM EI1 than 100 nM pinometostat may account for the lack of effect on <italic>HOXA9</italic> and <italic>MEIS1</italic> expression by pinometostat. Collectively, these data argue that the PRC2 pathway is largely independent of the FLT3-ITD-STAT5A pathway, culminating in distinct target gene expression consequences, that may converge for only a few targets, such as <italic>PIM1</italic> and <italic>ARID3B</italic>.</p><p>Next, we queried the functional consequences of rescuing EZH2 expression in the context of low-dose DOT1L inhibition. Inducible overexpression of <italic>EZH2</italic> was only able to partially rescue proliferation in M4;11 cells treated with pinometostat, suggesting that a small portion of the effects on MV4;11 viability is due to reduced PRC2 function (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). The nearly complete rescue from intervening in the FLT3-ITD-STAT5A pathway compared to the modest rescue from PRC2, suggests that the former is the predominant source of pinometostat-induced effects on proliferation in this leukemia background.</p></sec><sec id="s2-9"><title>STAT5A-CA overexpression rescues the viability of MV4;11 cells treated with MLL1 inhibitors</title><p>Our observations suggest that most of the toxicity from low-dose DOT1L inhibition in MLL-r, <italic>FLT3-ITD+</italic> leukemia cell lines stems from downregulation of <italic>FLT3</italic> and subsequent loss of STAT5A phosphorylation. We wanted to know if this effect was specific to H3K79me2 depletion, or attributable to disruption of MLL-fusion-induced gene activation. To distinguish between these two mechanisms, we employed small-molecule MLL1 inhibitors, potent and effective treatments for MLL-r leukemia (<xref ref-type="bibr" rid="bib10">Cao et al., 2014</xref>; <xref ref-type="bibr" rid="bib7">Borkin et al., 2015</xref>), as orthologous means of disrupting MLL-fusion function. These compounds inhibit MLL1 in different ways but both disrupt the leukemic gene expression profile, specifically downregulating the oncogenes <italic>HOXA9</italic>, <italic>MEIS1</italic>, <italic>FLT3</italic> and <italic>BCL2</italic> (<xref ref-type="bibr" rid="bib10">Cao et al., 2014</xref>; <xref ref-type="bibr" rid="bib7">Borkin et al., 2015</xref>). MI-503 competitively antagonizes binding of MENIN to MLL1, an interaction that is necessary for MLL-fusion complex localization to target genes and leukemogenesis (<xref ref-type="bibr" rid="bib7">Borkin et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Li et al., 2013a</xref>; <xref ref-type="bibr" rid="bib113">Yokoyama et al., 2005</xref>). Another small molecule, MM-401 inhibits the methyltransferase activity of MLL1 by disrupting its interaction with WDR5, a complex member necessary for full enzymatic activity of MLL1 but not MLL2-4 or SET1 complexes (<xref ref-type="bibr" rid="bib10">Cao et al., 2014</xref>). We treated MLL-r cell lines with low concentrations of MI-503 or MM-401 and observed greater reductions in the proliferation of <italic>MLL-r</italic>, <italic>FLT3-ITD+</italic> cells than their WT <italic>FLT3</italic> counterparts (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>STAT5A-CA overexpression rescues the viability of MV4;11 cells treated with MLL1 inhibitors.</title><p>Proliferation assay of MLL-r cell lines treated with (<bold>A</bold>) 250 nM MI-503 (MLL1-Menin interaction inhibitor) or (<bold>B</bold>) 10 µM MM-401 (MLL1 histone methyltransferase inhibitor) for 7 days. Viability was measured by CellTiter Glo 2.0 assay and results are displayed as the fraction of luminescence of inhibitor-treated over DMSO-treated cells. Means ± SE are shown for three independent experiments. Student’s t-test (* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001). (<bold>C</bold>) H3K4me3 histone methylation density from −2000 to +2000 of the TSS from quantitative ICeChIP-seq from MV4;11 cells treated with 100 nM pinometostat for 7 days for genes up- or downregulated by 100 nM pinometostat, the most highly expressed genes, MLL-AF4 target genes (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>) as well as those MLL-AF4 targets downregulated by 100 nM pinometostat. (<bold>D</bold> and <bold>E</bold>) Proliferation assay of MV4;11 <italic>STAT5A-CA</italic> clonal isolates induced to express <italic>STAT5A-CA</italic> or eGFP with 1 µg/mL doxycycline and treated with <bold>D</bold>. 250 nM MI-503 or (<bold>E</bold>) 10 µM MM-401. Viability was measured and results displayed as in A and B. Means ± SE are shown for three independent experiments. Student’s t-test (* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001). (<bold>F</bold>) Gene expression analysis by RT-qPCR of MLL-fusion and STAT5a targets in MV4;11 cells treated with 250 nM MI-503 MLL1 inhibitor, 100 nM pinometostat DOT1L inhibitor or a combination for 7 days. Means ± S.E.M. are shown for three independent experiments (* p &lt; 0.05). (<bold>G</bold>) Gene expression analysis by RT-qPCR of MLL-fusion and STAT5A targets in WT and STAT5A-CA MV4;11 cells treated with 250 nM MI-503 MLL1 inhibitor for 7 days. Means ± S.E.M. are shown for technical replicates of individual experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>MLL1 inhibitors reduce STAT5A phosphorylation.</title><p>(<bold>A</bold>) Western blots of whole cell extract from MV4;11 cells treated with 100 nM pinometostat for 7 days and blotted for H3K4me3 or LEDGF as a loading control. (<bold>B</bold>) Western blots of whole cell extract from MV4;11 cells treated with MLL1 inhibitors MI-503 (250 nM) or MM-401 (10 µM) or DMSO for 7 days and blotted for histone H3 lysine four trimethylation (H3K4me3) or GAPDH as a loading control. (<bold>C</bold>) Western blots of MV4;11 cell extract treated with MLL1 inhibitors MI-503 (250 nM) or MM-401 (10 µM) for 7 days and blotted for phosphorylated STAT5, histone H3 lysine 79 dimethylation (H3K79me2) or GAPDH as a loading control. (<bold>D</bold>) H3K79me2 meta promoter profiles ± 2000 bp of the TSS as in <xref ref-type="fig" rid="fig7">Figure 7C</xref>, representing 4 days, rather than seven days of 100 nM pinometostat treatment versus DMSO control. (<bold>E</bold>) ICe-ChIP-qPCR analysis of the percent H3K4me3 at the promoters of several genes both upregulated (BCL6, CSF3R, HLA-DRA) and downregulated (MEF2C, PIM1, ARID3B, and FLT3) by pinometostat as well as MLL-AF4 targets (HOXA9 and MEIS1) and an intergenic region (with little change) from two experiments as well as ICe-ChIP-seq (hashed lines) in MV4;11 cells ± 100 nM pinometostat for 7 days. Note that ICeChIP qPCR values are often slightly inflated as due to the capture of dinucleosomes that are over-represented due to avidity bias that are normally filtered out in ICeChIP. (<bold>F</bold>) MV4;11 cells were treated with DOT1L or MLL1 inhibitors alone or in combination for 7 days. Viability was analyzed using CellTiter Glo 2.0, showing the luminescence fraction of inhibited over DMSO-treated cells. Means ± SE are shown for three independent experiments. Student’s t-test of day 7 values: 100 nM pinometostat vs. 100 nM pinometostat + 250 nM MI-503 ** p &lt; 0.01 100 nM pinometostat vs. 100 nM pinometostat + 10 µM MM-401 * p &lt; 0.05. (<bold>G</bold>) Model of MLL-fusion-mediated activation of HOXA9/MEIS1 and STAT5A co-targets in MLL-r, <italic>FLT3-ITD+</italic> leukemia. MLL-AF4 activates <italic>HOXA9</italic>, <italic>MEIS1</italic>, and <italic>FLT3-ITD</italic> gene expression through recruitment of DOT1L and H3K79me2 hypermethylation (fuchsia). FLT3-ITD phosphorylates STAT5A allowing it to translocate to the nucleus to cooperatively bind HOXA9/MEIS1 targets with PBX3 and facilitate gene activation. (<bold>H</bold>) Scatterplot from ICeChIP-seq of MV4;11 cells ± 100 nM pinometostat of the log<sub>2</sub> (fold-change HMD of H3K79me2 vs. H3K4me3) of all expressed genes showing MLL-AF4 targets (red) and MLL-AF4 targets downregulated by pinometostat (purple). (<bold>I</bold>) The average fold-change in H3K4me3 HMD from ICeChIP-seq of MV4;11 cells ± 100 nM pinometostat at expressed genes in 20 bins grouped by decreasing expression (bin 1–20 sorted by highest to lowest FPKM of DMSO-treated cells).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-fig7-figsupp1-v2.tif"/></fig></fig-group><p>Given the similar effects of DOT1L and MLL1 inhibitors on MLL-r cell proliferation and gene expression, that both histone modifications are involved in transcriptional activation and the extensive literature describing dynamic cross-talk between chromatin modifications (<xref ref-type="bibr" rid="bib50">Kim et al., 2013</xref>; <xref ref-type="bibr" rid="bib15">Chen et al., 2015b</xref>; <xref ref-type="bibr" rid="bib92">Schmitges et al., 2011</xref>; <xref ref-type="bibr" rid="bib104">Voigt et al., 2012</xref>) we were curious as to how perturbations in H3K79 methylation might affect the distribution of H3K4me3. In order to accurately quantify histone methylation and observe differences in modification densities, we performed ICeChIP-seq for H3K4me3 in MV4;11 cells treated with pinometostat. H3K4me3 is deposited at promoters during active transcriptional initiation and promotes gene expression through several established mechanisms (<xref ref-type="bibr" rid="bib103">Vermeulen et al., 2007</xref>; <xref ref-type="bibr" rid="bib112">Yokoyama et al., 2004</xref>; <xref ref-type="bibr" rid="bib54">Krogan et al., 2002</xref>). Surprisingly, pinometostat treatment increased H3K4me3 at transcription start sites (TSS’s) genome-wide, with the largest increases at genes downregulated by pinometostat (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Pinometostat-downregulated MLL-AF4 targets had the highest H3K4me3 levels of all gene categories examined (<xref ref-type="fig" rid="fig7">Figure 7C</xref>), not only at the TSS but spreading downstream into the gene body, suggesting that the MLL-fusion protein is driving this increase. Similar upregulation is observed after only 4 days of pinometostat treatment (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D</xref>), and in two additional ICeChIP-seq experiments at 7 days of treatment we observed increases in promoter H3K4me3 by qPCR consistent with our ICeChIP-seq results at genes up and downregulated by pinometostat as well as MLL-AF4 targets (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1E</xref>). Reductions in H3K79me2 from pinometostat treatment are poorly correlated with increases in H3K4me3 (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1H</xref>), incompatible with a direct antagonism cross-talk mechanism. MLL-AF4 targets, particularly those downregulated by low-dose pinometostat, are slightly skewed toward increases in H3K4me3. Despite gains of the H3K4me3 mark during treatment, these genes are downregulated, consistent with a decoupling of active transcription initiation from productive elongation, the latter of which is more effectively correlated with H3K79me2 and H3K36me3 (<xref ref-type="bibr" rid="bib38">Guenther et al., 2007</xref>). However, when examining H3K4me3 fold changes stratified by gene expression level, we do not observe larger increases in H3K4me3 at more transcriptionally active genes, suggesting that the increase in H3K4me3 is not due to iterative methylation by MLL1 associated with a stalled pol II (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1I</xref>).</p><p>Intriguingly, the putative antagonism between modifications is not apparent in global H3K4me3 levels during DOT1L inhibition (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). However, reductions in H3K4me3 from MLL1 inhibitor treatment are also not readily apparent by Western blot, similar to what has been observed in other studies (<xref ref-type="bibr" rid="bib10">Cao et al., 2014</xref>; <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>). Conversely, global increases in H3K79me2 are more pronounced when treating cells with the MLL1 inhibitors (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C</xref>). Treatment with the MLL1 inhibitors also reduced STAT5A phosphorylation, suggesting that this orthologous means of disrupting MLL-fusion gene activation also reduces FLT3-ITD/STAT5A signaling (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C</xref>).</p><p>As with the DOT1L and FLT3 inhibitors, overexpression of <italic>STAT5A-CA</italic> was able to partially rescue survival of MV4;11 cells treated with MI-503 (<xref ref-type="fig" rid="fig7">Figure 7D</xref>), with the degree of rescue corresponding to the amount of <italic>STAT5A</italic> expression in each clone (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). When treated with the MM-401 inhibitor, STAT5A-CA clone 1 (with the highest exogenous <italic>STAT5A-CA</italic> expression), completely rescued proliferation (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). Unexpectedly, clones 2 and 3, that express <italic>STAT5A-CA</italic> at lower levels both displayed reduced proliferation when treated with MM-401 compared to WT or GFP-expressing cells (<xref ref-type="fig" rid="fig7">Figure 7E</xref>).</p><p>We observed an additive effect on proliferation when MV4;11 cells were co-treated with the MLL1 and DOT1L inhibitors (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1F</xref>), suggesting that either the inhibitors target different sets of genes through different mechanisms, or have an additive effect on the same genes. To distinguish between these two models, we compared gene expression of several MLL-AF4 and STAT5A targets in MV4;11 cells treated with MI-503 alone or MI-503 with pinometostat for 7 days (<xref ref-type="fig" rid="fig7">Figure 7F</xref>). Akin to low dose DOT1L inhibitor treatment, MI-503 reduced expression of <italic>FLT3</italic>, <italic>MEF2C, ARID3B</italic> and <italic>PIM1</italic>. The reduction in <italic>FLT3</italic> expression was only 30 ± 10% but doubled to 60 ± 10% when both inhibitors were used, recapitulating the 60% reduction observed with pinometostat alone. MI-503 had no significant effect on <italic>PBX3</italic> expression but both inhibitors reduced <italic>PBX3</italic> expression to 50 ± 10%, the same as the DOT1L inhibitor alone. However, unlike low-dose pinometostat, MI-503 treatment starkly reduced expression of <italic>HOXA9</italic> and <italic>MEIS1</italic> and combination treatment further reduced <italic>MEIS1</italic> expression from 40% to 30%. Taken together, low dose MLL1 and DOT1L inhibitors downregulate different, yet partially overlapping sets of genes (with <italic>FLT3</italic>, <italic>MEF2C</italic>, and <italic>PIM1</italic> in common), that are necessary for MLL-rearranged leukemia, consistent with the synergism arising from largely distinct pathways.</p><p>We wondered whether the <italic>STAT5A-CA</italic>-mediated rescue of proliferation in MV4;11 cells treated with MI-503 coincided with a rescue of STAT5A target genes. We examined expression of these targets in our 3 <italic>STAT5A-CA</italic> clones after treating cells with MI-503 for 7 days and observed increased expression of the STAT5A target genes <italic>PIM1, PIM2</italic>, and <italic>ARID3B</italic> (<xref ref-type="fig" rid="fig7">Figure 7G</xref>). Collectively, these data suggest that downregulation of <italic>FLT3-ITD</italic>, and crucially, reductions in STAT5A phosphorylation and gene activation are more sensitive to perturbations of MLL-fusion-mediated gene activation and are the main source of inhibitor effects on leukemia cell survival when expression of the canonical MLL-r proliferation mediators <italic>HOXA9</italic> and <italic>MEIS1</italic> are not substantially affected (model, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1G</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Little is known about why MLL-r leukemia cell lines have such disparate sensitivities to DOT1L inhibitors or how MLL-fusions might cooperate with co-occurring lesions. By investigating the effects of a DOT1L inhibitor at a low, as yet unexplored concentration, we revealed that MLL-r cell lines carrying <italic>FLT3-ITD</italic> lesions are more sensitive to DOT1L inhibition. We observed that a subset of MLL-AF4 targets, including <italic>FLT3,</italic> have aberrantly high H3K79me2 and that low-dose inhibitor treatment downregulates these genes, dramatically depleting H3K79me2, while resulting in increased H3K4me3 at promoters and reduced H3K27me3 genome-wide. Similar effects of both pinometostat and SGC0946, a distinct DOT1L inhibitor, argues that these effects are due to depletion of H3K79me2 rather than off-target effects of pinometostat. Our findings illustrate how MLL-fusions can cooperate mechanistically with <italic>FLT3-ITD</italic> mutations to facilitate leukemogenesis and how PRC2 function may be important for that disease state. FLT3-ITD-mediated STAT5A activation is crucial to the MLL-AF4 expression profile, potentially through direct interaction of STAT5A with HOXA9 and coactivation of some targets such as PIM1.</p><sec id="s3-1"><title>The FLT3-ITD signaling pathway accounts for the bulk of low-dose DOT1L inhibitor toxicity</title><p>A subset of MLL-AF4 targets were downregulated by low-dose DOT1L inhibition and the FLT3 locus was impacted earlier than other MLL-AF4 targets. <italic>FLT3</italic> expression was downregulated after only 2 days of low-dose pinometostat treatment, coinciding with reduced proliferation, increased apoptosis and gene expression changes consistent with differentiation. Reductions in <italic>FLT3-ITD</italic> expression precede reductions in other MLL-AF4 targets including <italic>PBX3</italic> and <italic>MEF2C</italic>, arguing that these effects are more primary or sensitive to DOT1L function. Although PBX3 interacts with both HOXA9 and MEIS1 to facilitate leukemogenesis and regulate the expression of common targets including <italic>FLT3</italic> (<xref ref-type="bibr" rid="bib61">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib60">Li et al., 2013b</xref>) we observed that <italic>PBX3</italic> expression could also be reduced by either FLT3 knockdown or inhibition (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). These results are in agreement with previous findings that <italic>PBX3</italic> was significantly upregulated in <italic>FLT3-ITD<sup>+</sup></italic> compared to WT <italic>FLT3,</italic> karyotypically normal AML patient samples (<xref ref-type="bibr" rid="bib11">Cauchy et al., 2015</xref>).</p><p>The FLT3 receptor has an outsized effect on myeloid differentiation and proliferation through its regulation of several myeloid transcription factors (<xref ref-type="bibr" rid="bib70">Mizuki et al., 2003</xref>; <xref ref-type="bibr" rid="bib89">Rosen et al., 2010</xref>), accounting for its predominance in AML patients (<xref ref-type="bibr" rid="bib76">Nagel et al., 2017</xref>; <xref ref-type="bibr" rid="bib58">Levis and Small, 2003</xref>; <xref ref-type="bibr" rid="bib70">Mizuki et al., 2003</xref>). Although stable transfection of <italic>FLT3-ITD</italic> has been observed to downregulate the PU.1 and C/EBPα transcription factors and regulators of myeloid differentiation (<xref ref-type="bibr" rid="bib70">Mizuki et al., 2003</xref>), we detected no discernable change in <italic>SPI1</italic> (PU.1) expression and a surprising ~twofold downregulation of <italic>CEBPA</italic> (C/EBPα) in MV4;11 cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>) treated with low-dose pinometostat. Much of the <italic>FLT3-ITD</italic>-driven effects on proliferation, inhibition of apoptosis and differentiation have been attributed to the activation of STAT5A (<xref ref-type="bibr" rid="bib70">Mizuki et al., 2003</xref>; <xref ref-type="bibr" rid="bib72">Moore et al., 2007</xref>; <xref ref-type="bibr" rid="bib89">Rosen et al., 2010</xref>; <xref ref-type="bibr" rid="bib117">Zhou et al., 2009</xref>; <xref ref-type="bibr" rid="bib97">Spiekermann et al., 2003</xref>). Constitutively active <italic>Stat5a</italic> can render mouse Ba/F3 cells growth factor-independent and resistant to apoptosis through upregulation of the <italic>Pim1-2</italic> protooncogenes (<xref ref-type="bibr" rid="bib1">Adam et al., 2006</xref>; <xref ref-type="bibr" rid="bib49">Kim et al., 2005</xref>; <xref ref-type="bibr" rid="bib90">Santos et al., 2001</xref>). We observe that 100 nM pinometostat downregulates <italic>FLT3-ITD</italic> with concomitant reductions in STAT5A phosphorylation and diminished expression of the STAT5A target genes <italic>PIM1</italic> and <italic>ARID3B,</italic> suggesting that low-dose DOT1L inhibition is able to disrupt FLT3-ITD-mediated signaling and downstream oncogene activation.</p><p>Exogenous expression of constitutively active human <italic>STAT5A</italic> (<italic>STAT5A-CA</italic>) in MV4;11 cells treated with 100 nM pinometostat rescues cells from apoptosis, almost completely rescues proliferation, and restores <italic>PIM1</italic> and <italic>ARID3B</italic> gene expression, suggesting that most of the toxicity from low-dose DOT1L inhibition is through loss of STAT5A activation. The ability of ectopic <italic>STAT5A-CA</italic> expression to rescue orthologous perturbations to MLL-fusion-mediated gene activation and proliferation from MLL1 inhibitors suggests that STAT5A activation is necessary for leukemogenesis and maintenance of the proliferative gene expression profile including <italic>PIM1</italic> in this context. Interestingly, <italic>PIM1</italic> is a downstream target of both FLT3-ITD and HOXA9 (<xref ref-type="bibr" rid="bib45">Huang et al., 2012</xref>; <xref ref-type="bibr" rid="bib49">Kim et al., 2005</xref>). Although both factors regulate <italic>PIM1</italic> expression, the FLT3-ITD axis is more sensitive and is responsible for <italic>PIM1</italic> downregulation with low-dose DOT1L inhibitor treatment in MLL-r leukemia also bearing the <italic>FLT3-ITD</italic> mutation. FLT3-ITD<italic>-</italic>mediated activation of STAT5A may promote HOXA9 localization to the <italic>PIM1</italic> locus or complement it, thereby facilitating expression of this common target and leukemogenesis.</p><p><italic>PIM1</italic> activation by both STAT5A and HOXA9 represents a common coregulation scenario for these hematopoietic transcription factors. Indeed, De Bock et al. discovered that HOXA9 binding sites have significant overlap with STAT5A, PBX3, and C/EBP targets genome-wide (<xref ref-type="bibr" rid="bib24">de Bock et al., 2018</xref>). We observed downregulation of both <italic>PBX3</italic> and <italic>C/EBPA</italic> by 100 nM DOT1L inhibition. It is possible that the dependence of MLL-r, <italic>FLT3-ITD<sup>+</sup></italic> leukemia on <italic>FLT3-ITD</italic> expression may be due to HOXA9 requiring STAT5A and/or PBX3 and C/EBPA to cooperatively bind select target genes. Huang et al. found that HOXA9 and MEIS1 preferentially localized to enhancer regions enriched with STAT5 binding motifs (<xref ref-type="bibr" rid="bib45">Huang et al., 2012</xref>) and identified STAT5A and C/EBPA in complex with HOXA9. Furthermore, <italic>HOXA9</italic> knockdown reduced STAT5A binding at common target sites (<xref ref-type="bibr" rid="bib45">Huang et al., 2012</xref>). If HOXA9 depends on STAT5A for chromatin localization then low-dose DOT1L inhibition may reduce HOXA9 binding at enhancer regions, reducing HOXA9 target gene activation without affecting <italic>HOXA9</italic> expression.</p><p>In addition to gene activation, STAT5A phosphorylation also results in gene repression, modulating the immune response and differentiation (<xref ref-type="bibr" rid="bib72">Moore et al., 2007</xref>; <xref ref-type="bibr" rid="bib119">Zhu et al., 2003</xref>). Viral transduction of constitutively active <italic>Stat5a</italic> affects T cell differentiation by repressing IFN-γ production (<xref ref-type="bibr" rid="bib119">Zhu et al., 2003</xref>; <xref ref-type="bibr" rid="bib87">Rani and Murphy, 2016</xref>). We found 2007 genes upregulated with 100 nM pinometostat treatment, including many MHC class II genes with large fold-changes that significantly overlapped with a set of genes consistently downregulated in FLT3-ITD+ (KN) leukemia samples (<xref ref-type="bibr" rid="bib11">Cauchy et al., 2015</xref>). Indeed, GO analysis of the pinometostat-upregulated genes indicated significant enrichment for the ‘IFN-γ-mediated signaling pathway’ and other immune-related categories (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Despite the increase in expression of IFN-γ-regulated genes we saw barely measurable levels of <italic>IFNG</italic> (IFN-γ) and no increase in expression with pinometostat treatment (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Many components of the IFN-γ pathway, such as IRF4 and IRF5 are involved in macrophage differentiation, a functional consequence of <italic>DOT1L</italic> deletion or inhibition that has been observed in other studies (<xref ref-type="bibr" rid="bib6">Bernt et al., 2011</xref>; <xref ref-type="bibr" rid="bib22">Daigle et al., 2011</xref>; <xref ref-type="bibr" rid="bib74">Mossadegh-Keller et al., 2013</xref>; <xref ref-type="bibr" rid="bib111">Yamamoto et al., 2011</xref>). With pinometostat treatment we observed upregulation of <italic>CSF1R</italic> and <italic>CSF3R,</italic> targets of IRF4 and critical signaling inducers of macrophage and neutrophil differentiation, respectively (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1.E</xref>; <xref ref-type="bibr" rid="bib74">Mossadegh-Keller et al., 2013</xref>; <xref ref-type="bibr" rid="bib52">Klimiankou et al., 2017</xref>). Additionally, expression increases in the macrophage cell surface markers <italic>ITGAM</italic> (CD11b), <italic>ITGAX</italic> (CD11c), and <italic>CD86</italic> suggest these cells are differentiating to a more macrophage-like state (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>), consistent with previous observations from DOT1L deletion and from a study using the DOT1L inhibitor EPZ004777 (<xref ref-type="bibr" rid="bib6">Bernt et al., 2011</xref>; <xref ref-type="bibr" rid="bib22">Daigle et al., 2011</xref>).</p></sec><sec id="s3-2"><title>Extensive histone modification cross-talk contributes to the survival of MLL-r, FLT3-ITD<sup>+</sup> leukemia</title><p><italic>FLT3</italic> is part of a subset of MLL-AF4 targets that are more sensitive to reductions in H3K79me2 than even the <italic>HOXA9</italic> and <italic>MEIS1</italic> oncogenes. We observed that MLL-AF4 targets (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>) that are downregulated by 100 nM pinometostat have higher levels of H3K79me2 than even the most highly expressed genes and show the largest reductions in methylation when treated with pinometostat. (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The greater reductions in H3K79me2 levels at downregulated genes is likely a contributing factor to their loss of gene expression. H3K79me2 hypermethylation antagonizes SIRT1 localization to MLL-AF4 targets, preventing H3K9ac and H3K16ac deacetylation, thereby facilitating gene expression (<xref ref-type="bibr" rid="bib14">Chen et al., 2015a</xref>). However, there are stark differences in methylation density and susceptibility to DOT1L inhibition even among MLL-fusion targets. MLL-AF4 ‘spreading’ genes (<xref ref-type="bibr" rid="bib48">Kerry et al., 2017</xref>) had H3K79me2 levels comparable to those MLL-AF4 targets whose expression was downregulated by pinometostat. Yet only 31% of ‘spreading genes’ were downregulated by 100 nM pinometostat, suggesting that effects on gene expression from depletion of H3K79me2 could be governed by other factors including changes to the distribution of other chromatin modifications.</p><p>To our surprise, the pinometostat-induced activation of MHC class II genes we observed did not appear to result from a loss of H3K27me3-mediated repression, despite PRC2 subunit downregulation. Treatment with PRC2 inhibitor EI1 had no effect on <italic>CIITA</italic> or MHC class II gene expression but significantly reduced proliferation in MV4;11 cells (<xref ref-type="fig" rid="fig6">Figure 6E</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). A growing body of evidence supports an essential role for the PRC2 complex in MLL-r leukemogenesis-- PRC2 is necessary for <italic>MLL-AF9</italic>-induced leukemogenesis in mouse progenitor cells and cooperates with MLL-AF9 to promote self-renewal of acute myeloid leukemia cells (<xref ref-type="bibr" rid="bib95">Shi et al., 2013</xref>; <xref ref-type="bibr" rid="bib77">Neff et al., 2012</xref>). The observed downregulation of the MLL-AF4 target oncogenes upon EZH2 inhibition (<xref ref-type="fig" rid="fig6">Figure 6F</xref>), suggests that MLL-fusion-mediated gene activation is in some way dependent on PRC2 methyltransferase activity. Consistent with this idea, ectopic expression of <italic>EZH2</italic> was able to provide a small but significant proliferation rescue when treating cells with 100 nM pinometostat (<xref ref-type="fig" rid="fig6">Figure 6G</xref>).</p><p>We identified pinometostat-induced increases in H3K4me3 at promoters genome-wide (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Although H3K4me3 promotes transcriptional initiation (<xref ref-type="bibr" rid="bib103">Vermeulen et al., 2007</xref>; <xref ref-type="bibr" rid="bib13">Chang et al., 2010b</xref>), the largest H3K4me3 increases were at downregulated MLL-AF4 targets that had the largest decreases in H3K79me2. Although DOT1L inhibition reduces global H3K27me3, this is unlikely to explain the massive increases in H3K4me3 that we observe (<xref ref-type="bibr" rid="bib50">Kim et al., 2013</xref>; <xref ref-type="bibr" rid="bib40">Hanson et al., 1999</xref>). Studies in human embryonic stem cells and mouse preadipocytes observed no genome-wide increases in H3K4me3 upon <italic>EZH2</italic> knockout and reductions in H3K27me3 (<xref ref-type="bibr" rid="bib20">Collinson et al., 2016</xref>; <xref ref-type="bibr" rid="bib107">Wang et al., 2010</xref>). The increase in H3K4me3 does not appear to be the result of a stalled transcriptional complex containing MLL1 near the TSS as more highly expressed genes do not show greater fold-changes in H3K4me3 upon pinometostat treatment (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1I</xref>). Additionally, the absence of an anti-correlation between H3K79me2 loss and increases in H3K4me3 suggests that there is not a direct antagonism between these modifications at genes (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1H</xref>). The increase in H3K4me3 further into the gene body of ‘MLL-spreading genes’ and the strong skew of downregulated MLL-AF4 targets toward increases in H3K4me3 suggests that the buildup of this modification is possibly the result of reduced recruitment or activity of the H3K4me2-histone demethylase LSD1. Previous studies have observed that knockout or inhibition of LSD1, a component of the MLL-supercomplex, results in apoptosis and differentiation of MLL-r cells, inhibits leukemogenesis in mouse models and increases H3K4me2/3 at MLL-target genes (<xref ref-type="bibr" rid="bib41">Harris et al., 2012</xref>; <xref ref-type="bibr" rid="bib31">Feng et al., 2016</xref>; <xref ref-type="bibr" rid="bib66">McGrath et al., 2016</xref>; <xref ref-type="bibr" rid="bib29">Fang et al., 2017</xref>). A more localized antagonism could be potentially mediated through H3K79me2-mediated recruitment/activation of LSD1.</p></sec><sec id="s3-3"><title>Broader clinical implications</title><p>In light of the heightened sensitivity we observed for a non-MLL-rearranged FLT3-ITD leukemia cell line to DOT1L inhibition and the coinciding reductions in cell viability and FLT3 expression, small molecules such as pinometostat may prove effective in treating the 30–40% of AML bearing FLT3-ITD mutations. Although several FLT3 inhibitors have undergone clinical trials, drug resistance has emerged as a formidable and so far, insurmountable barrier to an effective treatment. A previous study observed that siRNAs targeting FLT3 expression increased the efficacy of the FLT3 inhibitor tandutinib (<xref ref-type="bibr" rid="bib105">Walters et al., 2005</xref>). As a way of circumventing the difficulties associated with therapeutic siRNA delivery, DOT1L inhibitors that reduce FLT3 expression might serve as an effective adjunct treatment with FLT3 inhibitors. Our mechanistic studies provide impetus for exploration of these ideas in pre-clinical or patient-derived FLT3-ITD or MLL-PTD leukemias.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell culture</title><p>Human MV4;11 and MOLM13 leukemia cells and MLL1 inhibitor MM-401 were gifts from the laboratory of Yali Dou at the University of Michigan. MV4;11, MOLM13, THP-1, and K562 cells were validated by STR profiling through ATCC. Human THP-1 leukemia cells (cat # TIB-202) were purchased from American Type Culture Collection (ATCC). Human SEM (ACC546), EOL-1 (ACC386), and PL-21 (ACC536) leukemia cells were obtained from DSMZ- the German Collection of Microorganisms and Cell Cultures GmbH. Experiments using these purchased cell lines were performed within 1 year of receipt of the cell lines. All cell lines tested negative for mycoplasma with the Universal Mycoplasma Detection Kit from ATCC (cat # 30–1012K). Cells were cultured in RPMI-1640 medium containing 10% (v/v) FBessence (Seradigm cat # 3100–500), 1% L-glutamine at 37°C in humidified air containing 5% CO<sub>2</sub>. DOT1L inhibitor pinometostat (EPZ5676, Cayman Chemical cat # 16175), EZH2 inhibitor EI1 (Cayman Chemical cat # 19146–1), FLT3 inhibitor tandutinib (MLN518) (Selleckchem cat # S1043), MI-503 (Selleckchem cat # S7817), and PIM1 inhibitor (MedChemExpress cat # HY-15604) were resuspended in DMSO. Doxycycline (Alfa Aesar cat # J60422) was resuspended in water.</p><p>Plasmid generation pCMV-Gag-Pol plasmid, encoding HIV-1 derived <italic>gag</italic>, and <italic>pol,</italic> the pCMV-VSV-G vector encoding VSV-G envelope gene, pTRIPZ-YFP-EED and Tet-pLKO were purchased from Addgene. pTRIPZ-STAT5a-CA and pTRIPZ-FLT3-ITD were created by cloning <italic>STAT5A</italic> and <italic>FLT3-ITD</italic> from cDNA from MV4;11 cells. STAT5A-CA mutations were introduced at H298R and S710F and genes were inserted into the pTRIPZ plasmid at restriction sites AgeI and MluI. shRNA constructs were created by inserting annealed oligos of shRNA sequences (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) purchased from IDT into Tet-pLKO at the AgeI and EcoRI restriction sites.</p></sec><sec id="s4-2"><title>RNA-seq and gene expression analysis</title><p>Exponentially growing MV4;11 cells were grown in 150 mm<sup>2</sup> tissue culture-treated plates (Corning cat # 0877224) in 30 ml media ± 100 nM pinometostat for 7 days. Every 2 days, cells were spun down at 500 x g 5 min then resuspended in media ± 100 nM pinometostat. On day 7, 1 x 10<sup>7</sup> cells were spun down at 500 x g 5 min then cells were resuspended in 1 ml Trizol reagent (Life Technologies cat# 15596018), incubated 5 min at 25°C then 200 μl chloroform was added and samples were shaken rigorously for 15 s then incubated 3 min at 25°C and spun down 12,000 x g 15 min at 4°C. The aqueous layer (~ 500 μl) was removed and mixed with 500 μl EtOH and added to a Zymo Research RNA Clean and Concentrator column (cat # 11-353B) and spun 12,000 x g 1 min. A total of 100 μl DNase I (1:10 in buffered dH20) (Thermo Fisher Scientific cat # en0521) was added to the column and then spun 500 x g 5 min, incubated 15 min at 25°C and then spin 12,000 x g for 30 s. Combined 200 μl RNA binding buffer with 300 μl EtOH and then spun 12,000 x g for 30 s and the flow through was discarded. After each of the following were added to the column, it was spun down 12,000 x g for 30 s and the flow through was discarded: 400 μl RNA prep buffer; 700 μl RNA wash buffer; and 400 μl RNA wash buffer. RNA was eluted from column with 30 μl RNase-free dH<sub>2</sub>O. Added RNA standards to 2 μg of each RNA sample- Add the equivalent of 10 copies/cell yeast RAD51; 30 copies/cell RNL2; 200 copies/cell E coli MBP; and 2000 copies/cell yeast SUMO to each sample then proceed with rRNA removal Ribo Zero Gold kit (Illumina cat # MRZ11124C) according to manufacturer’s protocol. Libraries were prepared using the NEBNext Ultra Directional RNA Library prep kit (NEB cat # E7420S). Libraries were then sequenced on the Illumina NextSEQ500. Reads were aligned to the hg38 genome assembly using HISAT2 (<xref ref-type="bibr" rid="bib51">Kim et al., 2015</xref>) and differential gene expression analysis was done with Cufflinks (<xref ref-type="bibr" rid="bib101">Trapnell et al., 2012</xref>).</p></sec><sec id="s4-3"><title>Reverse transcription and quantitative real-time PCR</title><p>RNA was extracted from 10<sup>6</sup> cells using 500 μl Trizol and following the manufacturer’s protocol. One μg RNA was used for reverse transcription with 0.5 μl MMLV HP reverse transcriptase (Lucigen cat # RT80125K) per 20 μl rxn. RNA was then degraded by alkaline hydrolysis by adding 40 μl 150 mM KOH, 20 mM tris base and heating 95°C 10 min then cooling on ice and quenching with 40 μl 150 mM HCl and then adding 100 μl TE. Gene expression was assayed by real-time PCR in 10 μl reactions with 0.5 μl cDNA and 5 μl PowerUP SYBR Green master mix (Applied Biosystems cat # A25742) per reactions. qPCR was run on the Bio-Rad thermocycler CFX96 or CFX384 using the program: 50°C 2:00, 95°C 2:00, then 40 cycles 95°C 0:15, then 60°C 1:00. Expression was normalized to 18S rRNA. Primer sets are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-4"><title>Cell proliferation assay</title><p>Cells were seeded at 10<sup>5</sup> cells/ml in 80 μl in clear bottom 96-well plates (Corning 07200566) in three replicates. Everyday 40 μl of culture was transferred to 40 μl media in a new plate. On odd days, 30 μl of Cell TiterGlo 2 (Promega cat # G924A) was added to the remaining 40 μl culture and incubated 10 min at room temperature on a shaker at 600 rpm. Luminescence was measured on a Tecan Infinite F200 Pro plate reader and fraction viability was determined from the luminescence of treated over untreated cells.</p></sec><sec id="s4-5"><title>Apoptosis assay</title><p>Exponentially growing cells were incubated with increasing concentrations of pinometostat for 7 days in 3 ml media in six-well plates in three experimental replicates. 10<sup>6</sup> were harvested from each plate and washed twice in 1 ml PBS then resuspended in 1 ml binding buffer as per BD Biosciences manufacturer’s protocol. Add 5 μl FITC-conjugated Annexin V (BD Biosciences cat# 556420) and 2 μl propidium iodide (Alfa Aesar cat # J66584) to 100 μl cells and incubate 15 min at 25°C in the dark. Cells were then sorted on the BD FACSAriaII device for propidium iodide or FITC (Annexin V) positive cells. Data was analyzed using FlowJo software (Tree Star).</p></sec><sec id="s4-6"><title>Calibrated chromatin immunoprecipitation sequencing (ICeChIP-seq)</title><p>Native, internally calibrated ICeChIP-seq was carried out as described previously for H3K4me3 and H3K27me3 (<xref ref-type="bibr" rid="bib36">Grzybowski et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Grzybowski et al., 2019</xref>). A modified protocol was used for H3K79me2 that included cross-linking and denaturation because of greater difficulty in immunoprecipitation of this modification, likely due to reduced accessibility of this mark within the more highly structured nucleosome core. Briefly, MV4;11 cells were exposed to a gentle detergent lysis and spun through a sucrose gradient to obtain nuclei from 20 million cells. Nucleosome standards were added and then the chromatin was digested with micrococcal nuclease and purified using hydroxy apatite (HAP) resin. Of 280 μl total HAP-purified chromatin, 150 μl was removed for denaturative ICeChIP and crosslinked in 0.25% formaldehyde for 8 min on a nutator at 25°C, then quenched by adding 1M Tris pH 7.5 to 200 mM and incubated 5 min at 25°C on a nutator. Fifty μl of cross-linked chromatin was used for denaturation and 2.5 μl 20% SDS was added to 1% SDS final concentration and the sample was incubated 1 min at 55°C, then immediately placed on ice. This was then diluted with nine volumes water (450 μl) and 100 μl was used for each IP. For native ICeChIP, the HAP-purified chromatin was diluted to 20 μg/ml and the indicated amounts of chromatin, adjusted for the relative approximate abundance of each modification were added to the antibody/beads for immunoprecipitation. Antibodies for both the DMSO- and pinometostat-treated samples were processed together (12 μl antibody-bound beads per IP). Three μg of anti-H3K79me2 (Abcam cat # ab3594, lot # GR173874); 3 μg of anti-H3K4me3 (Abcam cat # 12209, lot # GR275790-1); and 0.6 μg of anti-H3K27me3 (Cell Signaling cat # 9733, lot # 8) were used per IP. For crosslinked IPs include 1 hr 65°C after proteinase K digest. Libraries were prepared using the NEBNext Ultra II DNA Library prep kit (NEB cat # E7645). Three cycles of PCR amplification were used for native inputs, four cycles for denaturated inputs and H3K27me3 IPs, seven cycles for H3K4me3 IPs and 10 cycles for H3K79me2 IPs. Analysis of histone methylation density (HMD) was carried out using the scripts and workflow from <xref ref-type="bibr" rid="bib37">Grzybowski et al., 2019</xref>.</p></sec><sec id="s4-7"><title>Western blotting</title><p>Ten Vl whole cell extracts of 2 x 10<sup>5</sup> cells in 40 μl 6X SDS loading buffer were run on 4–14% bis-tris gel (Invitrogen cat # NP0335). Membranes were transferred by semi-dry apparatus (Bio-Rad Transblot cat # 170–3940) at 200 mA, 25 V for 35 min to 0.45 μm nitrocellulose membrane (Millipore cat # IPVH00010). Membranes were then blocked for 1 hr with TBS-T 1% ECL Prime blocking reagent (GE Healthcare cat # RPN418) at 25°C on an orbital shaker and blotted with primary antibody for 1 hr at 25°C with gentle agitation. Membranes were then washed three times for 5 min while shaking with TBS-T and then incubated with secondary antibody at 25°C for 1 hr while shaking. A complete list of antibodies can be found in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p></sec><sec id="s4-8"><title>Transfection for lentiviral particle generation</title><p>Lentiviral particles were produced by Fugene transfection of the 293T packaging cell line in a six-well plate at ~70% confluency with pCMV-Gag-Pol, pCMV-VSV-G and 2 μg of the plasmid encoding the gene or shRNA of interest using a 3:1:4 ratio, respectively. Lentiviral particle enriched supernatants were collected 72 hr after transfection for immediate transduction.</p></sec><sec id="s4-9"><title>Lentiviral transduction</title><p>Four x 10<sup>5</sup> MV4;11 cells suspended in 1 ml RPMI-1640 medium containing 10% FBessence in a six-well plate were transduced by adding 2.5 ml of 0.45 μm filtered viral supernatants from 293 T cells. Then 0.8 μl polybrene (EMD Millipore cat. # TR-1003-G)/ml transduction reagent was added to the media and the plates were wrapped with parafilm and spun down at 2000 rpm for 2 hr at room temperature then incubated O/N at 37°C in humidified air containing 5% CO<sub>2</sub>. After 12 hr, cells were spun down and resuspended in RPMI-1640 10% FBessence. After 24 hr, 0.5 μg/ml puromycin was added to the wells and this selection media was refreshed every 3 days to select for transduced cells. Individual clones were purified by diluting cell cultures to 1 cell/100 μl and then plating 100 μl aliquots in a 96-well plate. Wells were visually assessed for individual clones and then grown out.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the American Cancer Society (130230-RSG-16-248-01-DMC to AJR) and National Institutes of Health (R01-GM115945 to AJR). WFR was supported by NIH Molecular and Cell Biology training grant T32-GM007183. We thank Peter Faber and Mikayla Marchuk of the University of Chicago Functional Genomics Core and Balaji Manicassamy for his kind help with lentivirus protocols. We also thank Mary Beth Neilly, Elizabeth Davis and the le Beau lab for their help in securing leukemia cell lines for our experiments.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>WFR conceived of and designed the study. Nearly all experiments were conducted by WFR under supervision from AJR, including ICeChIP-seq for all datasets except AR15. WFR also conducted bioinformatic analyses</p></fn><fn fn-type="con" id="con2"><p>RNS developed the ICeChIP methodology used in this study and performed ICeChIP-seq on the AR15 dataset. RNS also conducted bioinformatic analyses</p></fn><fn fn-type="con" id="con3"><p>AJR conceived of and designed this study, and supervised experiments conducted by WFR. Funding acquisition was conducted by AJR</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Blotting source files.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-64960-data1-v2.zip"/></supplementary-material><supplementary-material id="sdata2"><label>Source data 2.</label><caption><title>Blotting source files.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-64960-data2-v2.zip"/></supplementary-material><supplementary-material id="sdata3"><label>Source data 3.</label><caption><title>Blotting source files.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-64960-data3-v2.zip"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Oligonucleotide sequences.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64960-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Antibody information.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64960-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-64960-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>ICeChIP-seq and RNA-seq data have been deposited in GEO under the accession code GSE162441.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>WF</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>RNA-seq analysis of 10 nM pinometostat vs. DMSO-treated MV4;11 cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM4952087">GSM4952087</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>WF</given-names></name><name><surname>Shah</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>ICeChIP-seq of H3K79me2, H3K4me3, H3K27me3, H3K36me3 from MV4;11 cells treated with 10 nM pinometostat or DMSO</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM4952104">GSM4952104</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname> <given-names>M</given-names></name><name><surname>Pogacic</surname> <given-names>V</given-names></name><name><surname>Bendit</surname> <given-names>M</given-names></name><name><surname>Chappuis</surname> <given-names>R</given-names></name><name><surname>Nawijn</surname> <given-names>MC</given-names></name><name><surname>Duyster</surname> <given-names>J</given-names></name><name><surname>Fox</surname> <given-names>CJ</given-names></name><name><surname>Thompson</surname> <given-names>CB</given-names></name><name><surname>Cools</surname> <given-names>J</given-names></name><name><surname>Schwaller</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL</article-title><source>Cancer Research</source><volume>66</volume><fpage>3828</fpage><lpage>3835</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2309</pub-id><pub-id pub-id-type="pmid">16585210</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amson</surname> <given-names>R</given-names></name><name><surname>Sigaux</surname> <given-names>F</given-names></name><name><surname>Przedborski</surname> <given-names>S</given-names></name><name><surname>Flandrin</surname> <given-names>G</given-names></name><name><surname>Givol</surname> <given-names>D</given-names></name><name><surname>Telerman</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias</article-title><source>PNAS</source><volume>86</volume><fpage>8857</fpage><lpage>8861</lpage><pub-id pub-id-type="doi">10.1073/pnas.86.22.8857</pub-id><pub-id pub-id-type="pmid">2682662</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anglin</surname> <given-names>JL</given-names></name><name><surname>Song</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L</article-title><source>Journal of Medicinal Chemistry</source><volume>56</volume><fpage>8972</fpage><lpage>8983</lpage><pub-id pub-id-type="doi">10.1021/jm4007752</pub-id><pub-id pub-id-type="pmid">23879463</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname> <given-names>SA</given-names></name><name><surname>Staunton</surname> <given-names>JE</given-names></name><name><surname>Silverman</surname> <given-names>LB</given-names></name><name><surname>Pieters</surname> <given-names>R</given-names></name><name><surname>den Boer</surname> <given-names>ML</given-names></name><name><surname>Minden</surname> <given-names>MD</given-names></name><name><surname>Sallan</surname> <given-names>SE</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Korsmeyer</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia</article-title><source>Nature Genetics</source><volume>30</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1038/ng765</pub-id><pub-id pub-id-type="pmid">11731795</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname> <given-names>SA</given-names></name><name><surname>Kung</surname> <given-names>AL</given-names></name><name><surname>Mabon</surname> <given-names>ME</given-names></name><name><surname>Silverman</surname> <given-names>LB</given-names></name><name><surname>Stam</surname> <given-names>RW</given-names></name><name><surname>Den Boer</surname> <given-names>ML</given-names></name><name><surname>Pieters</surname> <given-names>R</given-names></name><name><surname>Kersey</surname> <given-names>JH</given-names></name><name><surname>Sallan</surname> <given-names>SE</given-names></name><name><surname>Fletcher</surname> <given-names>JA</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Griffin</surname> <given-names>JD</given-names></name><name><surname>Korsmeyer</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Inhibition of FLT3 in MLL. validation of a therapeutic target identified by gene expression based classification</article-title><source>Cancer Cell</source><volume>3</volume><fpage>173</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/s1535-6108(03)00003-5</pub-id><pub-id pub-id-type="pmid">12620411</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernt</surname> <given-names>KM</given-names></name><name><surname>Zhu</surname> <given-names>N</given-names></name><name><surname>Sinha</surname> <given-names>AU</given-names></name><name><surname>Vempati</surname> <given-names>S</given-names></name><name><surname>Faber</surname> <given-names>J</given-names></name><name><surname>Krivtsov</surname> <given-names>AV</given-names></name><name><surname>Feng</surname> <given-names>Z</given-names></name><name><surname>Punt</surname> <given-names>N</given-names></name><name><surname>Daigle</surname> <given-names>A</given-names></name><name><surname>Bullinger</surname> <given-names>L</given-names></name><name><surname>Pollock</surname> <given-names>RM</given-names></name><name><surname>Richon</surname> <given-names>VM</given-names></name><name><surname>Kung</surname> <given-names>AL</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L</article-title><source>Cancer Cell</source><volume>20</volume><fpage>66</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2011.06.010</pub-id><pub-id pub-id-type="pmid">21741597</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borkin</surname> <given-names>D</given-names></name><name><surname>He</surname> <given-names>S</given-names></name><name><surname>Miao</surname> <given-names>H</given-names></name><name><surname>Kempinska</surname> <given-names>K</given-names></name><name><surname>Pollock</surname> <given-names>J</given-names></name><name><surname>Chase</surname> <given-names>J</given-names></name><name><surname>Purohit</surname> <given-names>T</given-names></name><name><surname>Malik</surname> <given-names>B</given-names></name><name><surname>Zhao</surname> <given-names>T</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Wen</surname> <given-names>B</given-names></name><name><surname>Zong</surname> <given-names>H</given-names></name><name><surname>Jones</surname> <given-names>M</given-names></name><name><surname>Danet-Desnoyers</surname> <given-names>G</given-names></name><name><surname>Guzman</surname> <given-names>ML</given-names></name><name><surname>Talpaz</surname> <given-names>M</given-names></name><name><surname>Bixby</surname> <given-names>DL</given-names></name><name><surname>Sun</surname> <given-names>D</given-names></name><name><surname>Hess</surname> <given-names>JL</given-names></name><name><surname>Muntean</surname> <given-names>AG</given-names></name><name><surname>Maillard</surname> <given-names>I</given-names></name><name><surname>Cierpicki</surname> <given-names>T</given-names></name><name><surname>Grembecka</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo</article-title><source>Cancer Cell</source><volume>27</volume><fpage>589</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.02.016</pub-id><pub-id pub-id-type="pmid">25817203</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caldarelli</surname> <given-names>A</given-names></name><name><surname>Müller</surname> <given-names>JP</given-names></name><name><surname>Paskowski-Rogacz</surname> <given-names>M</given-names></name><name><surname>Herrmann</surname> <given-names>K</given-names></name><name><surname>Bauer</surname> <given-names>R</given-names></name><name><surname>Koch</surname> <given-names>S</given-names></name><name><surname>Heninger</surname> <given-names>AK</given-names></name><name><surname>Krastev</surname> <given-names>D</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Kasper</surname> <given-names>S</given-names></name><name><surname>Fischer</surname> <given-names>T</given-names></name><name><surname>Brodhun</surname> <given-names>M</given-names></name><name><surname>Böhmer</surname> <given-names>FD</given-names></name><name><surname>Buchholz</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling</article-title><source>Leukemia</source><volume>27</volume><fpage>2301</fpage><lpage>2310</lpage><pub-id pub-id-type="doi">10.1038/leu.2013.83</pub-id><pub-id pub-id-type="pmid">23508117</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvo</surname> <given-names>KR</given-names></name><name><surname>Sykes</surname> <given-names>DB</given-names></name><name><surname>Pasillas</surname> <given-names>MP</given-names></name><name><surname>Kamps</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1</article-title><source>Oncogene</source><volume>21</volume><fpage>4247</fpage><lpage>4256</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1205516</pub-id><pub-id pub-id-type="pmid">12082612</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname> <given-names>F</given-names></name><name><surname>Townsend</surname> <given-names>EC</given-names></name><name><surname>Karatas</surname> <given-names>H</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Ouillette</surname> <given-names>P</given-names></name><name><surname>Zhu</surname> <given-names>J</given-names></name><name><surname>Hess</surname> <given-names>JL</given-names></name><name><surname>Atadja</surname> <given-names>P</given-names></name><name><surname>Lei</surname> <given-names>M</given-names></name><name><surname>Qin</surname> <given-names>ZS</given-names></name><name><surname>Malek</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Dou</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia</article-title><source>Molecular Cell</source><volume>53</volume><fpage>247</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.12.001</pub-id><pub-id pub-id-type="pmid">24389101</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cauchy</surname> <given-names>P</given-names></name><name><surname>James</surname> <given-names>SR</given-names></name><name><surname>Zacarias-Cabeza</surname> <given-names>J</given-names></name><name><surname>Ptasinska</surname> <given-names>A</given-names></name><name><surname>Imperato</surname> <given-names>MR</given-names></name><name><surname>Assi</surname> <given-names>SA</given-names></name><name><surname>Piper</surname> <given-names>J</given-names></name><name><surname>Canestraro</surname> <given-names>M</given-names></name><name><surname>Hoogenkamp</surname> <given-names>M</given-names></name><name><surname>Raghavan</surname> <given-names>M</given-names></name><name><surname>Loke</surname> <given-names>J</given-names></name><name><surname>Akiki</surname> <given-names>S</given-names></name><name><surname>Clokie</surname> <given-names>SJ</given-names></name><name><surname>Richards</surname> <given-names>SJ</given-names></name><name><surname>Westhead</surname> <given-names>DR</given-names></name><name><surname>Griffiths</surname> <given-names>MJ</given-names></name><name><surname>Ott</surname> <given-names>S</given-names></name><name><surname>Bonifer</surname> <given-names>C</given-names></name><name><surname>Cockerill</surname> <given-names>PN</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Chronic FLT3-ITD signaling in acute myeloid leukemia is connected to a specific chromatin signature</article-title><source>Cell Reports</source><volume>12</volume><fpage>821</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.06.069</pub-id><pub-id pub-id-type="pmid">26212328</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>MJ</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Achille</surname> <given-names>NJ</given-names></name><name><surname>Reisenauer</surname> <given-names>MR</given-names></name><name><surname>Chou</surname> <given-names>CW</given-names></name><name><surname>Zeleznik-Le</surname> <given-names>NJ</given-names></name><name><surname>Hemenway</surname> <given-names>CS</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010a</year><article-title>Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes</article-title><source>Cancer Research</source><volume>70</volume><fpage>10234</fpage><lpage>10242</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-3294</pub-id><pub-id pub-id-type="pmid">21159644</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>PY</given-names></name><name><surname>Hom</surname> <given-names>RA</given-names></name><name><surname>Musselman</surname> <given-names>CA</given-names></name><name><surname>Zhu</surname> <given-names>L</given-names></name><name><surname>Kuo</surname> <given-names>A</given-names></name><name><surname>Gozani</surname> <given-names>O</given-names></name><name><surname>Kutateladze</surname> <given-names>TG</given-names></name><name><surname>Cleary</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2010">2010b</year><article-title>Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription</article-title><source>Journal of Molecular Biology</source><volume>400</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2010.05.005</pub-id><pub-id pub-id-type="pmid">20452361</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>CW</given-names></name><name><surname>Koche</surname> <given-names>RP</given-names></name><name><surname>Sinha</surname> <given-names>AU</given-names></name><name><surname>Deshpande</surname> <given-names>AJ</given-names></name><name><surname>Zhu</surname> <given-names>N</given-names></name><name><surname>Eng</surname> <given-names>R</given-names></name><name><surname>Doench</surname> <given-names>JG</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Chu</surname> <given-names>SH</given-names></name><name><surname>Qi</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Delaney</surname> <given-names>C</given-names></name><name><surname>Bernt</surname> <given-names>KM</given-names></name><name><surname>Root</surname> <given-names>DE</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia</article-title><source>Nature Medicine</source><volume>21</volume><fpage>335</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/nm.3832</pub-id><pub-id pub-id-type="pmid">25822366</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Wilkinson</surname> <given-names>AW</given-names></name><name><surname>Deshpande</surname> <given-names>AJ</given-names></name><name><surname>Sidoli</surname> <given-names>S</given-names></name><name><surname>Krajewski</surname> <given-names>K</given-names></name><name><surname>Strahl</surname> <given-names>BD</given-names></name><name><surname>Garcia</surname> <given-names>BA</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name><name><surname>Patel</surname> <given-names>DJ</given-names></name><name><surname>Gozani</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>The PZP domain of AF10 senses unmodified H3K27 to regulate DOT1L-Mediated methylation of H3K79</article-title><source>Molecular Cell</source><volume>60</volume><fpage>319</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.08.019</pub-id><pub-id pub-id-type="pmid">26439302</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhary</surname> <given-names>C</given-names></name><name><surname>Müller-Tidow</surname> <given-names>C</given-names></name><name><surname>Berdel</surname> <given-names>WE</given-names></name><name><surname>Serve</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Signal transduction of oncogenic Flt3</article-title><source>International Journal of Hematology</source><volume>82</volume><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1532/IJH97.05090</pub-id><pub-id pub-id-type="pmid">16146838</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhary</surname> <given-names>C</given-names></name><name><surname>Brandts</surname> <given-names>C</given-names></name><name><surname>Schwable</surname> <given-names>J</given-names></name><name><surname>Tickenbrock</surname> <given-names>L</given-names></name><name><surname>Sargin</surname> <given-names>B</given-names></name><name><surname>Ueker</surname> <given-names>A</given-names></name><name><surname>Böhmer</surname> <given-names>FD</given-names></name><name><surname>Berdel</surname> <given-names>WE</given-names></name><name><surname>Müller-Tidow</surname> <given-names>C</given-names></name><name><surname>Serve</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Activation mechanisms of STAT5 by oncogenic Flt3-ITD</article-title><source>Blood</source><volume>110</volume><fpage>370</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-05-024018</pub-id><pub-id pub-id-type="pmid">17356133</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cibull</surname> <given-names>TL</given-names></name><name><surname>Jones</surname> <given-names>TD</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Eble</surname> <given-names>JN</given-names></name><name><surname>Ann Baldridge</surname> <given-names>L</given-names></name><name><surname>Malott</surname> <given-names>SR</given-names></name><name><surname>Luo</surname> <given-names>Y</given-names></name><name><surname>Cheng</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Overexpression of Pim-1 during progression of prostatic adenocarcinoma</article-title><source>Journal of Clinical Pathology</source><volume>59</volume><fpage>285</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1136/jcp.2005.027672</pub-id><pub-id pub-id-type="pmid">16505280</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname> <given-names>JJ</given-names></name><name><surname>Cools</surname> <given-names>J</given-names></name><name><surname>Curley</surname> <given-names>DP</given-names></name><name><surname>Yu</surname> <given-names>JC</given-names></name><name><surname>Lokker</surname> <given-names>NA</given-names></name><name><surname>Giese</surname> <given-names>NA</given-names></name><name><surname>Gilliland</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518</article-title><source>Blood</source><volume>104</volume><fpage>2867</fpage><lpage>2872</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-12-4446</pub-id><pub-id pub-id-type="pmid">15256420</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collinson</surname> <given-names>A</given-names></name><name><surname>Collier</surname> <given-names>AJ</given-names></name><name><surname>Morgan</surname> <given-names>NP</given-names></name><name><surname>Sienerth</surname> <given-names>AR</given-names></name><name><surname>Chandra</surname> <given-names>T</given-names></name><name><surname>Andrews</surname> <given-names>S</given-names></name><name><surname>Rugg-Gunn</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Deletion of the Polycomb-Group protein EZH2 leads to compromised Self-Renewal and differentiation defects in human embryonic stem cells</article-title><source>Cell Reports</source><volume>17</volume><fpage>2700</fpage><lpage>2714</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.11.032</pub-id><pub-id pub-id-type="pmid">27926872</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corral</surname> <given-names>J</given-names></name><name><surname>Lavenir</surname> <given-names>I</given-names></name><name><surname>Impey</surname> <given-names>H</given-names></name><name><surname>Warren</surname> <given-names>AJ</given-names></name><name><surname>Forster</surname> <given-names>A</given-names></name><name><surname>Larson</surname> <given-names>TA</given-names></name><name><surname>Bell</surname> <given-names>S</given-names></name><name><surname>McKenzie</surname> <given-names>AN</given-names></name><name><surname>King</surname> <given-names>G</given-names></name><name><surname>Rabbitts</surname> <given-names>TH</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes</article-title><source>Cell</source><volume>85</volume><fpage>853</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81269-6</pub-id><pub-id pub-id-type="pmid">8681380</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daigle</surname> <given-names>SR</given-names></name><name><surname>Olhava</surname> <given-names>EJ</given-names></name><name><surname>Therkelsen</surname> <given-names>CA</given-names></name><name><surname>Majer</surname> <given-names>CR</given-names></name><name><surname>Sneeringer</surname> <given-names>CJ</given-names></name><name><surname>Song</surname> <given-names>J</given-names></name><name><surname>Johnston</surname> <given-names>LD</given-names></name><name><surname>Scott</surname> <given-names>MP</given-names></name><name><surname>Smith</surname> <given-names>JJ</given-names></name><name><surname>Xiao</surname> <given-names>Y</given-names></name><name><surname>Jin</surname> <given-names>L</given-names></name><name><surname>Kuntz</surname> <given-names>KW</given-names></name><name><surname>Chesworth</surname> <given-names>R</given-names></name><name><surname>Moyer</surname> <given-names>MP</given-names></name><name><surname>Bernt</surname> <given-names>KM</given-names></name><name><surname>Tseng</surname> <given-names>JC</given-names></name><name><surname>Kung</surname> <given-names>AL</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name><name><surname>Copeland</surname> <given-names>RA</given-names></name><name><surname>Richon</surname> <given-names>VM</given-names></name><name><surname>Pollock</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor</article-title><source>Cancer Cell</source><volume>20</volume><fpage>53</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2011.06.009</pub-id><pub-id pub-id-type="pmid">21741596</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daigle</surname> <given-names>SR</given-names></name><name><surname>Olhava</surname> <given-names>EJ</given-names></name><name><surname>Therkelsen</surname> <given-names>CA</given-names></name><name><surname>Basavapathruni</surname> <given-names>A</given-names></name><name><surname>Jin</surname> <given-names>L</given-names></name><name><surname>Boriack-Sjodin</surname> <given-names>PA</given-names></name><name><surname>Allain</surname> <given-names>CJ</given-names></name><name><surname>Klaus</surname> <given-names>CR</given-names></name><name><surname>Raimondi</surname> <given-names>A</given-names></name><name><surname>Scott</surname> <given-names>MP</given-names></name><name><surname>Waters</surname> <given-names>NJ</given-names></name><name><surname>Chesworth</surname> <given-names>R</given-names></name><name><surname>Moyer</surname> <given-names>MP</given-names></name><name><surname>Copeland</surname> <given-names>RA</given-names></name><name><surname>Richon</surname> <given-names>VM</given-names></name><name><surname>Pollock</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Potent inhibition of DOT1L as treatment of MLL-fusion leukemia</article-title><source>Blood</source><volume>122</volume><fpage>1017</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-04-497644</pub-id><pub-id pub-id-type="pmid">23801631</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bock</surname> <given-names>CE</given-names></name><name><surname>Demeyer</surname> <given-names>S</given-names></name><name><surname>Degryse</surname> <given-names>S</given-names></name><name><surname>Verbeke</surname> <given-names>D</given-names></name><name><surname>Sweron</surname> <given-names>B</given-names></name><name><surname>Gielen</surname> <given-names>O</given-names></name><name><surname>Vandepoel</surname> <given-names>R</given-names></name><name><surname>Vicente</surname> <given-names>C</given-names></name><name><surname>Vanden Bempt</surname> <given-names>M</given-names></name><name><surname>Dagklis</surname> <given-names>A</given-names></name><name><surname>Geerdens</surname> <given-names>E</given-names></name><name><surname>Bornschein</surname> <given-names>S</given-names></name><name><surname>Gijsbers</surname> <given-names>R</given-names></name><name><surname>Soulier</surname> <given-names>J</given-names></name><name><surname>Meijerink</surname> <given-names>JP</given-names></name><name><surname>Heinäniemi</surname> <given-names>M</given-names></name><name><surname>Teppo</surname> <given-names>S</given-names></name><name><surname>Bouvy-Liivrand</surname> <given-names>M</given-names></name><name><surname>Lohi</surname> <given-names>O</given-names></name><name><surname>Radaelli</surname> <given-names>E</given-names></name><name><surname>Cools</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>HOXA9 cooperates with activated JAK/STAT signaling to drive leukemia development</article-title><source>Cancer Discovery</source><volume>8</volume><fpage>616</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0583</pub-id><pub-id pub-id-type="pmid">29496663</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deneen</surname> <given-names>B</given-names></name><name><surname>Welford</surname> <given-names>SM</given-names></name><name><surname>Ho</surname> <given-names>T</given-names></name><name><surname>Hernandez</surname> <given-names>F</given-names></name><name><surname>Kurland</surname> <given-names>I</given-names></name><name><surname>Denny</surname> <given-names>CT</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins</article-title><source>Molecular and Cellular Biology</source><volume>23</volume><fpage>3897</fpage><lpage>3908</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.11.3897-3908.2003</pub-id><pub-id pub-id-type="pmid">12748291</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshpande</surname> <given-names>AJ</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Fazio</surname> <given-names>M</given-names></name><name><surname>Sinha</surname> <given-names>AU</given-names></name><name><surname>Bernt</surname> <given-names>KM</given-names></name><name><surname>Banka</surname> <given-names>D</given-names></name><name><surname>Dias</surname> <given-names>S</given-names></name><name><surname>Chang</surname> <given-names>J</given-names></name><name><surname>Olhava</surname> <given-names>EJ</given-names></name><name><surname>Daigle</surname> <given-names>SR</given-names></name><name><surname>Richon</surname> <given-names>VM</given-names></name><name><surname>Pollock</surname> <given-names>RM</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l</article-title><source>Blood</source><volume>121</volume><fpage>2533</fpage><lpage>2541</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-11-465120</pub-id><pub-id pub-id-type="pmid">23361907</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobson</surname> <given-names>CL</given-names></name><name><surname>Warren</surname> <given-names>AJ</given-names></name><name><surname>Pannell</surname> <given-names>R</given-names></name><name><surname>Forster</surname> <given-names>A</given-names></name><name><surname>Lavenir</surname> <given-names>I</given-names></name><name><surname>Corral</surname> <given-names>J</given-names></name><name><surname>Smith</surname> <given-names>AJ</given-names></name><name><surname>Rabbitts</surname> <given-names>TH</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis</article-title><source>The EMBO Journal</source><volume>18</volume><fpage>3564</fpage><lpage>3574</lpage><pub-id pub-id-type="doi">10.1093/emboj/18.13.3564</pub-id><pub-id pub-id-type="pmid">10393173</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname> <given-names>Y</given-names></name><name><surname>Spence</surname> <given-names>SE</given-names></name><name><surname>Jenkins</surname> <given-names>NA</given-names></name><name><surname>Copeland</surname> <given-names>NG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis</article-title><source>Blood</source><volume>106</volume><fpage>2498</fpage><lpage>2505</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-12-4840</pub-id><pub-id pub-id-type="pmid">15961513</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname> <given-names>J</given-names></name><name><surname>Ying</surname> <given-names>H</given-names></name><name><surname>Mao</surname> <given-names>T</given-names></name><name><surname>Fang</surname> <given-names>Y</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Zang</surname> <given-names>I</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Lin</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>M</given-names></name><name><surname>Luo</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Xiao</surname> <given-names>W</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Tan</surname> <given-names>W</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Lu</surname> <given-names>C</given-names></name><name><surname>Atadja</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>E</given-names></name><name><surname>Zhao</surname> <given-names>K</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Gu</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells</article-title><source>Oncotarget</source><volume>8</volume><fpage>85085</fpage><lpage>85101</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.18564</pub-id><pub-id pub-id-type="pmid">29156705</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fathi</surname> <given-names>AT</given-names></name><name><surname>Arowojolu</surname> <given-names>O</given-names></name><name><surname>Swinnen</surname> <given-names>I</given-names></name><name><surname>Sato</surname> <given-names>T</given-names></name><name><surname>Rajkhowa</surname> <given-names>T</given-names></name><name><surname>Small</surname> <given-names>D</given-names></name><name><surname>Marmsater</surname> <given-names>F</given-names></name><name><surname>Robinson</surname> <given-names>JE</given-names></name><name><surname>Gross</surname> <given-names>SD</given-names></name><name><surname>Martinson</surname> <given-names>M</given-names></name><name><surname>Allen</surname> <given-names>S</given-names></name><name><surname>Kallan</surname> <given-names>NC</given-names></name><name><surname>Levis</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A potential therapeutic target for FLT3-ITD AML: PIM1 kinase</article-title><source>Leukemia Research</source><volume>36</volume><fpage>224</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2011.07.011</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>Z</given-names></name><name><surname>Yao</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>F</given-names></name><name><surname>Wu</surname> <given-names>F</given-names></name><name><surname>Wei</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Dong</surname> <given-names>S</given-names></name><name><surname>Redell</surname> <given-names>M</given-names></name><name><surname>Mo</surname> <given-names>Q</given-names></name><name><surname>Song</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia</article-title><source>Journal of Hematology &amp; Oncology</source><volume>9</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1186/s13045-016-0252-7</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forster</surname> <given-names>A</given-names></name><name><surname>Pannell</surname> <given-names>R</given-names></name><name><surname>Drynan</surname> <given-names>LF</given-names></name><name><surname>McCormack</surname> <given-names>M</given-names></name><name><surname>Collins</surname> <given-names>EC</given-names></name><name><surname>Daser</surname> <given-names>A</given-names></name><name><surname>Rabbitts</surname> <given-names>TH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Engineering de novo reciprocal chromosomal translocations associated with mll to replicate primary events of human Cancer</article-title><source>Cancer Cell</source><volume>3</volume><fpage>449</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1016/S1535-6108(03)00106-5</pub-id><pub-id pub-id-type="pmid">12781363</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godfrey</surname> <given-names>L</given-names></name><name><surname>Crump</surname> <given-names>NT</given-names></name><name><surname>Thorne</surname> <given-names>R</given-names></name><name><surname>Lau</surname> <given-names>I-J</given-names></name><name><surname>Repapi</surname> <given-names>E</given-names></name><name><surname>Dimou</surname> <given-names>D</given-names></name><name><surname>Smith</surname> <given-names>AL</given-names></name><name><surname>Harman</surname> <given-names>JR</given-names></name><name><surname>Telenius</surname> <given-names>JM</given-names></name><name><surname>Oudelaar</surname> <given-names>AM</given-names></name><name><surname>Downes</surname> <given-names>DJ</given-names></name><name><surname>Vyas</surname> <given-names>P</given-names></name><name><surname>Hughes</surname> <given-names>JR</given-names></name><name><surname>Milne</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>10844-3</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10844-3</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname> <given-names>AS</given-names></name><name><surname>Maciel</surname> <given-names>TT</given-names></name><name><surname>Hospital</surname> <given-names>MA</given-names></name><name><surname>Yin</surname> <given-names>C</given-names></name><name><surname>Mazed</surname> <given-names>F</given-names></name><name><surname>Townsend</surname> <given-names>EC</given-names></name><name><surname>Pilorge</surname> <given-names>S</given-names></name><name><surname>Lambert</surname> <given-names>M</given-names></name><name><surname>Paubelle</surname> <given-names>E</given-names></name><name><surname>Jacquel</surname> <given-names>A</given-names></name><name><surname>Zylbersztejn</surname> <given-names>F</given-names></name><name><surname>Decroocq</surname> <given-names>J</given-names></name><name><surname>Poulain</surname> <given-names>L</given-names></name><name><surname>Sujobert</surname> <given-names>P</given-names></name><name><surname>Jacque</surname> <given-names>N</given-names></name><name><surname>Adam</surname> <given-names>K</given-names></name><name><surname>So</surname> <given-names>JC</given-names></name><name><surname>Kosmider</surname> <given-names>O</given-names></name><name><surname>Auberger</surname> <given-names>P</given-names></name><name><surname>Hermine</surname> <given-names>O</given-names></name><name><surname>Weinstock</surname> <given-names>DM</given-names></name><name><surname>Lacombe</surname> <given-names>C</given-names></name><name><surname>Mayeux</surname> <given-names>P</given-names></name><name><surname>Vanasse</surname> <given-names>GJ</given-names></name><name><surname>Leung</surname> <given-names>AY</given-names></name><name><surname>Moura</surname> <given-names>IC</given-names></name><name><surname>Bouscary</surname> <given-names>D</given-names></name><name><surname>Tamburini</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia</article-title><source>Science Advances</source><volume>1</volume><elocation-id>e1500221</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.1500221</pub-id><pub-id pub-id-type="pmid">26601252</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossmann</surname> <given-names>V</given-names></name><name><surname>Schnittger</surname> <given-names>S</given-names></name><name><surname>Poetzinger</surname> <given-names>F</given-names></name><name><surname>Kohlmann</surname> <given-names>A</given-names></name><name><surname>Stiel</surname> <given-names>A</given-names></name><name><surname>Eder</surname> <given-names>C</given-names></name><name><surname>Fasan</surname> <given-names>A</given-names></name><name><surname>Kern</surname> <given-names>W</given-names></name><name><surname>Haferlach</surname> <given-names>T</given-names></name><name><surname>Haferlach</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia</article-title><source>Leukemia</source><volume>27</volume><fpage>1933</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1038/leu.2013.90</pub-id><pub-id pub-id-type="pmid">23535558</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grzybowski</surname> <given-names>AT</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Ruthenburg</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Calibrating ChIP-Seq with nucleosomal internal standards to measure histone modification density genome wide</article-title><source>Molecular Cell</source><volume>58</volume><fpage>886</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.04.022</pub-id><pub-id pub-id-type="pmid">26004229</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grzybowski</surname> <given-names>AT</given-names></name><name><surname>Shah</surname> <given-names>RN</given-names></name><name><surname>Richter</surname> <given-names>WF</given-names></name><name><surname>Ruthenburg</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Native internally calibrated chromatin immunoprecipitation for quantitative studies of histone post-translational modifications</article-title><source>Nature Protocols</source><volume>14</volume><fpage>3275</fpage><lpage>3302</lpage><pub-id pub-id-type="doi">10.1038/s41596-019-0218-7</pub-id><pub-id pub-id-type="pmid">31723301</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guenther</surname> <given-names>MG</given-names></name><name><surname>Levine</surname> <given-names>SS</given-names></name><name><surname>Boyer</surname> <given-names>LA</given-names></name><name><surname>Jaenisch</surname> <given-names>R</given-names></name><name><surname>Young</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A chromatin landmark and transcription initiation at most promoters in human cells</article-title><source>Cell</source><volume>130</volume><fpage>77</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.05.042</pub-id><pub-id pub-id-type="pmid">17632057</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guenther</surname> <given-names>MG</given-names></name><name><surname>Lawton</surname> <given-names>LN</given-names></name><name><surname>Rozovskaia</surname> <given-names>T</given-names></name><name><surname>Frampton</surname> <given-names>GM</given-names></name><name><surname>Levine</surname> <given-names>SS</given-names></name><name><surname>Volkert</surname> <given-names>TL</given-names></name><name><surname>Croce</surname> <given-names>CM</given-names></name><name><surname>Nakamura</surname> <given-names>T</given-names></name><name><surname>Canaani</surname> <given-names>E</given-names></name><name><surname>Young</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia</article-title><source>Genes &amp; Development</source><volume>22</volume><fpage>3403</fpage><lpage>3408</lpage><pub-id pub-id-type="doi">10.1101/gad.1741408</pub-id><pub-id pub-id-type="pmid">19141473</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname> <given-names>RD</given-names></name><name><surname>Hess</surname> <given-names>JL</given-names></name><name><surname>Yu</surname> <given-names>BD</given-names></name><name><surname>Ernst</surname> <given-names>P</given-names></name><name><surname>van Lohuizen</surname> <given-names>M</given-names></name><name><surname>Berns</surname> <given-names>A</given-names></name><name><surname>van der Lugt</surname> <given-names>NMT</given-names></name><name><surname>Shashikant</surname> <given-names>CS</given-names></name><name><surname>Ruddle</surname> <given-names>FH</given-names></name><name><surname>Seto</surname> <given-names>M</given-names></name><name><surname>Korsmeyer</surname> <given-names>SJ</given-names></name><name><surname>Bd</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mammalian Trithorax and Polycomb-group homologues are antagonistic regulators of homeotic development</article-title><source>PNAS</source><volume>96</volume><fpage>14372</fpage><lpage>14377</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.25.14372</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname> <given-names>WJ</given-names></name><name><surname>Huang</surname> <given-names>X</given-names></name><name><surname>Lynch</surname> <given-names>JT</given-names></name><name><surname>Spencer</surname> <given-names>GJ</given-names></name><name><surname>Hitchin</surname> <given-names>JR</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Ciceri</surname> <given-names>F</given-names></name><name><surname>Blaser</surname> <given-names>JG</given-names></name><name><surname>Greystoke</surname> <given-names>BF</given-names></name><name><surname>Jordan</surname> <given-names>AM</given-names></name><name><surname>Miller</surname> <given-names>CJ</given-names></name><name><surname>Ogilvie</surname> <given-names>DJ</given-names></name><name><surname>Somervaille</surname> <given-names>TCP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells</article-title><source>Cancer Cell</source><volume>21</volume><fpage>473</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.03.014</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>MLL: a histone methyltransferase disrupted in leukemia</article-title><source>Trends in Molecular Medicine</source><volume>10</volume><fpage>500</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2004.08.005</pub-id><pub-id pub-id-type="pmid">15464450</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>daW</given-names></name><name><surname>Sherman</surname> <given-names>BT</given-names></name><name><surname>Lempicki</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009a</year><article-title>Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists</article-title><source>Nucleic Acids Research</source><volume>37</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn923</pub-id><pub-id pub-id-type="pmid">19033363</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>daW</given-names></name><name><surname>Sherman</surname> <given-names>BT</given-names></name><name><surname>Lempicki</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009b</year><article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title><source>Nature Protocols</source><volume>4</volume><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id><pub-id pub-id-type="pmid">19131956</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>Y</given-names></name><name><surname>Sitwala</surname> <given-names>K</given-names></name><name><surname>Bronstein</surname> <given-names>J</given-names></name><name><surname>Sanders</surname> <given-names>D</given-names></name><name><surname>Dandekar</surname> <given-names>M</given-names></name><name><surname>Collins</surname> <given-names>C</given-names></name><name><surname>Robertson</surname> <given-names>G</given-names></name><name><surname>MacDonald</surname> <given-names>J</given-names></name><name><surname>Cezard</surname> <given-names>T</given-names></name><name><surname>Bilenky</surname> <given-names>M</given-names></name><name><surname>Thiessen</surname> <given-names>N</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Zeng</surname> <given-names>T</given-names></name><name><surname>Hirst</surname> <given-names>M</given-names></name><name><surname>Hero</surname> <given-names>A</given-names></name><name><surname>Jones</surname> <given-names>S</given-names></name><name><surname>Hess</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Identification and characterization of Hoxa9 binding sites in hematopoietic cells</article-title><source>Blood</source><volume>119</volume><fpage>388</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-03-341081</pub-id><pub-id pub-id-type="pmid">22072553</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabbour</surname> <given-names>E</given-names></name><name><surname>O'Brien</surname> <given-names>S</given-names></name><name><surname>Konopleva</surname> <given-names>M</given-names></name><name><surname>Kantarjian</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia</article-title><source>Cancer</source><volume>121</volume><fpage>2517</fpage><lpage>2528</lpage><pub-id pub-id-type="doi">10.1002/cncr.29383</pub-id><pub-id pub-id-type="pmid">25891003</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname> <given-names>SY</given-names></name><name><surname>Granowicz</surname> <given-names>EM</given-names></name><name><surname>Maillard</surname> <given-names>I</given-names></name><name><surname>Thomas</surname> <given-names>D</given-names></name><name><surname>Hess</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation</article-title><source>Blood</source><volume>117</volume><fpage>4759</fpage><lpage>4768</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-12-327668</pub-id><pub-id pub-id-type="pmid">21398221</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerry</surname> <given-names>J</given-names></name><name><surname>Godfrey</surname> <given-names>L</given-names></name><name><surname>Repapi</surname> <given-names>E</given-names></name><name><surname>Tapia</surname> <given-names>M</given-names></name><name><surname>Blackledge</surname> <given-names>NP</given-names></name><name><surname>Ma</surname> <given-names>H</given-names></name><name><surname>Ballabio</surname> <given-names>E</given-names></name><name><surname>O'Byrne</surname> <given-names>S</given-names></name><name><surname>Ponthan</surname> <given-names>F</given-names></name><name><surname>Heidenreich</surname> <given-names>O</given-names></name><name><surname>Roy</surname> <given-names>A</given-names></name><name><surname>Roberts</surname> <given-names>I</given-names></name><name><surname>Konopleva</surname> <given-names>M</given-names></name><name><surname>Klose</surname> <given-names>RJ</given-names></name><name><surname>Geng</surname> <given-names>H</given-names></name><name><surname>Milne</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MLL-AF4 spreading identifies binding sites that are distinct from Super-Enhancers and that govern sensitivity to DOT1L inhibition in leukemia</article-title><source>Cell Reports</source><volume>18</volume><fpage>482</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.12.054</pub-id><pub-id pub-id-type="pmid">28076791</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>KT</given-names></name><name><surname>Baird</surname> <given-names>K</given-names></name><name><surname>Ahn</surname> <given-names>JY</given-names></name><name><surname>Meltzer</surname> <given-names>P</given-names></name><name><surname>Lilly</surname> <given-names>M</given-names></name><name><surname>Levis</surname> <given-names>M</given-names></name><name><surname>Small</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Pim-1 is up-regulated by Constitutively activated FLT3 and plays a role in FLT3-mediated cell survival</article-title><source>Blood</source><volume>105</volume><fpage>1759</fpage><lpage>1767</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-05-2006</pub-id><pub-id pub-id-type="pmid">15498859</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>DH</given-names></name><name><surname>Tang</surname> <given-names>Z</given-names></name><name><surname>Shimada</surname> <given-names>M</given-names></name><name><surname>Fierz</surname> <given-names>B</given-names></name><name><surname>Houck-Loomis</surname> <given-names>B</given-names></name><name><surname>Bar-Dagen</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>SK</given-names></name><name><surname>Muir</surname> <given-names>TW</given-names></name><name><surname>Roeder</surname> <given-names>RG</given-names></name><name><surname>Lee</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Histone H3K27 trimethylation inhibits H3 binding and function of SET1-like H3K4 methyltransferase complexes</article-title><source>Molecular and Cellular Biology</source><volume>33</volume><fpage>4936</fpage><lpage>4946</lpage><pub-id pub-id-type="doi">10.1128/MCB.00601-13</pub-id><pub-id pub-id-type="pmid">24126056</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Langmead</surname> <given-names>B</given-names></name><name><surname>Salzberg</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HISAT: a fast spliced aligner with low memory requirements</article-title><source>Nature Methods</source><volume>12</volume><fpage>357</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3317</pub-id><pub-id pub-id-type="pmid">25751142</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klimiankou</surname> <given-names>M</given-names></name><name><surname>Dannenmann</surname> <given-names>B</given-names></name><name><surname>Solovyeva</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Effects of CSF3R mutations on myeloid differentiation and proliferation of hematopoietic cells of congenital neutropenia patients</article-title><source>Blood</source><volume>130</volume><elocation-id>2278</elocation-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krivtsov</surname> <given-names>AV</given-names></name><name><surname>Twomey</surname> <given-names>D</given-names></name><name><surname>Feng</surname> <given-names>Z</given-names></name><name><surname>Stubbs</surname> <given-names>MC</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Faber</surname> <given-names>J</given-names></name><name><surname>Levine</surname> <given-names>JE</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name><name><surname>Gilliland</surname> <given-names>DG</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9</article-title><source>Nature</source><volume>442</volume><fpage>818</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1038/nature04980</pub-id><pub-id pub-id-type="pmid">16862118</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krogan</surname> <given-names>NJ</given-names></name><name><surname>Dover</surname> <given-names>J</given-names></name><name><surname>Khorrami</surname> <given-names>S</given-names></name><name><surname>Greenblatt</surname> <given-names>JF</given-names></name><name><surname>Schneider</surname> <given-names>J</given-names></name><name><surname>Johnston</surname> <given-names>M</given-names></name><name><surname>Shilatifard</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>COMPASS, a histone H3 (Lysine 4) methyltransferase required for telomeric silencing of gene expression</article-title><source>Journal of Biological Chemistry</source><volume>277</volume><fpage>10753</fpage><lpage>10755</lpage><pub-id pub-id-type="doi">10.1074/jbc.C200023200</pub-id><pub-id pub-id-type="pmid">11805083</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroon</surname> <given-names>E</given-names></name><name><surname>Krosl</surname> <given-names>J</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Baban</surname> <given-names>S</given-names></name><name><surname>Buchberg</surname> <given-names>AM</given-names></name><name><surname>Sauvageau</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b</article-title><source>The EMBO Journal</source><volume>17</volume><fpage>3714</fpage><lpage>3725</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.13.3714</pub-id><pub-id pub-id-type="pmid">9649441</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kühn</surname> <given-names>MW</given-names></name><name><surname>Hadler</surname> <given-names>MJ</given-names></name><name><surname>Daigle</surname> <given-names>SR</given-names></name><name><surname>Koche</surname> <given-names>RP</given-names></name><name><surname>Krivtsov</surname> <given-names>AV</given-names></name><name><surname>Olhava</surname> <given-names>EJ</given-names></name><name><surname>Caligiuri</surname> <given-names>MA</given-names></name><name><surname>Huang</surname> <given-names>G</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name><name><surname>Pollock</surname> <given-names>RM</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition</article-title><source>Haematologica</source><volume>100</volume><fpage>e190</fpage><lpage>e193</lpage><pub-id pub-id-type="doi">10.3324/haematol.2014.115337</pub-id><pub-id pub-id-type="pmid">25596271</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levis</surname> <given-names>M</given-names></name><name><surname>Allebach</surname> <given-names>J</given-names></name><name><surname>Tse</surname> <given-names>KF</given-names></name><name><surname>Zheng</surname> <given-names>R</given-names></name><name><surname>Baldwin</surname> <given-names>BR</given-names></name><name><surname>Smith</surname> <given-names>BD</given-names></name><name><surname>Jones-Bolin</surname> <given-names>S</given-names></name><name><surname>Ruggeri</surname> <given-names>B</given-names></name><name><surname>Dionne</surname> <given-names>C</given-names></name><name><surname>Small</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo</article-title><source>Blood</source><volume>99</volume><fpage>3885</fpage><lpage>3891</lpage><pub-id pub-id-type="doi">10.1182/blood.V99.11.3885</pub-id><pub-id pub-id-type="pmid">12010785</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levis</surname> <given-names>M</given-names></name><name><surname>Small</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>FLT3: itdoes matter in leukemia</article-title><source>Leukemia</source><volume>17</volume><fpage>1738</fpage><lpage>1752</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2403099</pub-id><pub-id pub-id-type="pmid">12970773</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>BE</given-names></name><name><surname>Gan</surname> <given-names>T</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Rabbitts</surname> <given-names>TH</given-names></name><name><surname>Ernst</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>Distinct pathways regulated by Menin and by MLL1 in hematopoietic stem cells and developing B cells</article-title><source>Blood</source><volume>122</volume><fpage>2039</fpage><lpage>2046</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-03-486647</pub-id><pub-id pub-id-type="pmid">23908472</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Arnovitz</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>P</given-names></name><name><surname>Huang</surname> <given-names>H</given-names></name><name><surname>Jiang</surname> <given-names>X</given-names></name><name><surname>Hong</surname> <given-names>GM</given-names></name><name><surname>Kunjamma</surname> <given-names>RB</given-names></name><name><surname>Ren</surname> <given-names>H</given-names></name><name><surname>He</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>CZ</given-names></name><name><surname>Elkahloun</surname> <given-names>AG</given-names></name><name><surname>Valk</surname> <given-names>PJ</given-names></name><name><surname>Döhner</surname> <given-names>K</given-names></name><name><surname>Neilly</surname> <given-names>MB</given-names></name><name><surname>Bullinger</surname> <given-names>L</given-names></name><name><surname>Delwel</surname> <given-names>R</given-names></name><name><surname>Löwenberg</surname> <given-names>B</given-names></name><name><surname>Liu</surname> <given-names>PP</given-names></name><name><surname>Morgan</surname> <given-names>R</given-names></name><name><surname>Rowley</surname> <given-names>JD</given-names></name><name><surname>Yuan</surname> <given-names>CS</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>PBX3 is an important cofactor of HOXA9 in leukemogenesis</article-title><source>Blood</source><volume>121</volume><fpage>1422</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-07-442004</pub-id><pub-id pub-id-type="pmid">23264595</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Chen</surname> <given-names>P</given-names></name><name><surname>Su</surname> <given-names>R</given-names></name><name><surname>Hu</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Elkahloun</surname> <given-names>AG</given-names></name><name><surname>Zuo</surname> <given-names>Z</given-names></name><name><surname>Gurbuxani</surname> <given-names>S</given-names></name><name><surname>Arnovitz</surname> <given-names>S</given-names></name><name><surname>Weng</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Huang</surname> <given-names>H</given-names></name><name><surname>Neilly</surname> <given-names>MB</given-names></name><name><surname>Wang</surname> <given-names>GG</given-names></name><name><surname>Jiang</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>PP</given-names></name><name><surname>Jin</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>PBX3 and MEIS1 cooperate in hematopoietic cells to drive acute myeloid leukemias characterized by a core transcriptome of the MLL-Rearranged disease</article-title><source>Cancer Research</source><volume>76</volume><fpage>619</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-1566</pub-id><pub-id pub-id-type="pmid">26747896</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>DC</given-names></name><name><surname>Shih</surname> <given-names>LY</given-names></name><name><surname>Fu</surname> <given-names>JF</given-names></name><name><surname>Li</surname> <given-names>HY</given-names></name><name><surname>Wang</surname> <given-names>HI</given-names></name><name><surname>Hung</surname> <given-names>IJ</given-names></name><name><surname>Yang</surname> <given-names>CP</given-names></name><name><surname>Jaing</surname> <given-names>TH</given-names></name><name><surname>Chen</surname> <given-names>SH</given-names></name><name><surname>Liu</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements</article-title><source>Cancer</source><volume>106</volume><fpage>950</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1002/cncr.21687</pub-id><pub-id pub-id-type="pmid">16404744</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname> <given-names>G</given-names></name><name><surname>Attarbaschi</surname> <given-names>A</given-names></name><name><surname>Schrappe</surname> <given-names>M</given-names></name><name><surname>De Lorenzo</surname> <given-names>P</given-names></name><name><surname>Peters</surname> <given-names>C</given-names></name><name><surname>Hann</surname> <given-names>I</given-names></name><name><surname>De Rossi</surname> <given-names>G</given-names></name><name><surname>Felice</surname> <given-names>M</given-names></name><name><surname>Lausen</surname> <given-names>B</given-names></name><name><surname>Leblanc</surname> <given-names>T</given-names></name><name><surname>Szczepanski</surname> <given-names>T</given-names></name><name><surname>Ferster</surname> <given-names>A</given-names></name><name><surname>Janka-Schaub</surname> <given-names>G</given-names></name><name><surname>Rubnitz</surname> <given-names>J</given-names></name><name><surname>Silverman</surname> <given-names>LB</given-names></name><name><surname>Stary</surname> <given-names>J</given-names></name><name><surname>Campbell</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>CK</given-names></name><name><surname>Suppiah</surname> <given-names>R</given-names></name><name><surname>Biondi</surname> <given-names>A</given-names></name><name><surname>Vora</surname> <given-names>A</given-names></name><name><surname>Valsecchi</surname> <given-names>MG</given-names></name><name><surname>Pieters</surname> <given-names>R</given-names></name><collab>Interfant-99 Study Group</collab></person-group><year iso-8601-date="2010">2010</year><article-title>Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 study</article-title><source>Blood</source><volume>116</volume><fpage>2644</fpage><lpage>2650</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-03-273532</pub-id><pub-id pub-id-type="pmid">20592248</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname> <given-names>DI</given-names></name><name><surname>Moorman</surname> <given-names>AV</given-names></name><name><surname>Chilton</surname> <given-names>L</given-names></name><name><surname>Paietta</surname> <given-names>E</given-names></name><name><surname>Enshaie</surname> <given-names>A</given-names></name><name><surname>DeWald</surname> <given-names>G</given-names></name><name><surname>Harrison</surname> <given-names>CJ</given-names></name><name><surname>Fielding</surname> <given-names>AK</given-names></name><name><surname>Foroni</surname> <given-names>L</given-names></name><name><surname>Goldstone</surname> <given-names>AH</given-names></name><name><surname>Litzow</surname> <given-names>MR</given-names></name><name><surname>Luger</surname> <given-names>SM</given-names></name><name><surname>McMillan</surname> <given-names>AK</given-names></name><name><surname>Racevskis</surname> <given-names>J</given-names></name><name><surname>Rowe</surname> <given-names>JM</given-names></name><name><surname>Tallman</surname> <given-names>MS</given-names></name><name><surname>Wiernik</surname> <given-names>P</given-names></name><name><surname>Lazarus</surname> <given-names>HM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial</article-title><source>Haematologica</source><volume>98</volume><fpage>945</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.3324/haematol.2012.081877</pub-id><pub-id pub-id-type="pmid">23349309</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marschalek</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mechanisms of leukemogenesis by MLL fusion proteins</article-title><source>British Journal of Haematology</source><volume>152</volume><fpage>141</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2010.08459.x</pub-id><pub-id pub-id-type="pmid">21118195</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGrath</surname> <given-names>JP</given-names></name><name><surname>Williamson</surname> <given-names>KE</given-names></name><name><surname>Balasubramanian</surname> <given-names>S</given-names></name><name><surname>Odate</surname> <given-names>S</given-names></name><name><surname>Arora</surname> <given-names>S</given-names></name><name><surname>Hatton</surname> <given-names>C</given-names></name><name><surname>Edwards</surname> <given-names>TM</given-names></name><name><surname>O'Brien</surname> <given-names>T</given-names></name><name><surname>Magnuson</surname> <given-names>S</given-names></name><name><surname>Stokoe</surname> <given-names>D</given-names></name><name><surname>Daniels</surname> <given-names>DL</given-names></name><name><surname>Bryant</surname> <given-names>BM</given-names></name><name><surname>Trojer</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pharmacological inhibition of the histone lysine demethylase KDM1A suppresses the growth of multiple acute myeloid leukemia subtypes</article-title><source>Cancer Research</source><volume>76</volume><fpage>1975</fpage><lpage>1988</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-2333</pub-id><pub-id pub-id-type="pmid">26837761</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname> <given-names>C</given-names></name><name><surname>Burmeister</surname> <given-names>T</given-names></name><name><surname>Gröger</surname> <given-names>D</given-names></name><name><surname>Tsaur</surname> <given-names>G</given-names></name><name><surname>Fechina</surname> <given-names>L</given-names></name><name><surname>Renneville</surname> <given-names>A</given-names></name><name><surname>Sutton</surname> <given-names>R</given-names></name><name><surname>Venn</surname> <given-names>NC</given-names></name><name><surname>Emerenciano</surname> <given-names>M</given-names></name><name><surname>Pombo-de-Oliveira</surname> <given-names>MS</given-names></name><name><surname>Barbieri Blunck</surname> <given-names>C</given-names></name><name><surname>Almeida Lopes</surname> <given-names>B</given-names></name><name><surname>Zuna</surname> <given-names>J</given-names></name><name><surname>Trka</surname> <given-names>J</given-names></name><name><surname>Ballerini</surname> <given-names>P</given-names></name><name><surname>Lapillonne</surname> <given-names>H</given-names></name><name><surname>De Braekeleer</surname> <given-names>M</given-names></name><name><surname>Cazzaniga</surname> <given-names>G</given-names></name><name><surname>Corral Abascal</surname> <given-names>L</given-names></name><name><surname>van der Velden</surname> <given-names>VHJ</given-names></name><name><surname>Delabesse</surname> <given-names>E</given-names></name><name><surname>Park</surname> <given-names>TS</given-names></name><name><surname>Oh</surname> <given-names>SH</given-names></name><name><surname>Silva</surname> <given-names>MLM</given-names></name><name><surname>Lund-Aho</surname> <given-names>T</given-names></name><name><surname>Juvonen</surname> <given-names>V</given-names></name><name><surname>Moore</surname> <given-names>AS</given-names></name><name><surname>Heidenreich</surname> <given-names>O</given-names></name><name><surname>Vormoor</surname> <given-names>J</given-names></name><name><surname>Zerkalenkova</surname> <given-names>E</given-names></name><name><surname>Olshanskaya</surname> <given-names>Y</given-names></name><name><surname>Bueno</surname> <given-names>C</given-names></name><name><surname>Menendez</surname> <given-names>P</given-names></name><name><surname>Teigler-Schlegel</surname> <given-names>A</given-names></name><name><surname>Zur Stadt</surname> <given-names>U</given-names></name><name><surname>Lentes</surname> <given-names>J</given-names></name><name><surname>Göhring</surname> <given-names>G</given-names></name><name><surname>Kustanovich</surname> <given-names>A</given-names></name><name><surname>Aleinikova</surname> <given-names>O</given-names></name><name><surname>Schäfer</surname> <given-names>BW</given-names></name><name><surname>Kubetzko</surname> <given-names>S</given-names></name><name><surname>Madsen</surname> <given-names>HO</given-names></name><name><surname>Gruhn</surname> <given-names>B</given-names></name><name><surname>Duarte</surname> <given-names>X</given-names></name><name><surname>Gameiro</surname> <given-names>P</given-names></name><name><surname>Lippert</surname> <given-names>E</given-names></name><name><surname>Bidet</surname> <given-names>A</given-names></name><name><surname>Cayuela</surname> <given-names>JM</given-names></name><name><surname>Clappier</surname> <given-names>E</given-names></name><name><surname>Alonso</surname> <given-names>CN</given-names></name><name><surname>Zwaan</surname> <given-names>CM</given-names></name><name><surname>van den Heuvel-Eibrink</surname> <given-names>MM</given-names></name><name><surname>Izraeli</surname> <given-names>S</given-names></name><name><surname>Trakhtenbrot</surname> <given-names>L</given-names></name><name><surname>Archer</surname> <given-names>P</given-names></name><name><surname>Hancock</surname> <given-names>J</given-names></name><name><surname>Möricke</surname> <given-names>A</given-names></name><name><surname>Alten</surname> <given-names>J</given-names></name><name><surname>Schrappe</surname> <given-names>M</given-names></name><name><surname>Stanulla</surname> <given-names>M</given-names></name><name><surname>Strehl</surname> <given-names>S</given-names></name><name><surname>Attarbaschi</surname> <given-names>A</given-names></name><name><surname>Dworzak</surname> <given-names>M</given-names></name><name><surname>Haas</surname> <given-names>OA</given-names></name><name><surname>Panzer-Grümayer</surname> <given-names>R</given-names></name><name><surname>Sedék</surname> <given-names>L</given-names></name><name><surname>Szczepański</surname> <given-names>T</given-names></name><name><surname>Caye</surname> <given-names>A</given-names></name><name><surname>Suarez</surname> <given-names>L</given-names></name><name><surname>Cavé</surname> <given-names>H</given-names></name><name><surname>Marschalek</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The MLL recombinome of acute leukemias in 2017</article-title><source>Leukemia</source><volume>32</volume><fpage>273</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1038/leu.2017.213</pub-id><pub-id pub-id-type="pmid">28701730</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname> <given-names>TA</given-names></name><name><surname>Martin</surname> <given-names>ME</given-names></name><name><surname>Brock</surname> <given-names>HW</given-names></name><name><surname>Slany</surname> <given-names>RK</given-names></name><name><surname>Hess</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Leukemogenic MLL fusion proteins bind across a broad region of the hox a9 locus, promoting transcription and multiple histone modifications</article-title><source>Cancer Research</source><volume>65</volume><fpage>11367</fpage><lpage>11374</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1041</pub-id><pub-id pub-id-type="pmid">16357144</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname> <given-names>TA</given-names></name><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>GG</given-names></name><name><surname>Stadler</surname> <given-names>SC</given-names></name><name><surname>Basrur</surname> <given-names>V</given-names></name><name><surname>Whitcomb</surname> <given-names>SJ</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Ruthenburg</surname> <given-names>AJ</given-names></name><name><surname>Elenitoba-Johnson</surname> <given-names>KS</given-names></name><name><surname>Roeder</surname> <given-names>RG</given-names></name><name><surname>Allis</surname> <given-names>CD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis</article-title><source>Molecular Cell</source><volume>38</volume><fpage>853</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.05.011</pub-id><pub-id pub-id-type="pmid">20541448</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuki</surname> <given-names>M</given-names></name><name><surname>Schwable</surname> <given-names>J</given-names></name><name><surname>Steur</surname> <given-names>C</given-names></name><name><surname>Choudhary</surname> <given-names>C</given-names></name><name><surname>Agrawal</surname> <given-names>S</given-names></name><name><surname>Sargin</surname> <given-names>B</given-names></name><name><surname>Steffen</surname> <given-names>B</given-names></name><name><surname>Matsumura</surname> <given-names>I</given-names></name><name><surname>Kanakura</surname> <given-names>Y</given-names></name><name><surname>Böhmer</surname> <given-names>FD</given-names></name><name><surname>Müller-Tidow</surname> <given-names>C</given-names></name><name><surname>Berdel</surname> <given-names>WE</given-names></name><name><surname>Serve</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations</article-title><source>Blood</source><volume>101</volume><fpage>3164</fpage><lpage>3173</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-06-1677</pub-id><pub-id pub-id-type="pmid">12468433</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohan</surname> <given-names>M</given-names></name><name><surname>Herz</surname> <given-names>HM</given-names></name><name><surname>Takahashi</surname> <given-names>YH</given-names></name><name><surname>Lin</surname> <given-names>C</given-names></name><name><surname>Lai</surname> <given-names>KC</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Washburn</surname> <given-names>MP</given-names></name><name><surname>Florens</surname> <given-names>L</given-names></name><name><surname>Shilatifard</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Linking H3K79 trimethylation to wnt signaling through a novel Dot1-containing complex (DotCom)</article-title><source>Genes &amp; Development</source><volume>24</volume><fpage>574</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1101/gad.1898410</pub-id><pub-id pub-id-type="pmid">20203130</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname> <given-names>MA</given-names></name><name><surname>Dorn</surname> <given-names>DC</given-names></name><name><surname>Schuringa</surname> <given-names>JJ</given-names></name><name><surname>Chung</surname> <given-names>KY</given-names></name><name><surname>Morrone</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells</article-title><source>Experimental Hematology</source><volume>35</volume><fpage>105</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.exphem.2007.01.018</pub-id><pub-id pub-id-type="pmid">17379095</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Lindgren</surname> <given-names>CM</given-names></name><name><surname>Eriksson</surname> <given-names>KF</given-names></name><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Sihag</surname> <given-names>S</given-names></name><name><surname>Lehar</surname> <given-names>J</given-names></name><name><surname>Puigserver</surname> <given-names>P</given-names></name><name><surname>Carlsson</surname> <given-names>E</given-names></name><name><surname>Ridderstråle</surname> <given-names>M</given-names></name><name><surname>Laurila</surname> <given-names>E</given-names></name><name><surname>Houstis</surname> <given-names>N</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Patterson</surname> <given-names>N</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Spiegelman</surname> <given-names>B</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Hirschhorn</surname> <given-names>JN</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name><name><surname>Groop</surname> <given-names>LC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes</article-title><source>Nature Genetics</source><volume>34</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/ng1180</pub-id><pub-id pub-id-type="pmid">12808457</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mossadegh-Keller</surname> <given-names>N</given-names></name><name><surname>Sarrazin</surname> <given-names>S</given-names></name><name><surname>Kandalla</surname> <given-names>PK</given-names></name><name><surname>Espinosa</surname> <given-names>L</given-names></name><name><surname>Stanley</surname> <given-names>ER</given-names></name><name><surname>Nutt</surname> <given-names>SL</given-names></name><name><surname>Moore</surname> <given-names>J</given-names></name><name><surname>Sieweke</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>M-CSF instructs myeloid lineage fate in single haematopoietic stem cells</article-title><source>Nature</source><volume>497</volume><fpage>239</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1038/nature12026</pub-id><pub-id pub-id-type="pmid">23575636</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muhlethaler-Mottet</surname> <given-names>A</given-names></name><name><surname>Di Berardino</surname> <given-names>W</given-names></name><name><surname>Otten</surname> <given-names>LA</given-names></name><name><surname>Mach</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1</article-title><source>Immunity</source><volume>8</volume><fpage>157</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80468-9</pub-id><pub-id pub-id-type="pmid">9491997</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagel</surname> <given-names>G</given-names></name><name><surname>Weber</surname> <given-names>D</given-names></name><name><surname>Fromm</surname> <given-names>E</given-names></name><name><surname>Erhardt</surname> <given-names>S</given-names></name><name><surname>Lübbert</surname> <given-names>M</given-names></name><name><surname>Fiedler</surname> <given-names>W</given-names></name><name><surname>Kindler</surname> <given-names>T</given-names></name><name><surname>Krauter</surname> <given-names>J</given-names></name><name><surname>Brossart</surname> <given-names>P</given-names></name><name><surname>Kündgen</surname> <given-names>A</given-names></name><name><surname>Salih</surname> <given-names>HR</given-names></name><name><surname>Westermann</surname> <given-names>J</given-names></name><name><surname>Wulf</surname> <given-names>G</given-names></name><name><surname>Hertenstein</surname> <given-names>B</given-names></name><name><surname>Wattad</surname> <given-names>M</given-names></name><name><surname>Götze</surname> <given-names>K</given-names></name><name><surname>Kraemer</surname> <given-names>D</given-names></name><name><surname>Heinicke</surname> <given-names>T</given-names></name><name><surname>Girschikofsky</surname> <given-names>M</given-names></name><name><surname>Derigs</surname> <given-names>HG</given-names></name><name><surname>Horst</surname> <given-names>HA</given-names></name><name><surname>Rudolph</surname> <given-names>C</given-names></name><name><surname>Heuser</surname> <given-names>M</given-names></name><name><surname>Göhring</surname> <given-names>G</given-names></name><name><surname>Teleanu</surname> <given-names>V</given-names></name><name><surname>Bullinger</surname> <given-names>L</given-names></name><name><surname>Thol</surname> <given-names>F</given-names></name><name><surname>Gaidzik</surname> <given-names>VI</given-names></name><name><surname>Paschka</surname> <given-names>P</given-names></name><name><surname>Döhner</surname> <given-names>K</given-names></name><name><surname>Ganser</surname> <given-names>A</given-names></name><name><surname>Döhner</surname> <given-names>H</given-names></name><name><surname>Schlenk</surname> <given-names>RF</given-names></name><collab>German-Austrian AML Study Group (AMLSG)</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)</article-title><source>Annals of Hematology</source><volume>96</volume><fpage>1993</fpage><lpage>2003</lpage><pub-id pub-id-type="doi">10.1007/s00277-017-3150-3</pub-id><pub-id pub-id-type="pmid">29090343</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neff</surname> <given-names>T</given-names></name><name><surname>Sinha</surname> <given-names>AU</given-names></name><name><surname>Kluk</surname> <given-names>MJ</given-names></name><name><surname>Zhu</surname> <given-names>N</given-names></name><name><surname>Khattab</surname> <given-names>MH</given-names></name><name><surname>Stein</surname> <given-names>L</given-names></name><name><surname>Xie</surname> <given-names>H</given-names></name><name><surname>Orkin</surname> <given-names>SH</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Polycomb repressive complex 2 is required for MLL-AF9 leukemia</article-title><source>PNAS</source><volume>109</volume><fpage>5028</fpage><lpage>5033</lpage><pub-id pub-id-type="doi">10.1073/pnas.1202258109</pub-id><pub-id pub-id-type="pmid">22396593</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname> <given-names>Y</given-names></name><name><surname>Feng</surname> <given-names>Q</given-names></name><name><surname>Lin</surname> <given-names>Y</given-names></name><name><surname>Jiang</surname> <given-names>Q</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Coffield</surname> <given-names>VM</given-names></name><name><surname>Su</surname> <given-names>L</given-names></name><name><surname>Xu</surname> <given-names>G</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>hDOT1L links histone methylation to leukemogenesis</article-title><source>Cell</source><volume>121</volume><fpage>167</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.02.020</pub-id><pub-id pub-id-type="pmid">15851025</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname> <given-names>H</given-names></name><name><surname>Stanojevic</surname> <given-names>B</given-names></name><name><surname>Kanai</surname> <given-names>A</given-names></name><name><surname>Kawamura</surname> <given-names>T</given-names></name><name><surname>Takahashi</surname> <given-names>S</given-names></name><name><surname>Matsui</surname> <given-names>H</given-names></name><name><surname>Takaori-Kondo</surname> <given-names>A</given-names></name><name><surname>Yokoyama</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia</article-title><source>Journal of Clinical Investigation</source><volume>127</volume><fpage>1918</fpage><lpage>1931</lpage><pub-id pub-id-type="doi">10.1172/JCI91406</pub-id><pub-id pub-id-type="pmid">28394257</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onishi</surname> <given-names>M</given-names></name><name><surname>Nosaka</surname> <given-names>T</given-names></name><name><surname>Misawa</surname> <given-names>K</given-names></name><name><surname>Mui</surname> <given-names>AL</given-names></name><name><surname>Gorman</surname> <given-names>D</given-names></name><name><surname>McMahon</surname> <given-names>M</given-names></name><name><surname>Miyajima</surname> <given-names>A</given-names></name><name><surname>Kitamura</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation</article-title><source>Molecular and Cellular Biology</source><volume>18</volume><fpage>3871</fpage><lpage>3879</lpage><pub-id pub-id-type="doi">10.1128/MCB.18.7.3871</pub-id><pub-id pub-id-type="pmid">9632771</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ono</surname> <given-names>R</given-names></name><name><surname>Nakajima</surname> <given-names>H</given-names></name><name><surname>Ozaki</surname> <given-names>K</given-names></name><name><surname>Kumagai</surname> <given-names>H</given-names></name><name><surname>Kawashima</surname> <given-names>T</given-names></name><name><surname>Taki</surname> <given-names>T</given-names></name><name><surname>Kitamura</surname> <given-names>T</given-names></name><name><surname>Hayashi</surname> <given-names>Y</given-names></name><name><surname>Nosaka</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis</article-title><source>Journal of Clinical Investigation</source><volume>115</volume><fpage>919</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1172/JCI200522725</pub-id><pub-id pub-id-type="pmid">15761502</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orlando</surname> <given-names>DA</given-names></name><name><surname>Chen</surname> <given-names>MW</given-names></name><name><surname>Brown</surname> <given-names>VE</given-names></name><name><surname>Solanki</surname> <given-names>S</given-names></name><name><surname>Choi</surname> <given-names>YJ</given-names></name><name><surname>Olson</surname> <given-names>ER</given-names></name><name><surname>Fritz</surname> <given-names>CC</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name><name><surname>Guenther</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Quantitative ChIP-Seq normalization reveals global modulation of the epigenome</article-title><source>Cell Reports</source><volume>9</volume><fpage>1163</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.10.018</pub-id><pub-id pub-id-type="pmid">25437568</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paukku</surname> <given-names>K</given-names></name><name><surname>Silvennoinen</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>15</volume><fpage>435</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2004.09.001</pub-id><pub-id pub-id-type="pmid">15561601</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peltola</surname> <given-names>K</given-names></name><name><surname>Hollmen</surname> <given-names>M</given-names></name><name><surname>Maula</surname> <given-names>SM</given-names></name><name><surname>Rainio</surname> <given-names>E</given-names></name><name><surname>Ristamäki</surname> <given-names>R</given-names></name><name><surname>Luukkaa</surname> <given-names>M</given-names></name><name><surname>Sandholm</surname> <given-names>J</given-names></name><name><surname>Sundvall</surname> <given-names>M</given-names></name><name><surname>Elenius</surname> <given-names>K</given-names></name><name><surname>Koskinen</surname> <given-names>PJ</given-names></name><name><surname>Grenman</surname> <given-names>R</given-names></name><name><surname>Jalkanen</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Pim-1 kinase expression predicts radiation response in Squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor</article-title><source>Neoplasia</source><volume>11</volume><fpage>629</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1593/neo.81038</pub-id><pub-id pub-id-type="pmid">19568408</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieters</surname> <given-names>R</given-names></name><name><surname>Schrappe</surname> <given-names>M</given-names></name><name><surname>De Lorenzo</surname> <given-names>P</given-names></name><name><surname>Hann</surname> <given-names>I</given-names></name><name><surname>De Rossi</surname> <given-names>G</given-names></name><name><surname>Felice</surname> <given-names>M</given-names></name><name><surname>Hovi</surname> <given-names>L</given-names></name><name><surname>LeBlanc</surname> <given-names>T</given-names></name><name><surname>Szczepanski</surname> <given-names>T</given-names></name><name><surname>Ferster</surname> <given-names>A</given-names></name><name><surname>Janka</surname> <given-names>G</given-names></name><name><surname>Rubnitz</surname> <given-names>J</given-names></name><name><surname>Silverman</surname> <given-names>L</given-names></name><name><surname>Stary</surname> <given-names>J</given-names></name><name><surname>Campbell</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>CK</given-names></name><name><surname>Mann</surname> <given-names>G</given-names></name><name><surname>Suppiah</surname> <given-names>R</given-names></name><name><surname>Biondi</surname> <given-names>A</given-names></name><name><surname>Vora</surname> <given-names>A</given-names></name><name><surname>Valsecchi</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial</article-title><source>The Lancet</source><volume>370</volume><fpage>240</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)61126-X</pub-id><pub-id pub-id-type="pmid">17658395</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quentmeier</surname> <given-names>H</given-names></name><name><surname>Reinhardt</surname> <given-names>J</given-names></name><name><surname>Zaborski</surname> <given-names>M</given-names></name><name><surname>Drexler</surname> <given-names>HG</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>FLT3 mutations in acute myeloid leukemia cell lines</article-title><source>Leukemia</source><volume>17</volume><fpage>120</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2402740</pub-id><pub-id pub-id-type="pmid">12529668</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rani</surname> <given-names>A</given-names></name><name><surname>Murphy</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>STAT5 in Cancer and Immunity</article-title><source>Journal of Interferon &amp; Cytokine Research</source><volume>36</volume><fpage>226</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1089/jir.2015.0054</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname> <given-names>D</given-names></name><name><surname>Melão</surname> <given-names>A</given-names></name><name><surname>van Boxtel</surname> <given-names>R</given-names></name><name><surname>Santos</surname> <given-names>CI</given-names></name><name><surname>Silva</surname> <given-names>A</given-names></name><name><surname>Silva</surname> <given-names>MC</given-names></name><name><surname>Cardoso</surname> <given-names>BA</given-names></name><name><surname>Coffer</surname> <given-names>PJ</given-names></name><name><surname>Barata</surname> <given-names>JT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells</article-title><source>Blood Advances</source><volume>2</volume><fpage>2199</fpage><lpage>2213</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2018021063</pub-id><pub-id pub-id-type="pmid">30185437</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname> <given-names>DB</given-names></name><name><surname>Minden</surname> <given-names>MD</given-names></name><name><surname>Kornblau</surname> <given-names>SM</given-names></name><name><surname>Cohen</surname> <given-names>A</given-names></name><name><surname>Gayko</surname> <given-names>U</given-names></name><name><surname>Putta</surname> <given-names>S</given-names></name><name><surname>Woronicz</surname> <given-names>J</given-names></name><name><surname>Evensen</surname> <given-names>E</given-names></name><name><surname>Fantl</surname> <given-names>WJ</given-names></name><name><surname>Cesano</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP)</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e13543</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0013543</pub-id><pub-id pub-id-type="pmid">21048955</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname> <given-names>SC</given-names></name><name><surname>Lacronique</surname> <given-names>V</given-names></name><name><surname>Bouchaert</surname> <given-names>I</given-names></name><name><surname>Monni</surname> <given-names>R</given-names></name><name><surname>Bernard</surname> <given-names>O</given-names></name><name><surname>Gisselbrecht</surname> <given-names>S</given-names></name><name><surname>Gouilleux</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway</article-title><source>Oncogene</source><volume>20</volume><fpage>2080</fpage><lpage>2090</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1204308</pub-id><pub-id pub-id-type="pmid">11360192</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheeren</surname> <given-names>FA</given-names></name><name><surname>Naspetti</surname> <given-names>M</given-names></name><name><surname>Diehl</surname> <given-names>S</given-names></name><name><surname>Schotte</surname> <given-names>R</given-names></name><name><surname>Nagasawa</surname> <given-names>M</given-names></name><name><surname>Wijnands</surname> <given-names>E</given-names></name><name><surname>Gimeno</surname> <given-names>R</given-names></name><name><surname>Vyth-Dreese</surname> <given-names>FA</given-names></name><name><surname>Blom</surname> <given-names>B</given-names></name><name><surname>Spits</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression</article-title><source>Nature Immunology</source><volume>6</volume><fpage>303</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1038/ni1172</pub-id><pub-id pub-id-type="pmid">15711548</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitges</surname> <given-names>FW</given-names></name><name><surname>Prusty</surname> <given-names>AB</given-names></name><name><surname>Faty</surname> <given-names>M</given-names></name><name><surname>Stützer</surname> <given-names>A</given-names></name><name><surname>Lingaraju</surname> <given-names>GM</given-names></name><name><surname>Aiwazian</surname> <given-names>J</given-names></name><name><surname>Sack</surname> <given-names>R</given-names></name><name><surname>Hess</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Zhou</surname> <given-names>S</given-names></name><name><surname>Bunker</surname> <given-names>RD</given-names></name><name><surname>Wirth</surname> <given-names>U</given-names></name><name><surname>Bouwmeester</surname> <given-names>T</given-names></name><name><surname>Bauer</surname> <given-names>A</given-names></name><name><surname>Ly-Hartig</surname> <given-names>N</given-names></name><name><surname>Zhao</surname> <given-names>K</given-names></name><name><surname>Chan</surname> <given-names>H</given-names></name><name><surname>Gu</surname> <given-names>J</given-names></name><name><surname>Gut</surname> <given-names>H</given-names></name><name><surname>Fischle</surname> <given-names>W</given-names></name><name><surname>Müller</surname> <given-names>J</given-names></name><name><surname>Thomä</surname> <given-names>NH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Histone methylation by PRC2 is inhibited by active chromatin marks</article-title><source>Molecular Cell</source><volume>42</volume><fpage>330</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2011.03.025</pub-id><pub-id pub-id-type="pmid">21549310</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schübeler</surname> <given-names>D</given-names></name><name><surname>MacAlpine</surname> <given-names>DM</given-names></name><name><surname>Scalzo</surname> <given-names>D</given-names></name><name><surname>Wirbelauer</surname> <given-names>C</given-names></name><name><surname>Kooperberg</surname> <given-names>C</given-names></name><name><surname>van Leeuwen</surname> <given-names>F</given-names></name><name><surname>Gottschling</surname> <given-names>DE</given-names></name><name><surname>O'Neill</surname> <given-names>LP</given-names></name><name><surname>Turner</surname> <given-names>BM</given-names></name><name><surname>Delrow</surname> <given-names>J</given-names></name><name><surname>Bell</surname> <given-names>SP</given-names></name><name><surname>Groudine</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote</article-title><source>Genes &amp; Development</source><volume>18</volume><fpage>1263</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1101/gad.1198204</pub-id><pub-id pub-id-type="pmid">15175259</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname> <given-names>RN</given-names></name><name><surname>Grzybowski</surname> <given-names>AT</given-names></name><name><surname>Cornett</surname> <given-names>EM</given-names></name><name><surname>Johnstone</surname> <given-names>AL</given-names></name><name><surname>Dickson</surname> <given-names>BM</given-names></name><name><surname>Boone</surname> <given-names>BA</given-names></name><name><surname>Cheek</surname> <given-names>MA</given-names></name><name><surname>Cowles</surname> <given-names>MW</given-names></name><name><surname>Maryanski</surname> <given-names>D</given-names></name><name><surname>Meiners</surname> <given-names>MJ</given-names></name><name><surname>Tiedemann</surname> <given-names>RL</given-names></name><name><surname>Vaughan</surname> <given-names>RM</given-names></name><name><surname>Arora</surname> <given-names>N</given-names></name><name><surname>Sun</surname> <given-names>ZW</given-names></name><name><surname>Rothbart</surname> <given-names>SB</given-names></name><name><surname>Keogh</surname> <given-names>MC</given-names></name><name><surname>Ruthenburg</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Examining the roles of H3K4 methylation states with systematically characterized antibodies</article-title><source>Molecular Cell</source><volume>72</volume><fpage>162</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.08.015</pub-id><pub-id pub-id-type="pmid">30244833</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>E</given-names></name><name><surname>Zuber</surname> <given-names>J</given-names></name><name><surname>Rappaport</surname> <given-names>A</given-names></name><name><surname>Taylor</surname> <given-names>M</given-names></name><name><surname>Johns</surname> <given-names>C</given-names></name><name><surname>Lowe</surname> <given-names>SW</given-names></name><name><surname>Vakoc</surname> <given-names>CR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia</article-title><source>Oncogene</source><volume>32</volume><fpage>930</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.110</pub-id><pub-id pub-id-type="pmid">22469984</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiekermann</surname> <given-names>K</given-names></name><name><surname>Pau</surname> <given-names>M</given-names></name><name><surname>Schwab</surname> <given-names>R</given-names></name><name><surname>Schmieja</surname> <given-names>K</given-names></name><name><surname>Franzrahe</surname> <given-names>S</given-names></name><name><surname>Hiddemann</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells</article-title><source>Experimental Hematology</source><volume>30</volume><fpage>262</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/S0301-472X(01)00787-1</pub-id><pub-id pub-id-type="pmid">11882364</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiekermann</surname> <given-names>K</given-names></name><name><surname>Bagrintseva</surname> <given-names>K</given-names></name><name><surname>Schwab</surname> <given-names>R</given-names></name><name><surname>Schmieja</surname> <given-names>K</given-names></name><name><surname>Hiddemann</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells</article-title><source>Clinical Cancer Res</source><volume>9</volume><fpage>2140</fpage><lpage>2150</lpage><pub-id pub-id-type="pmid">12796379</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stehling-Sun</surname> <given-names>S</given-names></name><name><surname>Dade</surname> <given-names>J</given-names></name><name><surname>Nutt</surname> <given-names>SL</given-names></name><name><surname>DeKoter</surname> <given-names>RP</given-names></name><name><surname>Camargo</surname> <given-names>FD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Regulation of lymphoid versus myeloid fate 'choice' by the transcription factor Mef2c</article-title><source>Nature Immunology</source><volume>10</volume><fpage>289</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1038/ni.1694</pub-id><pub-id pub-id-type="pmid">19169261</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stubbs</surname> <given-names>MC</given-names></name><name><surname>Kim</surname> <given-names>YM</given-names></name><name><surname>Krivtsov</surname> <given-names>AV</given-names></name><name><surname>Wright</surname> <given-names>RD</given-names></name><name><surname>Feng</surname> <given-names>Z</given-names></name><name><surname>Agarwal</surname> <given-names>J</given-names></name><name><surname>Kung</surname> <given-names>AL</given-names></name><name><surname>Armstrong</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment</article-title><source>Leukemia</source><volume>22</volume><fpage>66</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2404951</pub-id><pub-id pub-id-type="pmid">17851551</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name><name><surname>Gillette</surname> <given-names>MA</given-names></name><name><surname>Paulovich</surname> <given-names>A</given-names></name><name><surname>Pomeroy</surname> <given-names>SL</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname> <given-names>C</given-names></name><name><surname>Roberts</surname> <given-names>A</given-names></name><name><surname>Goff</surname> <given-names>L</given-names></name><name><surname>Pertea</surname> <given-names>G</given-names></name><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Kelley</surname> <given-names>DR</given-names></name><name><surname>Pimentel</surname> <given-names>H</given-names></name><name><surname>Salzberg</surname> <given-names>SL</given-names></name><name><surname>Rinn</surname> <given-names>JL</given-names></name><name><surname>Pachter</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and cufflinks</article-title><source>Nature Protocols</source><volume>7</volume><fpage>562</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1038/nprot.2012.016</pub-id><pub-id pub-id-type="pmid">22383036</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname> <given-names>K</given-names></name><name><surname>Yoshimi</surname> <given-names>A</given-names></name><name><surname>Kagoya</surname> <given-names>Y</given-names></name><name><surname>Nishikawa</surname> <given-names>S</given-names></name><name><surname>Marquez</surname> <given-names>VE</given-names></name><name><surname>Nakagawa</surname> <given-names>M</given-names></name><name><surname>Kurokawa</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16</article-title><source>Cancer Science</source><volume>105</volume><fpage>512</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1111/cas.12386</pub-id><pub-id pub-id-type="pmid">24612037</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeulen</surname> <given-names>M</given-names></name><name><surname>Mulder</surname> <given-names>KW</given-names></name><name><surname>Denissov</surname> <given-names>S</given-names></name><name><surname>Pijnappel</surname> <given-names>WW</given-names></name><name><surname>van Schaik</surname> <given-names>FM</given-names></name><name><surname>Varier</surname> <given-names>RA</given-names></name><name><surname>Baltissen</surname> <given-names>MP</given-names></name><name><surname>Stunnenberg</surname> <given-names>HG</given-names></name><name><surname>Mann</surname> <given-names>M</given-names></name><name><surname>Timmers</surname> <given-names>HT</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4</article-title><source>Cell</source><volume>131</volume><fpage>58</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.08.016</pub-id><pub-id pub-id-type="pmid">17884155</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voigt</surname> <given-names>P</given-names></name><name><surname>LeRoy</surname> <given-names>G</given-names></name><name><surname>Drury</surname> <given-names>WJ</given-names></name><name><surname>Zee</surname> <given-names>BM</given-names></name><name><surname>Son</surname> <given-names>J</given-names></name><name><surname>Beck</surname> <given-names>DB</given-names></name><name><surname>Young</surname> <given-names>NL</given-names></name><name><surname>Garcia</surname> <given-names>BA</given-names></name><name><surname>Reinberg</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Asymmetrically modified nucleosomes</article-title><source>Cell</source><volume>151</volume><fpage>181</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.09.002</pub-id><pub-id pub-id-type="pmid">23021224</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname> <given-names>DK</given-names></name><name><surname>Stoffregen</surname> <given-names>EP</given-names></name><name><surname>Heinrich</surname> <given-names>MC</given-names></name><name><surname>Deininger</surname> <given-names>MW</given-names></name><name><surname>Druker</surname> <given-names>BJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518</article-title><source>Blood</source><volume>105</volume><fpage>2952</fpage><lpage>2954</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-07-2758</pub-id><pub-id pub-id-type="pmid">15585651</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>GG</given-names></name><name><surname>Pasillas</surname> <given-names>MP</given-names></name><name><surname>Kamps</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes</article-title><source>Molecular and Cellular Biology</source><volume>26</volume><fpage>3902</fpage><lpage>3916</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.10.3902-3916.2006</pub-id><pub-id pub-id-type="pmid">16648484</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Jin</surname> <given-names>Q</given-names></name><name><surname>Lee</surname> <given-names>JE</given-names></name><name><surname>Su</surname> <given-names>IH</given-names></name><name><surname>Ge</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Histone H3K27 methyltransferase Ezh2 represses wnt genes to facilitate adipogenesis</article-title><source>PNAS</source><volume>107</volume><fpage>7317</fpage><lpage>7322</lpage><pub-id pub-id-type="doi">10.1073/pnas.1000031107</pub-id><pub-id pub-id-type="pmid">20368440</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wierenga</surname> <given-names>AT</given-names></name><name><surname>Vellenga</surname> <given-names>E</given-names></name><name><surname>Schuringa</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels</article-title><source>Molecular and Cellular Biology</source><volume>28</volume><fpage>6668</fpage><lpage>6680</lpage><pub-id pub-id-type="doi">10.1128/MCB.01025-08</pub-id><pub-id pub-id-type="pmid">18779318</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname> <given-names>AC</given-names></name><name><surname>Ballabio</surname> <given-names>E</given-names></name><name><surname>Geng</surname> <given-names>H</given-names></name><name><surname>North</surname> <given-names>P</given-names></name><name><surname>Tapia</surname> <given-names>M</given-names></name><name><surname>Kerry</surname> <given-names>J</given-names></name><name><surname>Biswas</surname> <given-names>D</given-names></name><name><surname>Roeder</surname> <given-names>RG</given-names></name><name><surname>Allis</surname> <given-names>CD</given-names></name><name><surname>Melnick</surname> <given-names>A</given-names></name><name><surname>de Bruijn</surname> <given-names>MF</given-names></name><name><surname>Milne</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction</article-title><source>Cell Reports</source><volume>3</volume><fpage>116</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2012.12.016</pub-id><pub-id pub-id-type="pmid">23352661</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winters</surname> <given-names>AC</given-names></name><name><surname>Bernt</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MLL-Rearranged Leukemias-An update on science and clinical approaches</article-title><source>Frontiers in Pediatrics</source><volume>5</volume><fpage>11</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.3389/fped.2017.00004</pub-id><pub-id pub-id-type="pmid">28232907</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname> <given-names>M</given-names></name><name><surname>Kato</surname> <given-names>T</given-names></name><name><surname>Hotta</surname> <given-names>C</given-names></name><name><surname>Nishiyama</surname> <given-names>A</given-names></name><name><surname>Kurotaki</surname> <given-names>D</given-names></name><name><surname>Yoshinari</surname> <given-names>M</given-names></name><name><surname>Takami</surname> <given-names>M</given-names></name><name><surname>Ichino</surname> <given-names>M</given-names></name><name><surname>Nakazawa</surname> <given-names>M</given-names></name><name><surname>Matsuyama</surname> <given-names>T</given-names></name><name><surname>Kamijo</surname> <given-names>R</given-names></name><name><surname>Kitagawa</surname> <given-names>S</given-names></name><name><surname>Ozato</surname> <given-names>K</given-names></name><name><surname>Tamura</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Shared and distinct functions of the transcription factors IRF4 and IRF8 in myeloid cell development</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e25812</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0025812</pub-id><pub-id pub-id-type="pmid">22003407</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname> <given-names>A</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Wysocka</surname> <given-names>J</given-names></name><name><surname>Sanyal</surname> <given-names>M</given-names></name><name><surname>Aufiero</surname> <given-names>DJ</given-names></name><name><surname>Kitabayashi</surname> <given-names>I</given-names></name><name><surname>Herr</surname> <given-names>W</given-names></name><name><surname>Cleary</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with Menin to regulate hox gene expression</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>5639</fpage><lpage>5649</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.13.5639-5649.2004</pub-id><pub-id pub-id-type="pmid">15199122</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname> <given-names>A</given-names></name><name><surname>Somervaille</surname> <given-names>TC</given-names></name><name><surname>Smith</surname> <given-names>KS</given-names></name><name><surname>Rozenblatt-Rosen</surname> <given-names>O</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Cleary</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis</article-title><source>Cell</source><volume>123</volume><fpage>207</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.09.025</pub-id><pub-id pub-id-type="pmid">16239140</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>W</given-names></name><name><surname>Chory</surname> <given-names>EJ</given-names></name><name><surname>Wernimont</surname> <given-names>AK</given-names></name><name><surname>Tempel</surname> <given-names>W</given-names></name><name><surname>Scopton</surname> <given-names>A</given-names></name><name><surname>Federation</surname> <given-names>A</given-names></name><name><surname>Marineau</surname> <given-names>JJ</given-names></name><name><surname>Qi</surname> <given-names>J</given-names></name><name><surname>Barsyte-Lovejoy</surname> <given-names>D</given-names></name><name><surname>Yi</surname> <given-names>J</given-names></name><name><surname>Marcellus</surname> <given-names>R</given-names></name><name><surname>Iacob</surname> <given-names>RE</given-names></name><name><surname>Engen</surname> <given-names>JR</given-names></name><name><surname>Griffin</surname> <given-names>C</given-names></name><name><surname>Aman</surname> <given-names>A</given-names></name><name><surname>Wienholds</surname> <given-names>E</given-names></name><name><surname>Li</surname> <given-names>F</given-names></name><name><surname>Pineda</surname> <given-names>J</given-names></name><name><surname>Estiu</surname> <given-names>G</given-names></name><name><surname>Shatseva</surname> <given-names>T</given-names></name><name><surname>Hajian</surname> <given-names>T</given-names></name><name><surname>Al-awar</surname> <given-names>R</given-names></name><name><surname>Dick</surname> <given-names>JE</given-names></name><name><surname>Vedadi</surname> <given-names>M</given-names></name><name><surname>Brown</surname> <given-names>PJ</given-names></name><name><surname>Arrowsmith</surname> <given-names>CH</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name><name><surname>Schapira</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors</article-title><source>Nature Communications</source><volume>3</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/ncomms2304</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname> <given-names>W</given-names></name><name><surname>Xie</surname> <given-names>J</given-names></name><name><surname>Long</surname> <given-names>C</given-names></name><name><surname>Erdjument-Bromage</surname> <given-names>H</given-names></name><name><surname>Ding</surname> <given-names>X</given-names></name><name><surname>Zheng</surname> <given-names>Y</given-names></name><name><surname>Tempst</surname> <given-names>P</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Zhu</surname> <given-names>B</given-names></name><name><surname>Reinberg</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Heterogeneous nuclear ribonucleoprotein L is a subunit of human KMT3a/Set2 complex required for H3 Lys-36 trimethylation activity in vivo</article-title><source>Journal of Biological Chemistry</source><volume>284</volume><fpage>15701</fpage><lpage>15707</lpage><pub-id pub-id-type="doi">10.1074/jbc.M808431200</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeisig</surname> <given-names>BB</given-names></name><name><surname>Milne</surname> <given-names>T</given-names></name><name><surname>García-Cuéllar</surname> <given-names>MP</given-names></name><name><surname>Schreiner</surname> <given-names>S</given-names></name><name><surname>Martin</surname> <given-names>ME</given-names></name><name><surname>Fuchs</surname> <given-names>U</given-names></name><name><surname>Borkhardt</surname> <given-names>A</given-names></name><name><surname>Chanda</surname> <given-names>SK</given-names></name><name><surname>Walker</surname> <given-names>J</given-names></name><name><surname>Soden</surname> <given-names>R</given-names></name><name><surname>Hess</surname> <given-names>JL</given-names></name><name><surname>Slany</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>617</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.2.617-628.2004</pub-id><pub-id pub-id-type="pmid">14701735</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>J</given-names></name><name><surname>Bi</surname> <given-names>C</given-names></name><name><surname>Janakakumara</surname> <given-names>JV</given-names></name><name><surname>Liu</surname> <given-names>SC</given-names></name><name><surname>Chng</surname> <given-names>WJ</given-names></name><name><surname>Tay</surname> <given-names>KG</given-names></name><name><surname>Poon</surname> <given-names>LF</given-names></name><name><surname>Xie</surname> <given-names>Z</given-names></name><name><surname>Palaniyandi</surname> <given-names>S</given-names></name><name><surname>Yu</surname> <given-names>H</given-names></name><name><surname>Glaser</surname> <given-names>KB</given-names></name><name><surname>Albert</surname> <given-names>DH</given-names></name><name><surname>Davidsen</surname> <given-names>SK</given-names></name><name><surname>Chen</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML</article-title><source>Blood</source><volume>113</volume><fpage>4052</fpage><lpage>4062</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-05-156422</pub-id><pub-id pub-id-type="pmid">19144991</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>J</given-names></name><name><surname>Bi</surname> <given-names>C</given-names></name><name><surname>Cheong</surname> <given-names>LL</given-names></name><name><surname>Mahara</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>SC</given-names></name><name><surname>Tay</surname> <given-names>KG</given-names></name><name><surname>Koh</surname> <given-names>TL</given-names></name><name><surname>Yu</surname> <given-names>Q</given-names></name><name><surname>Chng</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML</article-title><source>Blood</source><volume>118</volume><fpage>2830</fpage><lpage>2839</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-07-294827</pub-id><pub-id pub-id-type="pmid">21734239</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>J</given-names></name><name><surname>Cote-Sierra</surname> <given-names>J</given-names></name><name><surname>Guo</surname> <given-names>L</given-names></name><name><surname>Paul</surname> <given-names>WE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Stat5 activation plays a critical role in Th2 differentiation</article-title><source>Immunity</source><volume>19</volume><fpage>739</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(03)00292-9</pub-id><pub-id pub-id-type="pmid">14614860</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><boxed-text><table-wrap id="keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type (species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">cell line (<italic>Homo-sapiens</italic>)</td><td valign="top">SEM</td><td valign="top">DSMZ</td><td valign="top">ACC546</td><td valign="top"/></tr><tr><td valign="top">cell line (<italic>Homo-sapiens</italic>)</td><td valign="top">MOLM13</td><td valign="top">Duo laboratory University of Michigan</td><td valign="top"/><td valign="top">Verified by STR profiling ATCC</td></tr><tr><td valign="top">cell line (<italic>Homo-sapiens</italic>)</td><td valign="top">THP-1</td><td valign="top">ATCC</td><td valign="top">TIB-202</td><td valign="top">Verified by STR profiling ATCC</td></tr><tr><td valign="top">cell line (<italic>Homo- sapiens</italic>)</td><td valign="top">MV4;11</td><td valign="top">Duo laboratory University of Michigan</td><td valign="top"/><td valign="top">Verified by STR profiling ATCC</td></tr><tr><td valign="top">Gene (<italic>Homo- sapiens</italic>)</td><td valign="top">STAT5A-CA</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Constitutively active human STAT5A.</td></tr><tr><td valign="top">recombinant DNA reagent</td><td valign="top">pTRIPZ-STAT5A-CA (plasmid)</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Lentiviral construct to transfect and express the gene.</td></tr><tr><td valign="top">recombinant DNA reagent</td><td valign="top">pTRIPZ-EZH2 (plasmid)</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Lentiviral construct to transfect and express the gene.</td></tr><tr><td valign="top">recombinant DNA reagent</td><td valign="top">Tet-pLKO-puro</td><td valign="top">Addgene</td><td valign="top">Cat # 21915</td><td valign="top"/></tr><tr><td valign="top">recombinant DNA reagent</td><td valign="top">PLKO-shFLT3 (plasmid)</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Lentiviral construct to transfect and knock down gene.</td></tr><tr><td valign="top">recombinant DNA reagent</td><td valign="top">PLKO-shscrambled (plasmid)</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Lentiviral construct to transfect and knock down gene.</td></tr><tr><td valign="top">recombinant DNA reagent</td><td valign="top">pTRIPZ-GFP (plasmid)</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Lentiviral construct to transfect and express the gene.</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-MEIS1 (Rabbit polyclonal)</td><td valign="top">EMD Millipore</td><td valign="top">Cat# ABE2864</td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-H3 (Rabbit polyclonal)</td><td valign="top">Active Motif</td><td valign="top">Cat#: 61277</td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-H3K79me2 (Rabbit polyclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab3594</td><td valign="top">WB (1:2000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-H3K27me3 (Rabbit polyclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 9733S</td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-H3K4me3 (mouse monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 9751S</td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-H4 (Rabbit polyclonal)</td><td valign="top">Active Motif</td><td valign="top">Cat# 61299</td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-H2B (Rabbit polyclonal)</td><td valign="top">Proteintech</td><td valign="top">Cat# 2S2899-2</td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-FLT3 (Rabbit polyclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat. #: 33462S</td><td valign="top">WB (1:500)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-GAPDH (Rabbit polyclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 5174S</td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-STAT5A (Rabbit polyclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 94205T</td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-p- STAT5 (Rabbit polyclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 9359S</td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-EZH2 (Rabbit polyclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat. #: 5246S</td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-LEDGF (Rabbit polyclonal)</td><td valign="top">Bethyl</td><td valign="top">Cat# A300-848A</td><td valign="top">WB (1:2000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-RBBP5 (Rabbit polyclonal)</td><td valign="top">Bethyl</td><td valign="top">Cat# A300-109A</td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-HNRNPK (Rabbit polyclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab70492</td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-MBD3 (Rabbit polyclonal)</td><td valign="top">Bethyl</td><td valign="top">Cat. #: A302-529A</td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-rabbit (secondary HRP-conjugated)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 7074S</td><td valign="top">WB (1:10000)</td></tr><tr><td valign="top">antibody</td><td valign="top">anti-mouse (secondary HRP-conjugated)</td><td valign="top">Bethyl</td><td valign="top">Cat# 31432</td><td valign="top">WB (1:10000)</td></tr><tr><td valign="top">chemical compound, drug</td><td valign="top">Pinometostat (EPZ5676)</td><td valign="top">Cayman Chemical</td><td valign="top">Cat# a16175</td><td valign="top"/></tr><tr><td valign="top">chemical compound, drug</td><td valign="top">Tandutinib (MLN518)</td><td valign="top">Selleckchem</td><td valign="top">Cat. #: S1043</td><td valign="top"/></tr><tr><td valign="top">chemical compound, drug</td><td valign="top">EI1</td><td valign="top">Cayman Chemical</td><td valign="top">Cat# 19146–1</td><td valign="top"/></tr><tr><td valign="top">chemical compound, drug</td><td valign="top">MI-503</td><td valign="top">Selleckchem</td><td valign="top">Cat. #: S7817</td><td valign="top"/></tr><tr><td valign="top">chemical compound, drug</td><td valign="top">PIM1 inhibitor</td><td valign="top">MedChemExpress</td><td valign="top">Cat# HY-15604</td><td valign="top"/></tr><tr><td valign="top">chemical compound, drug</td><td valign="top">MM-401</td><td valign="top">Duo laboratory University of Michigan</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">chemical compound, drug</td><td valign="top">Propidium iodide</td><td valign="top">Alfa Aesar</td><td valign="top">Cat # J66584</td><td valign="top"/></tr><tr><td valign="top">recombinant DNA reagent</td><td valign="top">pCMV-Gag-Pol (plasmid)</td><td valign="top">Manicassamy lab</td><td valign="top"/><td valign="top">Lentiviral construct to transfect for viral particle assembly.</td></tr><tr><td valign="top">recombinant DNA reagent</td><td valign="top">pCMV-vsvg (plasmid)</td><td valign="top">Manicassamy lab</td><td valign="top"/><td valign="top">Lentiviral construct to transfect for viral particle assembly.</td></tr><tr><td valign="top">recombinant DNA reagent</td><td valign="top">pTRIPZ-FLT3-ITD</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Lentiviral construct to transfect and express the gene.</td></tr><tr><td valign="top">recombinant DNA reagent</td><td valign="top">RiboZero Gold</td><td valign="top">Illumina</td><td valign="top">Cat # MRZ11124C</td><td valign="top">Ribosomal rRNA removal from total RNA.</td></tr><tr><td valign="top">commercial assay or kit</td><td valign="top">NEBNext Ultra Directional RNA Library prep kit</td><td valign="top">NEB</td><td valign="top">Cat # E7420S</td><td valign="top">cDNA library kit.</td></tr><tr><td valign="top">commercial assay or kit</td><td valign="top">Trizol reagent</td><td valign="top">Life Technologies</td><td valign="top">Cat # 15596018</td><td valign="top">RNA extraction.</td></tr><tr><td valign="top">commercial assay or kit</td><td valign="top">Zymo Research RNA Clean and Concentrator</td><td valign="top">Zymo Research</td><td valign="top">Cat # 11-353B</td><td valign="top"/></tr><tr><td valign="top">commercial assay or kit</td><td valign="top">NEBNext Ultra II DNA Library prep kit</td><td valign="top">NEB</td><td valign="top">Cat # E7645</td><td valign="top">DNA library kit.</td></tr><tr><td valign="top">commercial assay or kit</td><td valign="top">PowerUP SYBR Green master mix</td><td valign="top">Applied Biosystems</td><td valign="top">Cat # A25742</td><td valign="top">qPCR reagent</td></tr><tr><td valign="top">commercial assay or kit</td><td valign="top">MMLV HP reverse transcriptase</td><td valign="top">Lucigen</td><td valign="top">Cat # RT80125K</td><td valign="top"/></tr><tr><td valign="top">commercial assay or kit</td><td valign="top">Cell TiterGlo 2</td><td valign="top">Promega</td><td valign="top">Cat # G924A</td><td valign="top">Cell proliferation assay.</td></tr><tr><td valign="top">software, algorithm</td><td valign="top">HISAT2</td><td valign="top"><xref ref-type="bibr" rid="bib51">Kim et al., 2015</xref></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">software, algorithm</td><td valign="top">Cufflinks</td><td valign="top"><xref ref-type="bibr" rid="bib101">Trapnell et al., 2012</xref></td><td valign="top"/><td valign="top"/></tr><tr><td>peptide, recombinant protein</td><td>FITC-conjugated Annexin V</td><td>BD Biosciences</td><td>Cat # 556420</td><td>Apoptosis detection reagent.</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">HLD-DRA qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CTCAGGAATCATGGGCTATCAA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">HLA-DRA qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CTCATCACCATCAAAGTCAAACAT</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">HLA-DRB1 qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GTGACACTGATGGTGCTGAG</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">HLA-DRB1 qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GCTCCGTCCCATTGAAGAAA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">MEF2C qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GTCTGAGGACAAGTACAGGAAAA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">MEF2C qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GAGACTGGCATCTCGAAGTT</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">FLT3 qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">ATCATATCCCATGGTATCAGAATCC</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">FLT3 qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GAAGCAGATACATCCACTTCCA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">ARID3B qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">AGACCATACCAAAGATGCTTCC</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">ARID3B qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">ATCATCACTCCAGGCCAAAC</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">STAT5A qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CAGATGCAGGTGCTGTACG</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">STAT5A qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">TGTCCAAGTCAATGGCATCC</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">PIM2 qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">ATGTTGACCAAGCCTCTACA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">PIM2 qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">TCGATACTCGGCCTCGAA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">MEIS1 qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">AGACGATAGAGAAGGAGGATCAA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">MEIS1 qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CCGTGTCATCATGATCTCTGTT</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">HOXA9 qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">AGGCGCCTTCTCTGAAA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">HOXA9 qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GTTGGCTGCTGGGTTATTG</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">PBX3 qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CCACCAGATCATGACCATCAC</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">PBX3 qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">AAGAGCGCTGGTTTCATTCT</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">CEBPA qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CCTTCAACGACGAGTTCCT</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">CEBPA qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GCCCGGGTAGTCAAAGTC</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">CSF1R qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GCCATCCACCTCTATGTCAAA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">CSF1R qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">AGCAGACAGGGCAGTAGT</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">B2M qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CTCTCTCTTTCTGGCCTGGAG</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">B2M qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">TCTGCTGGATGACGTGAGTA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">SPI1 qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">TGCCCTATGACACGGATCTA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">SPI1 qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GTCCCAGTAATGGTCGCTATG</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">CSF3R qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CTATGGCAAGGCTGGGAAA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">CSF3R qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GGGCTGAGACACTGATGTG</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">PIM1 qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GTGGAGAAGGACCGGATTTC</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">PIM1 qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">TTCTTCAGCAGGACCACTTC</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">PBX3 qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CAAAGAAACATGCCCTGAACTG</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">PBX3 qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CTCTGATGCTGAGACCTGTTT</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">18S (RNA18S5) F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CGCAGCTAGGAATAATGGAATAGG</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">18S (RNA18S5) R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GCCTCAGTTCCGAAAACCAA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">CIITA qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CTGTGCCTCTACCACTTCTATG</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">CIITA qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GTCGCAGTTGATGGTGTCT</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">EZH2 qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GGAGGATCACCGAGATGATAAAG</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">EZH2 qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">TTCTGCTGTGCCCTTATCTG</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">EED qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CTGGCACAGTAAAGAAGGAGAT</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">EED qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GCATCAGCATCCACGTAAGA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">MEF2C promoter qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">TCTGGACGAGTCTGGTTACTT</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">MEF2C promoter qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">AGGAAGAAGGAGGAGGAAGAG</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">PIM1 promoter qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">ctcagcgaaacggagagc</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">PIM1 promoter qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">cgtatcgattcaaacccaaacaa</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">FLT3 promoter qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">ctttctcagggcctcaaagat</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">FLT3 promoter qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">ccgaactctgtcgtttggat</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">ARID3B promoter qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">acgagaacctctgaggaaga</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">ARID3B promoter qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">gctgggaggaaagtaactaaaga</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">CSF3R promoter qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GCAGAACCATTGTGGGTAAAC</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">CSF3R promoter qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">ggcagatggagaaacaggaa</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">BCL6 promoter qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">agctcgatctgctgagtttatg</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">BCL6 promoter qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">gcctctggaattctgagaactaat</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">HOXA9 promoter qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GCCTTATGGCATTAAACCTGAAC</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">HOXA9 promoter qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GAGGAGAACCACAAGCATAGTC</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">MEIS1 promoter qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">GGAGAGAGAGGGAGAGAAAGAA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">MEIS1 promoter qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CAAATGCACAAAGCCCTAGC</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">HLA-DRA promoter qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CAGAGCGCCCAAGAAGAA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">HLA-DRA promoter qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">cctcagcacctacCTTTGATAG</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">intergenic qPCR F</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">TACACGACAGAGGACTGGAA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">intergenic qPCR R</td><td valign="top">This paper</td><td valign="top">PCR primers</td><td valign="bottom">CCTTCATGGGTGAGGGTAATG</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">scrambled shRNA F</td><td valign="top"><xref ref-type="bibr" rid="bib115">Yuan et al., 2009</xref></td><td valign="top">shRNA construct for gene knockdown</td><td valign="bottom">CCGG TTCTCCGAACGTGTCACGTTT CTCGAG AAACGTGACACGTTCGGAGAA TTTTT</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">scrambled shRNA R</td><td valign="top"><xref ref-type="bibr" rid="bib115">Yuan et al., 2009</xref></td><td valign="top">shRNA construct for gene knockdown</td><td valign="bottom">AATTAAAAA TTCTCCGAACGTGTCACGTTT CTCGAG AAACGTGACACGTTCGGAGAA</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">FLT3 shRNA F</td><td valign="top"><xref ref-type="bibr" rid="bib34">Green et al., 2015</xref></td><td valign="top">shRNA construct for gene knockdown</td><td valign="bottom">CCGG GCATCCCAGTCAATCAGCTTT CTCGAG AAAGCTGATTGACTGGGATGC TTTTT</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">FLT3 shRNA R</td><td valign="top"><xref ref-type="bibr" rid="bib34">Green et al., 2015</xref></td><td valign="top">shRNA construct for gene knockdown</td><td valign="bottom">AATTAAAAA GCATCCCAGTCAATCAGCTTT CTCGAG AAAGCTGATTGACTGGGATGC</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">GFP shRNA F</td><td valign="top"><xref ref-type="bibr" rid="bib91">Scheeren et al., 2005</xref></td><td valign="top">shRNA construct for gene knockdown</td><td valign="bottom">CCGG GCAAGCTGACCCTGAAGTTCAT CTCGAG ATGAACTTCAGGGTCAGCTTGC TTTTT</td></tr><tr><td valign="top">sequence-based reagent</td><td valign="bottom">GFP shRNA R</td><td valign="top"><xref ref-type="bibr" rid="bib91">Scheeren et al., 2005</xref></td><td valign="top">shRNA construct for gene knockdown</td><td valign="bottom">AATTAAAAA GCAAGCTGACCCTGAAGTTCAT CTCGAG ATGAACTTCAGGGTCAGCTTGC</td></tr></tbody></table></table-wrap></boxed-text></app></app-group></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64960.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Shi</surname><given-names>Xiaobing</given-names></name><role>Reviewing Editor</role><aff><institution>Van Andel Institute</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Shi</surname><given-names>Xiaobing</given-names> </name><role>Reviewer</role><aff><institution>Van Andel Institute</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Your study of non-canonical H3K79 methylation dependent pathways reveals alternative mechanisms to the canonical DOT1L-H3K79me2-HOXA9/MEIS1 axis in MLL-r leukemia, providing novel insight into epigenetic regulation and transcriptional controls as well as potentially new approaches for leukemia therapy. This well executed study will be of interest to the readership of <italic>eLife</italic>.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Xiaobing Shi as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Maureen Murphy as the Senior Editor.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our policy on revisions we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in eLife but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data. Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in eLife, either of which would be linked to the original paper.</p><p>The manuscript by Richter et al., describes the discovery of non-canonical pathways dysregulated by low-dose pinometostat, a DOT1L specific inhibitor. MLL rearranged leukemia has been a focus for rational development of small molecule inhibitors targeting key regulatory pathways. Among these efforts, DOT1L inhibitor shows some efficacy in the MLL models. The prevalent view is that DOT1L inhibitors mainly target the HOXA9/MEIS1 pathway and down regulate expression of these leukemia transcription factors. However, under low-dose pinometostat treatment, where the expression of HOXA9 and MEIS1 is not affected, thousands of genes display differential expression, along with a disproportionate depletion of H3K79me2. Among the downregulated genes, the FLT3-ITD signaling axis is a major pathway that is sensitive to low-dose pinometostat treatment. Loss-of-FLT3-function recapitulates the cytotoxicity and gene expression consequences of low-dose pinometostat, whereas overexpression of constitutively active STAT5A, a target of FLT3-ITD-signalling, largely rescues these defects. These results suggest that co-occurring FLT3-ITD mutations sensitize MLL-r leukemias to DOT1L inhibition. Mechanistically, H3K79me2 depletion changes the distribution of other histone modifications, including genome-wide increases in H3K4me3 and a global reduction in H3K27me3. DOT1L inhibition downregulates the expression of EZH2 and EED components of the PRC2 complex, likely accounting for global reductions in H3K27me3 and cell proliferation defects. Overall, this is a comprehensive study that reveals interesting H3K79me dynamics and how it contributes to the leukemic transcription program. This study reveals alternative mechanisms to the canonical DOT1L-H3K79me2-HOXA9/MEIS1 axis in MLL-r leukemia, providing novel insights into epigenetic regulation and transcriptional controls as well as potentially new approaches for leukemia therapy. Addressing the following concerns would improve the manuscript:</p><p>1. The finding that the FLT3-ITD-signalling pathway is more sensitive to DOT1L inhibition than the canonical MLL-fusion targets (HOXA9 and MEIS1) is very interesting. However, all experiments are carried out in MLL-r leukemia cell lines, which somewhat limits the impact of the study. It would greatly enhance the impact of this study if the authors could look into leukemia cells beyond MLL-rearrangement. Specifically, does low-dose pinomeostat suppress the FLT3-STAT5A pathway and show therapeutic efficacy in FLT3-ITD+ leukemia w/o the MLL-rearrangement? Of note, FLT3-ITD occurs in 25% AML that have MLL PTD. It would be interesting to determine the effect of low-dose pinomeostat in some MLL-PTD cell lines.</p><p>2. The RNA-seq data have three replicates each, which is good. However, most of the ChIP-seq data appear to have no biological replicates. As many of the conclusions are largely based upon ChIP-seq results, biological repeats are needed for all ChIP-seq data.</p><p>3. All the experiments are performed using a single DOT1L inhibitor, pinometostat. To exclude potential off-target effects, an independent DOT1L inhibitor should be tested in some key experiments.</p><p>4. It is interesting that there is an increase of H3K4me after DOT1L inhibition. The authors propose it is due to Pol lI stalling, which leads to accumulation of H3K4me3. If this is the case, then accumulation of H3K4me3 might be more significant at highly expressed genes. However, the increase of H3K4me3 seems to be high regardless of absolute expression levels. There is also significant increase of H3K4me3 at gene bodies in the 'MLL-AF4 spread' genes. These need to be taken into consideration. Are the genes that show increase of H3K4me3 responsive to MLL inhibitor treatment?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64960.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>1. The finding that the FLT3-ITD-signalling pathway is more sensitive to DOT1L inhibition than the canonical MLL-fusion targets (HOXA9 and MEIS1) is very interesting. However, all experiments are carried out in MLL-r leukemia cell lines, which somewhat limits the impact of the study. It would greatly enhance the impact of this study if the authors could look into leukemia cells beyond MLL-rearrangement. Specifically, does low-dose pinomeostat suppress the FLT3-STAT5A pathway and show therapeutic efficacy in FLT3-ITD+ leukemia w/o the MLL-rearrangement? Of note, FLT3-ITD occurs in 25% AML that have MLL PTD. It would be interesting to determine the effect of low-dose pinomeostat in some MLL-PTD cell lines.</p></disp-quote><p>We would like to thank the reviewers for these excellent suggestions—we initially tried to source a number of cell lines that had FLT3-ITD, MLL-PTD or both genetic lesions combined through existing repositories (ATCC and DSMZ) and requesting lines from other investigators. After an exhaustive effort that was no doubt limited by COVID-19 and ~$1200 in costs, the only lines we could obtain were PL-21(heterozygous FLT3-ITD with intact MLL1), and EOL-1 (MLL1-PTD with normal FLT3 status). Even these lines took &gt; 2 months to arrive. Despite these challenges, the results are an impactful and exciting addition to this work – we present these new data in Figures 4H,I,J, and K.</p><p>The possibility that FLT3-ITD leukemias might respond to DOT1L inhibition is one of the more exciting implications from our first submission, and some preliminary testing of this concept in available cell lines certainly does boost the impact of our study. In new experiments, we find that PL-21 (FLT3<sup>+/ITD</sup>, MLL1<sup>+/+</sup>) cell viability was reduced after 10 µM pinometostat treatment for 9 days (Figure 4H), whereas at this dose we see no compromise to viability of K562 cells (an erythroleukemic cell line with a BCR-ABL translocation). Notably, in this FLT-ITD heterozygous line, there is a significant reduction of FLT3 and PIM1 expression upon treatment under conditions that begin to impact growth while canonical MLL-r drivers are below the limit of detection (Figure 4I). We also observe similar ablation of both H3K79me2 levels and STAT5A phosphorylation under these conditions (Figure 4J). These data are all consistent with our former speculation that FLT-ITD leukemias may be susceptible to DOT1L inhibition via the transcriptional down-regulation of FLT3, and consequent reduction in signaling activity. Moreover, this heterozygous FLT3-ITD leukemia line represents a conservative case, there is reason to anticipate a homozygous FLT3-ITD leukemia would be even more sensitive, as it is in the MLL-r backgrounds (Figure 4A). Although our studies are restricted to one cell line, these new data make a much more compelling case that this concept should be explored clinically in FLT3-ITD mutant AML (clinical frequency ~ 30-40%).</p><p>Unfortunately, we were unable to obtain an MLL1-PTD line that also bears a FLT3-ITD mutation. However, we were able to perform experiments that extend our MLL-AF4/AF9 translocation line experiments into the domain of MLL-PTD mutants that lack FLT3 mutations, which are more common in clinical presentation of acute leukemia (5-10%) than the MLL-r lesions we previously deployed. In brief, we observe highly similar proliferation defects in EOL-1 (FLT3<sup>+/+</sup>, MLL1<sup>+/PTD</sup>) as compared to MLL-r cell lines (Figure 4A and H). In EOL-1 cells, 100 nM pinometostat treatment for 7 days sharply reduced FLT3 expression with no observable effect on HOXA9, MEIS1 or PIM1 expression (Figure 4K). However, pinometostat treatment at a much higher dose (10 µM) reduced both HOXA9 and PIM1 expression (Figure 4K). These results are consistent with previous observations (Kuhn et al. Haematologica. 2015) where lower pinometostat doses are able to reduce the survival of EOL-1 rat xenografts without affecting HOXA9 expression. However, we observe that FLT3 expression is reduced at this lower concentration, perhaps accounting for the observed reduction in proliferation. Although we did not observe reduced phosphorylation of STAT5A upon 100 nM pinometostat treatment in EOL-1 cells (Figure 4J), this is not surprising as previous studies have found that WT FLT3 does not typically activate STAT5A (Choudhary et al., Int. J. Hematol. 2005). WT FLT3 is upregulated by MLL-fusions and is able to activate other pathways involved in cell growth and proliferation such as PI3K/AKT, RAS and AP-1 (Armstrong et al., Nat. Gent. 2002, Choudhary et al. Int. J. Hematol. 2005, Cauchy et al., Cell Rep. 2015). One or more of the aforementioned alternative growth signaling pathways may be essential for EOL-1 and MLL-PTD leukemia cell survival.</p><p>These new data strengthen the case that the sensitivity of the FLT3 locus to DOT1L inhibition also extends beyond MLL-rearranged leukemia to not only MLL-PTD but, leukemias bearing FLT3-ITD and intact MLL1.</p><disp-quote content-type="editor-comment"><p>2. The RNA-seq data have three replicates each, which is good. However, most of the ChIP-seq data appear to have no biological replicates. As many of the conclusions are largely based upon ChIP-seq results, biological repeats are needed for all ChIP-seq data.</p></disp-quote><p>In our initial submission we had performed one replicate of ICeChIP-seq to examine histone modification density upon pinometostat treatment at subsets of genes and specific gene loci. For conventional ChIP-seq this is perhaps insufficient for an analysis as central to the conclusions of our manuscript, however, among the advantages of ICeChIP-seq is the striking reproducibility of this method due to much lower experimental variance (Grzybowski et al., Mol. Cell. 2015, Shah et al., Mol. Cell. 2018). The cost of this reproducibility is the requirement for much greater sequencing depth of input, typically ~400-500 M reads per replicate, and to restrict the analysis to mono-nucleosomes, this must be paired-end data. This becomes extremely expensive per replicate ($3800). Nevertheless, we appreciate the broader point about reproducibility, and to demonstrate it unambiguously in this work, we present independent triplicate ICeChIP-seq measurements for the most important comparisons of H3K79me2 ICeChIP-seq in MV4;11 cells treated for 7 days with 100 nM pinometostat versus DMSO treated controls. Our two additional replicates of H3K79me2 ICeChIP-seq with 100 nM pinometostat treatment for 7 days very closely recapitulate all the effects, magnitudes, and features of the initial replicate to the point of being indistinguishable (Figure S3D (replicates 2 and 3), compare to replicate 1 in Figure 3D). These data are further supported by an independent experiment with only 4 days of treatment (Figures 3D, 3E S3A) that display the progressive H3K79me2 loss and mirrored the enrichment of H3K79me2 at MLL-AF4 targets and downregulated genes. For these comparisons we have also have added replicates of DMSO-treated cells (Figure S3D). The superb reproducibility of ICeChIP is demonstrated by scatterplot comparisons of the DMSO-treated H3K79me2 HMD from 0 to +2000 bp from the TSS at all genes expressed. We observe a strong correlation of H3K79me2 density in the gene bodies not only among replicate IPs performed side-by-side (Figure S3C (left)), but also on separate occasions months apart by a different person (Figure S3C (right)).</p><p>ENCODE and modENCODE have advocated duplicates of ChIP-seq data, coupled to metrics of irreproducibility amongst replicates (Landt et al. Genome Res. 2012). Compared to their example of a “highly reproducible” ChIP experiment, our HMD data from ICeChIP is far more correlated, even as compared to a log-log scale presentation (Figure S3C).</p><p>As they are an ancillary to the major points of the paper, we had trouble justifying $15,200 for additional H3K4me3 and H3K27me3 ICeChIP measurements under these conditions, but rather confirmed our findings with two additional independent ICeChIP-qPCR experiments for each modification at a number of key loci (Figures S6H and S7D). In support, we also now include a previously obtained independent ICeChIP-seq experiment for H3K4me3 after 100 nM pinometostat treatment for only 4 days which also displays increases in methylation even in this shorter timeframe (Figure S7D, compare to Figure 7C). Our two experimental replicates of H3K27me3 ICeChIP-qPCR ± 100 nM pinometostat display reductions in methylation at genes both up and downregulated by pinometostat, confirming our initial observations of global reductions in H3K27me3 by ICeChIP-seq and Western blot (Figure S6H, compare to 6B and 6C). Likewise, the two additional H3K4me3 ICeChIP experiments show increases in this modification upon pinometostat treatment near transcription start sites by qPCR (Figure S7E), consistent with our initial ICeChIP-seq analysis (Figure 7C). And just as in our ICeChIP-seq analysis H3K4me3 is increased not only at promoters of MLL-AF4 targets but at non-MLL-AF4 target genes both up- and downregulated by pinometostat treatment suggesting a genome-wide increase in H3K4me3 not limited to genes activated by MLL-AF4.</p><disp-quote content-type="editor-comment"><p>3. All the experiments are performed using a single DOT1L inhibitor, pinometostat. To exclude potential off-target effects, an independent DOT1L inhibitor should be tested in some key experiments.</p></disp-quote><p>While pinometostat is extraordinarily selective (&gt;37,000-fold over a large panel of histone methyltransferases; Daigle et al., Blood 2013), to exclude any potential off-target effects as causal in many of our critical experimental readouts, we employed SGC0946. SGC0946 is a distinct, but still highly selective DOT1L inhibitor (&gt;100-fold selectivity for DOT1L over other histone methyltransferases; Yu et al., Nat. Comm. 2012). Like pinometostat, we found that low concentration SGC0946 treatment (50 nM) reduced MV4;11 viability without significantly affecting HOXA9 and MEIS1 expression (Figure S1A and B). Just as with pinometostat, low dose SGC0946 reduced H3K79me2 levels (Figure S4B), as well as FLT3-ITD expression and STAT5A signaling (Figure S4B). Importantly, overexpression of constitutively active STAT5A was able to rescue the proliferation of MV4;11 cells treated with SGC0946 to a similar extent (Figure S5E). Collectively, the strikingly similar effects of both pinometostat and SGC0946 on MLL-rearranged leukemia in these key assays powerfully argues that reductions in FLT3-ITD/STAT5A signaling and attendant viability losses are due to depletion of H3K79me2 and not some off-target effect of pinometostat.</p><disp-quote content-type="editor-comment"><p>4. It is interesting that there is an increase of H3K4me after DOT1L inhibition. The authors propose it is due to Pol lI stalling, which leads to accumulation of H3K4me3. If this is the case, then accumulation of H3K4me3 might be more significant at highly expressed genes. However, the increase of H3K4me3 seems to be high regardless of absolute expression levels. There is also significant increase of H3K4me3 at gene bodies in the 'MLL-AF4 spread' genes. These need to be taken into consideration. Are the genes that show increase of H3K4me3 responsive to MLL inhibitor treatment?</p></disp-quote><p>We suggested one possible explanation for the genome-wide increase in H3K4me3 after pinometostat treatment could be due to reduced transcriptional elongation, resulting in more dwell time of poll II complex-associated MLL1 and increased H3K4me3. If this was the case, we reasoned that H3K4me3 increases due to pinometostat treatment would be correlated with transcriptional activity and would be scale with transcriptional activity. However, in new analysis prompted by this question, we find that if we group genes by increasing FPKM as a readout of transcriptional activity, there is no correlation with increased H3K4me3 at more highly expressed genes (Figure S7I), suggesting that increased H3K4me3 is not due to pol II stalling. The reviewers rightfully pointed out that the “MLL-AF4 spreading” genes show an increase in H3K4me3 not just after at the transcription start site but, far into the gene body, consistent with previous observations of the downstream spreading of the MLL-fusion and MLL1 complexes at these genes. It is also possible that these modifications each inhibit the enzymatic activity of the other complex. If this were the case, we would expect to see increases in H3K4me3 that are inversely proportional to the reduction in H3K79me2. The anticorrelation between these two modifications after pinometostat treatment is very poor (Figure S7H, R<sup>2</sup> = 0.0023), suggesting that the increase in H3K4me3 it is not merely due reduced inhibition from ablation of H3K79me2. We also note that MLL-AF4 targets downregulated by pinometostat (Figure S7H purple) and all MLL-AF4 targets (Figure S7H red) show greater reductions in H3K79me2 than mean, but as a whole only display modest increases in H3K4me3, slightly above the overall distribution increases. Another possibility is that the increase in H3K4me3 is the result of the loss of recruitment or activity of the H3K4me2 demethylase LSD1 (KDM1A), an alternative possibility that we have added to the Discussion section (p. 16). LSD1, a component of the MLL1 supercomplex (Nakamura et al., Mol. Cell. 2002), and an ELL complex that also contains components of pTEFb (Biswas et al. Proc. Natl. Acad. Sci. USA. 2011). LSD1 is necessary for the leukemogenic expression program in murine MLL-AF9-transformed bone marrow cells (Harris et al. Cancer Cell. 2012). Knockdown or inhibition of this demethylase reduces the leukemogenic expression program, survival of MLL-AF9 leukemia cells and results in increases in H3K4me2/3 genome-wide (Harris et al., Cancer Cell. 2012, McGrath et al., Cancer Res. 2016). If H3K79me2 is necessary for full LSD1 activity or recruitment, reductions in H3K79me2 may result in an increase in H3K4me3. This is of course, speculative with the present data, and we are clear about the limits of our interpretation on this point in the discussion.</p><p>Related to the second question, we do not observe that the genes that show increases in H3K4me3 upon low-dose pinometostostat treatment are dependent on MLL1 function for their expression as treatment with the MLL1 inhibitor MI-503 has no effect on the expression of B2M, PIM2 and PBX3 (Figure 7F and <xref ref-type="fig" rid="respfig1">Author response image 1</xref>), three genes that show moderate to large increases in H3K4me3 (<xref ref-type="fig" rid="respfig1">Author response image 1</xref>).</p><fig id="respfig1"><label>Author response image 1.</label><caption><title>(left) H3K4me3 HMD percent enrichment from ICeChIP-seq at the promoter regions of the indicated genes.</title><p>(right) B2M expression fold-change ± 250 nM MI-503.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64960-resp-fig1-v2.tif"/></fig></body></sub-article></article>